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Breast cancer is a major health concern in both developed and developing countries. 
Although there are many factors that can increase one’s risk of breast cancer; 
mammographic breast density is labelled as the greatest, modifiable risk factor of breast 
cancer. So much so, it has been used as a surrogate endpoint in breast cancer intervention 
trials.  
 
Mammographic breast density does have its flaws, especially when being used to monitor 
therapeutic interventions used to reduce breast cancer risk in clinical practice or clinical 
trials. To name a few, mammographic breast density responds to interventions slowly, taking 
up to one and a half years to show significant changes within the breast tissue. 
Mammographic breast density also requires women to have mammograms, which are not 
the most pleasant experience, and can lead to women not attending breast cancer 
screenings or high attrition rates in breast cancer trials. Also, the quantification of 
mammographic breast density itself can occur in a subjective manner, which can lead to 
substantial assessor influence on the results.  
 
There appears to be a gap in the literature for a biomarker for mammographic breast density, 
which responds (in a timelier manner) to treatments aimed at reducing mammographic 
breast density and subsequently breast cancer risk. This thesis aimed to investigate if breast 
elasticity, as measured by shear wave elastography, is a viable biomarker for mammographic 
breast density, which can be used in clinical practice or research.  
 
This thesis consisted of two main focuses. Firstly, determining if elasticity responds to 
treatment that also alter mammographic breast density. Secondly, determining a 
standardised protocol to objectively measure whole breast elasticity, using the SuperSonic™ 
Imagine Aixplorer® ShearWave™ elastography machine. The first focus consisted of three 
clinical trials. The first, an analysis of a patient database of women who used HAVAHT+Ai™ to 
reduce mammographic breast density. The second, a three-month, open-labelled, 
pharmacokinetic sub-study, determining if breast elasticity changes occurred with 
HAVAHT+Ai™, as it was shown to reduce mammographic breast density in the initial study. 
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Lastly, a 12-month, open labelled, clinical trial of a combination of a selective androgen 
receptor modulator and an aromatase inhibitor. Analysing the effect of this combination on 
mammographic breast density and breast elasticity, enabling the determination of 
consistency with the elasticity response with two interventions that were shown to reduce 
mammographic breast density. Correlations between breast elasticity and mammographic 
breast density variables are also discussed with the potential favourable uses of these in 
clinical and research settings.   
 
The second focus included two studies. The first, an analysis of what shear wave elastography 
protocols created the most precise data. Secondly, an eight-week study, determining the 
effects of the hormonal changes of the menstrual cycle, patient position, and repeat 
measurements of breast elasticity, using shear wave elastography. Using this data to create a 
description of a standardised protocol to use when using shear wave elastography to 
measure whole breast elasticity, which will aid and standardised future use and research of 
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Shear Wave Elastography Preface  
 
Shear wave elastography is a new form of medical imaging which uses shear wave acoustic 
waves, induced by the radiation force of a focussed ultrasonic beam, to image and 
characterise tissue structures (Sarvazyan, Rudenko et al. 1998). Further details pertaining to 
the science behind shear wave elastography are provided in Section 1.5.2 within this thesis. 
 
This preface will provide a description of some of the key features of the equipment and a 
glossary of terms specific to this piece of equipment. The purpose of this preface and 
glossary is to be used as an introduction to the machine and be used as a reference as 
required by the reader. 
 
The machine used within this thesis was the SuperSonic™ Imagine Aixplorer®, which can 
provide real-time ShearWave™ Elastography (SWE), pictures in Figure 1. 
 
 
Figure 1: SuperSonic™ Imagine Aixplorer® ShearWave™ Elastography Machine 
 
As this is an ultrasound machine, a transducer head is required to be used; for this research 
the SuperLinear™ SL15-4 linear transducer was used, pictured in Figure 2. This transducer 
head had a bandwidth of 2-10 megahertz (MHz) and can be used for breast ultrasounds, as 




Figure 2: SuperLinear™ SL15-4 Linear Transducer Head 
 
A generic, water-based ultrasound gel was also used on both the skin and on the transducer 
head. The ultrasound gel and the ultrasound gel on the transducer head are pictures in 
Figure 3 and 4, respectively.  
 
 




Figure 4: Ultrasound gel on the Linear transducer head 
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B-mode ultrasound is a widely accepted method of ultrasound, where a 
linear array of transducer simultaneously scans a place through the body. 
This scan can be viewed as a two-dimensional image on the screen 
(Carovac, Smajlovic et al. 2011). On the Supersonic™ Aixplorer® SWE 
machine the B-mode ultrasound is displayed simultaneously with the SWE 





The SWE mode uses shear waves and measures the speed at which they 
travel through the tissue and displays information about tissue elasticity. 
It is displayed as an easy to interpret colour-coded image on the 
Supersonic™ Aixplorer® SWE machine, as pictured in Figure 5. This 
elasticity can also be viewed as a quantitative value, with the local 




The region of interest is the area of the ultrasound output that is the 
focus of the image (the focal zone), as pictured in Figure 5. For the 
Supersonic™ Aixplorer® SWE system, the ROI is within a box on the image, 




Figure 5: SuperSonic™ Imagine Aixplorer® SWE machine output with the ShearWave Elastography mode and B-mode 






The commonly used term for the quantification box is the Q-Box™. This is 
a customisable circle that you place on the image to accurately quantify 
the elasticity (also called the stiffness) of an area. The Q-Box™ can be 
resized and/or moved across the image and anchored to display to 
elasticity within that selected area. A singular 10-millimetre Q-Box™ is 
pictured in Figure 6. 
 
 
Figure 6: The Q-Box™ displayed on both the SWE mode and the B-mode ultrasound output 
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Q-Box™ Ratio: The Q-Box™ ratio is similar to the Q-Box™ but it allows you to compare 
the elasticity of two areas of the same image. Within this thesis, one 
circle, that again could be resized or moved, was placed on an area of the 
image that was fibroglandular tissue and one was placed on an area of 





This is when you manually trace a Q-Box™ on the SWE image, it provides 
the elasticity values within the traced area. The area can be traced using 
the trackball on the Aixplorer® SWE machine or with the stylus attached. 
The Q-Box™ trace is pictured in Figure 7. 
 
 
Figure 7: The SWE mode image with the Q-Box™ trace function used to trace and create a custom shaped Q-Box™ to 
include the area within the ROI for which will be included in the elasticity 
Export: The data that was generated from the shear wave elastography image can 
be exported from the machine as either a comma separated value (CSV) 
excel files, DICOM files or as generated reports with the relevant images 








Figure 9: A sample of the reports generated by the machine that can be exported with both the image and the 
quantitative data 
Black Hole: Areas of the Shear Wave Image where the shear waves have not 




Figure 10: A Shear Wave ultrasound image with a black hole present 
Artefacts: Areas on the colour elasticity image that might not be a 
representation of the mechanical properties of the breast tissue but 
rather an issue with the SWE. The areas in the image that have 
artefacts have extremely high elasticity values, which do not 





%BD Per cent breast density 
%FV Per cent fibroglandular Volume 
%VBD Percentage volumetric breast density 
5α-DHT 5α-dihydrotestosterone 
6 x 3mm Q-Box™ Six, three-millimetre Q-Box™ 
6 x 6mm Q-Box™ Six, six-millimetre Q-Box™ 
ADH Atypical ductal hyperplasia 
AE Adverse event 
Ai Aromatase Inhibitors 
ALH Atypical lobular hyperplasia 
ALT Alanine aminotransferase 
AMPK Adenosine monophosphate-activated protein kinase 
ARFI Acoustic radiation force impulses 
BBD Benign breast disease 
BC Breast cancer 
BD Breast density 
Bi-RADs Breast imaging reporting and data systems 
BMI Body mass index 
Boyd’s SCC Boyd’s six class categories 
CCHT Continuous combined hormone therapy  
CCS Case control study 
CI Confidence Interval 
Cm Centimetre 
Cm3 Cubic centimetre 
CS Cohort study 
CV Coefficient of variation 
DHEAS Dehydroepiondrosterone sulphate 
DHT Dihydrotestosterone 
DNA Deoxyribonucleic acid 
E/A Ratio Oestrogen/androgen Ratio 
E1 Oestrone 
E2 Oestradiol 
ECM Extracellular matrix 
EOS End of study 
FAI Free androgen index 
FGV Absolute volume of fibroglandular tissue 
FSH Follicle-stimulating hormone 
GnRH Gonadotropin releasing hormone 
Gtx-024 Enobosarm 
HAVAHT+Ai™ HAVAH proprietary limited testosterone and anastrozole 
HER2 Human epidermal growth factor receptor 2 
HREC Human research ethics committee 
HRT Hormonal replacement therapy  
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IBIS-I International breast cancer intervention study I 
ICMD International consortium on mammographic density 
IMI Image mean index 
Kg Kilogram 
kPa Kilopascal 
LCIS Lobular carcinoma in situ 
LH Lutenizing hormone 
LVI Lymphovascular Invasion 
m/s-1 Meters per second 
MBD Mammographic breast density 
MDA Malondialdehyde 
MDEST Mammographic density estimation 




MMPs Matrix metalloproteinases 
MRI Magnetic resonance Imaging 
MRIV Magnetic resonance Imaging Volume 
MRS Menopause rating scale 
N/m2 Newton per square meter 
NSAIDs Non-steroidal anti-inflammatory drugs 
OR Odds ratio 
Pa Pascal 
PMD Percentage mammographic density 
PT Preferred term 
RAS Restricted analysis set 
RCT Randomised controlled Trial 
ROI Region of interest 
SARM Selective androgen receptor modulator 
SCC Six class categories 
SEER National Cancer Institute age-specific surveillance, epidemiology and 
end results program 
SERM Selective oestrogen receptor modulators 
SHBG Sex hormone binding globulin 
SOC  System organ class 
SWE Shear wave elastography 
T Testosterone 
TBV Total breast volume 
TDLUs Terminal duct lobular units 
TFV Total fibroglandular volume 
TIMP Tissue inhibitor of metalloproteinases 
TIMP-3 Tissue inhibitor of metalloproteinases-3 
TM Trademark 
u/L Unites per litre 
VAS Visual analogue scale 
VPD Volumetric per cent density 
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Chapter 1 Introduction and Background 
1.1 Introduction 
Breast cancer is one of the most prevalent types of cancer among women and affects women 
of both developed and developing countries. While there has been great progress into 
diagnostic and treatment techniques, there remains a substantial morbidity and mortality 
burden of this disease with more than two million cases diagnosed and more than 600,000 
patients dying from this condition worldwide annually (Bray, Ferlay et al. 2018). There has 
been a great deal of research undertaken to establish the many risk factors that have been 
linked to an increased risk of developing breast cancer; and that there is heterogeneity in 
regard to the risk factors associated with breast cancers of different subtypes (oestrogen or 
progesterone receptor positive or Human Epidermal Growth Factor Receptor 2 (HER2) 
tumours) (Althuis, Fergenbaum et al. 2004, Ma, Bernstein et al. 2006, Yang, Chang-Claude et 
al. 2011). Broadly, McPherson, Steel et al. (2000) summarised these risk factors which 
include; 
• Increasing age (up to the onset of menopause) 
• Geographical location 
• Early menarche 
• Late menopause 
• Family history 
• Age at first birth (with nulliparity and late age of first birth increases the risk) 
• Previous benign breast disease (BBD) 
• Exposure to radiation 
Furthermore, lifestyle factors may also contribute to an increased risk of breast cancer, these 
factors include; 
• Diet (dietary fat intake is correlated with an increased incidence of breast cancer) 
• Obesity in postmenopausal women (among premenopausal women obesity is 
associated with a reduced incidence of breast cancer) 
• Alcohol consumption 
• The use of oral contraceptives  
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• Hormonal replacement therapy (HRT), with the risk of breast cancer appearing higher 
in combined oestrogen and progesterone combinations (McPherson, Steel et al. 
2000). 
 
In addition to the risk factors listed above, in recent years, it has been discovered that 
mammographic breast density (MBD) is a major independent and modifiable risk factor for 
breast cancer. With previous research predicting that a third of breast cancers could be linked 
to a woman having highly dense breasts (Boyd, Martin et al. 2010). 
 
1.2 Mammographic Breast Density 
Mammographic breast density refers to the percentage of dense tissue compared to fatty 
tissue within a woman’s breast. The fatty tissue is radiologically lucent and appears dark on a 
mammogram, while in contrast, epithelium and stroma are radiographically dense and appear 
light on the mammographic breast image. Mammographic breast density is highly variable 
and differs significantly amongst individuals of the same age and race (Ingleby and Gershon-
Cohen 1960). An association between the mammographic parenchymal pattern of the breast 
and breast cancer risk was initially proposed in 1976 by Dr John Wolfe (Wolfe 1976), and this 
has led to advancing research within this field. 
 
Boyd, Lockwood et al. (1998) measured the proportions of mammographic images occupied 
by radiographically dense tissue. They found, without exception, a compelling association 
between increasing densities and increasing risk of breast cancer. Furthermore, McCormack 
and dos Santos Silva (2006) conducted a meta-analysis of 42 studies which included 14,000 
cases and 226,000 non-cases; finding that there was a consistent relationship with higher 
percentage mammographic density (PMD), which is another method of quantifying breast 
area, and an association with breast cancer risk. In addition, there are further studies 
revealing that breast cancers arising from areas of high MBD are more frequently related to 
factors suggestive of a poorer prognosis, including large tumour size, higher histologic grade, 
lymphovascular invasion (LVI) and the cancer being discovered at a more advanced stage, 
compared to those arising within an area of low MBD tissue (Aiello, Buist et al. 2005). 
Although some of the previously mentioned risk factors for breast cancer are associated with 
or can influence MBD; after adjustment for the effects of these factors, MBD remains an 
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independent risk factor for the development of breast cancer (McCormack and dos Santos 
Silva 2006, Boyd, Martin et al. 2010, Kerlikowske, Shepherd et al. 2005).  
 
1.2.1 Histology of the Tissue Associated with Mammographic Breast Density 
Mammographic breast density is a trait that is linked to the variation in the fibro-epithelial 
architecture of the breast (Boyd, Lockwood et al. 1998). The histology of the tissue of 
differing MBD’s has been studied, utilising both surgical biopsies and mastectomy specimens. 
These studies demonstrated that epithelial and stromal proliferation was associated with 
increased MBD (Wellings and Wolfe 1978, Bland, Kuhns et al. 1982, Bright, Morrison et al. 
1988, Urbanski, Jensen et al. 1988, Bartow, Pathak et al. 1990, Boyd, Jensen et al. 1992). 
However, the samples examined within these studies were taken from women with known or 
suspected breast disease. It needs to be noted that this may not be an appropriate sample to 
represent the general population of women with high MBD. Furthermore, Li, Sun et al. (2005) 
examined breast tissue samples obtained from forensic autopsy and found that tissue with 
high PMD was associated with a greater proportion of collagen, a greater area of glandular 
structures and a greater nuclear area of both epithelial and non-epithelial cells when 
compared to tissue of a lesser PMD. This larger proportion of collagen accounted for 29% of 
the variance in the PMD with other tissue measurements (area of glandular structures and 
area of epithelial and non-epithelial cells) accounting for between 4% and 7% of the variance 
in PMD (Li, Sun et al. 2005). 
 
Additionally, Turashvili, McKinney et al. (2009), using the same tissue samples as the Li, Sun et 
al. (2005) case-series, found that premenopausal women who had high MBD at a younger age 
demonstrated pre-neoplastic cellular changes, with the presence of columnar cell lesions 
being associated with high MBD. Columnar Cell Lesions having been proposed to represent 
the earliest identifiable histological, but non-obligatory precursor, of low-grade breast 
carcinomas (Sewell 2004, Simpson, Gale et al. 2005). Additionally, tissues with high MBD 
share key histological features with stromal components of malignant breast lesions, 
specifically low adipocytes and high extracellular matrix (ECM) content (DeFilippis, Chang et 
al. 2012).  
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Furthermore, Lisanti, Reeves et al. (2014) reported that there are similarities in the gene 
expression in high MBD fibroblasts and those seen in cancer associated fibroblasts. In 
particular, high density up-genes showing associations with gene sets related to cancer, the 
stress response, inflammation, stemness, and signal transduction. In their study, Lisanti, 
Reeves et al. (2014) demonstrated that there was a strong resemblance between high MBD 
fibroblasts and human tumours, including breast cancers with these results potentially 
reflecting functional similarities between cancer associated fibroblasts and high MBD 
fibroblasts; which are a major component of the tumour stroma in most solid tumours.  
 
1.2.2 Measuring Mammographic Breast Density 
Since MBD has been identified as an important breast characteristic linked to breast cancer, 
more advanced methods and technologies have been developed to quantify this 
characteristic. To date, three different broad methodological categories exist to quantify 
MBD, these being manual, semi-automated and fully automated methods. 
 
1.2.2.1  Manual Methods 
Dr John Wolfe, as previously mentioned in Section 1.2, was the first individual credited as 
linking the breast parenchymal pattern to breast a woman’s breast cancer risk. To do this, 
originally Wolfe applied a method, using both qualitative as well as quantitative criteria, to 
classify and categorise the parenchymal patterns of the breast. Wolfe (1976) created the 
following descriptions of these categories; 
• N1 category – this refers to breast parenchyma, which is composed primarily of fat, 
with at most, a small amount of dysplasia; no ducts are visible for this category 
• P1 category – this refers to parenchyma composed chiefly of fat, with prominent ducts 
in the anterior portion to one fourth the volume of the breast; also, maybe a thin band 
of ducts extending into a quadrant 
• P2 category – this refers to severe involvement with dysplasia, with prominent ductal 
patterns occupying more than one-fourth the volume of the breast 
• DY category – this refers to severe involvement with dysplasia, often obscuring an 
underlying prominent ductal pattern 
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As this method of classification is subjective, it has resulted in inconsistencies in the 
application of these categories when analysing mammographic images. Oza and Boyd (1993) 
conducted a review to determine the reliability of the Wolfe classification categories; they 
found that the inter-observer agreement was 52% to 97% and that there was an intra-
observer agreement of 69% to 97%. In terms of monitoring changes in MBD, the variability 
that is associated with this method leads to unreliable results and for this reason, in the early 
1980s attempts began to develop a reproducible, quantitative method of assessing and 
classifying MBD (Boyd, O'sullivan et al. 1982). 
 
A further method of manually classifying MBD is using a visual estimation of the percentage of 
the breast occupied by dense tissue, with several different models being utilised each with 
differing variables and categories (Boyd, O'sullivan et al. 1982, Boyd, Byng et al. 1995, Vachon, 
King et al. 1999). In the United States of America, the Breast Imaging Reporting and Data 
Systems (BI-RADs) was developed to standardise the reporting terminology of the 
mammography assessment categories (American College of Radiology 1998). The BI-RADs 
method is based on qualitative visual assessments and can be highly influenced by the 
reviewer as the density classification is assigned by the radiologist based on the visual 
inspection of the image (Jeffers, Sieh et al. 2016). This method distinguishes four categories; 
A. Almost entirely fatty 
B. Scattered areas of fibroglandular densities 
C. Heterogeneously dense 
D. Extremely dense 
 
The BI-RADs method has a moderate inter-observer agreement, with a kappa coefficient 
value of 0.43 to 0.59 (Kerlikowske, Grady et al. 1998, Berg, Campassi et al. 2000). The BI-RAD 
system, however, was not intended to provide a quantification of MBD, it was included in the 
mammography report to inform the referring physician of the impact of the sensitivity and 
the interpretation of the image based on the level of breast density (Harvey and Bovbjerg 
2004). This impact on the mammogram interpretation is due to a decreased level of 
sensitivity to detect lesions on mammograms with high BI-RAD categorisation (Harvey and 
Bovbjerg 2004), which is a phenomenon called masking; which occurs when the breast lesions 
are hidden by the dense tissue on the mammogram as they both appear white on the 
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imaging. The BI-RAD scale was also not intended to quantitate changes in the breast tissue 
density over time. 
 
1.2.2.2 Semi-automated Methods 
To reduce some of the limitations faced by the previously discussed manual visual estimation 
methods, more consistent semi-automated, computer-assisted methods of MBD 
quantification have been developed. The most common of these methods is a piece of 
software called Cumulus (University of Toronto, Toronto, Canada)(Byng, Boyd et al. 1994, Eng, 
Gallant et al. 2014), which uses semi-automated, user-interactive thresholding of the image 
to estimate the percentage of breast area that is dense tissue. The Cumulus method uses 
two-dimensional images of the breast; which has limitations because breast density is three-
dimensional and potentially variable in appearance on two-dimensional mammograms due to 
differences in compression and the projection angle (Yaffe 2008). Also, different 
manufacturers of mammography machines have different imaging properties, which can alter 
the mean brightness of the image, in particular within areas that are difficult to penetrate 
such as fibroglandular tissue (Shaw, Albagli et al. 2004, Rivetti, Lanconelli et al. 2006), this 
difference can influence the measured MBD (Mahesh 2004, Shaw, Albagli et al. 2004, Rivetti, 
Lanconelli et al. 2006, McCullagh, Baldelli et al. 2011).  Cumulus is also limited by intra- and 
inter-reader variability in establishing the threshold for segmenting dense tissue from the 
surrounding fatty tissue. The processes of measuring MBD with this method is labour 
intensive and time-consuming; this may be acceptable within research environments; 
however, the applicability of such methods in the real-world may be challenging (Jeffreys, 
Harvey et al. 2010). 
 
1.2.2.3 Fully Automated Methods 
The benefit of fully automated methods is that they decrease the subjectivity and operator 
dependency of the outcome measure. Four main fully automated methods have been 
validated: CumulusV™ (Sunnybrook Health Sciences Centre, Toronto, ON, Canada), Quantra™ 
(Hologic Inc, Bedford, MA, USA), VolparaDensity™ (Volpara Health Technologies, Wellington, 
New Zealand) and Densitas™ (Densitas Inc, Halifax, NS, Canada). These systems use images 
generated by digital mammography; algorithms calibrate pixels values in, depending on the 
system, the raw “for processing” or processed, full-field digital mammography images using a 
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model of X-ray physics and imaging parameters. These systems provide the outputs of 
volumetric per cent density (VPD) or as an absolute measure of dense and non-dense tissue 
(Highnam, Brady et al. 1996, Alonzo-Proulx, Mawdsley et al. 2015, Astley, Harkness et al. 
2018). In the local setting of this research, VolparaDensity™ is the predominant software used 
and will be described in greater detail.  
 
VolparaDensity™ is a volumetric breast density assessment software; it uses an algorithm to 
map the brightness across the mammogram. This brightness represents either the thickness 
of fibroglandular tissue or fatty tissue that is present between the pixel and the x-ray source. 
As the VolparaDensity™ algorithm runs across the image, it calculates the total fibroglandular 
volume (TFV); by using the compressed breast thickness and projected area, the total breast 
volume (TBV) is also able to be calculated. When the TFV is divided by the TBV, the 
percentage volumetric breast density (%VBD) is calculated. The breast density is provided per 
breast, which is obtained from averaging the values of the craniocaudal and mediolateral 
oblique images (Lee, Sohn et al. 2015).  
 
Automated breast density analysis techniques rely on the brightness of the glandular and 
fatty tissue. For this reason, to date, there have been resulting difficulties with the 
consistency and reproducibility, as differences in the imaging parameters that change the 
brightness and contrasts of the image may affect the breast density calculations (Jeffreys, 
Harvey et al. 2010). 
 
1.2.3 Factors that can Influence Mammographic Breast Density 
1.2.3.1 Heritability and Mammographic Breast Density 
Two studies have demonstrated that genetics may influence a woman’s MBD (Boyd, Dite et 
al. 2002, Ursin, Lillie et al. 2009). Boyd, Dite et al. (2002) conducted a study on two samples of 
female monozygotic (identical) and dizygotic (non-identical) twins from Australia, Canada and 
The United States. After adjustments for age and other covariates, the combined correlation 
coefficient was 0.63 for monozygotic pairs and 0.27 for dizygotic pairs. Similarly, Ursin, Lillie et 
al. (2009), also studying monozygotic and dizygotic twins found that after adjustments for 
exposure and non-heritable risk factors that are known to influence MBD, genetics accounted 
for 53% in the variance for PMD and 59% for the variance in absolute breast density. Both of 
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these studies observing a greater correlation with MBD between members of monozygotic 
twins rather than dizygotic twins, alluding to potential genetic influence. 
 
1.2.3.2 Parity Status and Number of Births 
Numerous studies have linked MBD to parity and number of births. It has been demonstrated 
that parity is strongly correlated with MBD, with nulliparous (given birth to no children) 
women having a greater MBD compared to primiparous (given birth to one child) and 
multiparous women given (birth to multiple children) (de Waard, Rombach et al. 1984, Oza 
and Boyd 1993, Gram, Funkhouser et al. 1995, Hendriks, Otten et al. 2000, Li, Sun et al. 2005). 
It has also been shown that the number of births has a negative association with MBD (Li, Sun 
et al. 2005) with one study finding 47% of the nulliparous women had >25% density, 
compared to 37% of the women with one to three children and 19% of the women with more 
than three children (Hendriks, Otten et al. 2000). It is hypothesised that the strong 
relationship between parity and MBD is the reason parity has a protective effect regarding 
breast cancer risk (de Waard, Rombach et al. 1984). 
 
1.2.3.3 Race and Ethnicity 
There is conflicting evidence that race and ethnicity have an influence on MBD with the 
International Consortium on Mammographic Density (ICMD) (McCormack, Burton et al. 2016) 
being established to generate more evidence on this topic. One study by Heller, Hudson et al 
(2015) found that Chinese women were found to have significantly greater PMD and the 
lowest overall breast volume. Furthermore, the PMD of black females did not differ 
substantially from the cohort, having both a higher fibroglandular volume and also overall 
breast volume (Heller, Hudson et al. 2015). 
 
McCormack, Perry et al. (2008) conducted a study comparing the MBD of Afro-Caribbean, 
South Asian and Caucasian women living in the United Kingdom. After adjusting for age, body 
mass index (BMI), menopausal status, use of hormone therapy, number of live births, age at 
first birth, family history of breast cancer and use of oral contraceptives. Afro-Caribbean and 
South Asian women had a lower mean MBD of -1.3% (95% confidence interval (CI) -3.7% to 
1.3%) and -3.8% (95% CI -6.3% to 1.1%) compared to Caucasians, respectively. In regard to 
the Afro-Caribbean women, 60% of the differences in MBD were attributed to a higher mean 
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BMI, earlier menopause, lower prevalence of hormone therapy and a greater number of live 
births. As for the South Asian women one third of the reduced density was explained by BMI 
and reproductive characteristics, but the fully adjusted differences remained statistically 
significant.  
 
Mariapun, Li et al. (2015) examined MBD in Chinese, Malay and Indian women and found that 
Chinese women had significantly higher PMD compared to Malay and Indian women after 
adjustment for age, BMI, menopausal status, parity and age at first full term pregnancy. The 
difference in MBD between the ethnicities predominately coming from the lower non-dense 
area in Chinese women. 
 
Del Carmen, Halpern et al. (2007) reported that MBD amongst Asian women was significantly 
greater compared to Caucasian, African American, Indian and Caribbean or non-disclosed 
races. However, within this study in all the other groups, breast density did not correlate with 
race beyond what can be attributed to differences in BMI, bra size and cup size. Maskarinec, 
Nagata et al. (2002) compared the MBD of three groups of women, these being white 
women, Japanese women living in Hawaii, and Japanese women living in Japan; the findings 
showing that PMD was higher in Japanese women in Hawaii compared to those living in 
Japan. The conclusion was that the size of the TBV differs primarily by race and the proportion 
of dense area by place of residence (Maskarinec, Nagata et al. 2002). 
 
The evidence currently shows that race and ethnicity may be an influencing factor for MBD; 
however other environmental factors and exposures, such as where the woman is living, may 
have been more influential for MBD differences. Other unexamined factors that may explain 
ethnic differences include dietary intake, in particular with calcium, vitamin D, fat, and 
phytoestrogens, which in some studies have been related to MBD (Knight, Martin et al. 1999, 
Vachon, Kushi et al. 2000, Bérubé, Diorio et al. 2004, Maskarinec, Takata et al. 2004). In 
addition, known lifestyle determinants of MBD do not fully account for the ethnic variations in 
MBD, in particular within Asian cohorts.   
 
1.2.3.4 Age and Mammographic Breast Density 
It is known that hormonal changes that occur during menopause lead to alterations of the 
glandular features of the breast tissue. Two studies have examined the relationship between 
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age and MBD (Li, Sun et al. 2005, Checka, Chun et al. 2012) and both found an inverse 
relationship between these two variables. Checka, Chun et al. (2012) found that 74% of 
patients between 40 and 49 years of age had dense breasts, this decreasing to 57% of women 
in their 50’s, 44% of women in their 60s and 36% of women in their 70’s. Within these results, 
there were exceptions across all age groups, and there was similar variability within each age 
group. These studies demonstrate that age may not be a perfect surrogate for breast density 
but remains an influencing factor.   
 
A further study by Burton, Maskarinec et al. (2017) examined differences in MBD, concerning 
the age and menopausal status, from data collected from women from 22 countries. It was 
found that regardless of ethnicity or the country the women were from, MBD was much 
lower in postmenopausal compared to premenopausal women of the same age. In addition to 
this, proportionally to the breast area, the breast density was lower in older women both 
among premenopausal and postmenopausal women. In premenopausal women, MBD 
changed with age without an increase in the breast area; however, the latter (breast area) 
also increased amongst postmenopausal women. These findings demonstrate that within a 
population of women from multiple countries, there is a consistent effect of age and 
menopausal state on MBD, suggesting that these associations may reflect a common 
biological process. At the tissue level, changes which involve the area of high density arise 
from changes in the stromal tissue or in the epithelial tissue or both stromal tissue and 
epithelial tissue. At the same time, the changes in the PMD are also affected by changes in 
the adipose tissue within the breast. Areas of decreasing density likely reflect involution of 
terminal duct lobular units (TDLUs). X-rays of histological tissues showed that TDLUs have 
raised concentrations of radiologically dense areas and that these areas also declined with 
age (Gierach, Patel et al. 2016). The age-related decline in MBD may, however, be modified 
by external factors such as hormonal or reproductive factors or lifestyle or environmental 
factors.  
 
1.2.3.5 Use of Hormonal Therapies and Mammographic Breast Density 
Hormonal therapies and natural hormonal fluctuations that occur throughout a woman’s life 
are known to influence and have the ability to modify MBD. Even the fluctuations during a 
woman’s menstrual cycle can significantly alter MBD (Ursin, Parisky et al. 2001). As 
mentioned in Section 1.2.3.4, MBD decreases throughout menopause in response to changes 
 11 
that occur in a woman’s hormones. Combination HRT has consistently been shown to 
increase MBD (Persson, Thurfjell et al. 1997, Greendale, Reboussin et al. 1999, Lundström, 
Wilczek et al. 1999, McTiernan, Martin et al. 2005, (Chlebowski, Hendrix et al. 2003), 
specifically oestrogen with progestin therapy, which has been found to increase MBD five to 
seven times more than oestrogen alone, which had a small or negligible effect (Greendale, 
Reboussin et al. 1999). In addition to this, tamoxifen, which is a partial antiestrogenic therapy, 
has consistently shown to decrease MBD (Atkinson, Warren et al. 1999, Brisson, Brisson et al. 
2000, Chow, Venzon et al. 2000, Konez, Goyal et al. 2001, Cuzick, Warwick et al. 2004).  
 
1.2.4 Current Interventions for Reducing Mammographic Breast Density 
1.2.4.1 Hormonal Interventions 
As mentioned in Section 1.2.3.5, MBD can be influenced in response to changes in hormonal 
exposures. Androgens and oestrogens have competing actions within normal breast tissue, 
and the regulation of oestrone (E1), oestrone-sulphate and oestradiol (E2) levels rather than 
the concentration of oestrogen in the breast tissue may be associated with changes in MBD 
(Vachon, Suman et al. 2013). As the breast is embryologically a modified sweat gland, it 
responds like a sweat gland to any alteration to its oestrogen and androgen (E/A) ratio 
(McNally and Stein 2017). When there is a shift in the E/A ratio towards an androgenic tissue 
environment in the breast, there is a substantial change in MBD (as is seen following 
menopause (Boyd, Martin et al. 2002)). Therefore, to reduce MBD, there needs to be a 
profound impact on oestrogenic action, which is difficult in premenopausal women without 
imposing undue systematic effects; therefore, outweighing the benefit of therapy. To date, 
two classes of pharmaceutical interventions have shown to be efficacious at reducing MBD; 
these are selective oestrogen receptor modulators (SERMs) and aromatase inhibitors (Ais). In 
addition, non-steroidal anti-inflammatory drugs (NSAIDs) and the antidiabetic agent 
metformin have also been evaluated for effect on MBD reduction. 
 
1.2.4.2 Selective Oestrogen Receptor Modulators (SERMS) 
Two SERMs have been examined for the use of reducing MBD in both premenopausal and 
postmenopausal women; these are tamoxifen and raloxifene. Selective oestrogen receptor 
modulators exert agonist or antagonist effects on various oestrogen target tissues (Riggs and 
Hartmann 2003). Shang and Brown (2002) found that tamoxifen and raloxifene act as anti-
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oestrogens within the breast, and as partial agonists of oestrogen, they can cause significant 
alterations in both breasts and systemic oestrogenic stimulation. This change in systemic 
oestrogenic stimulation causes a shift in the E/A ratio, creating a more androgenic 
environment and reducing cellular proliferation in the breast, thus having the ability to reduce 
MBD.  
 
There have been ten studies which have assessed the use of tamoxifen for MBD, seven of 
these including both pre-and postmenopausal women. Within these ten studies, all of them 
reported tamoxifen mediated MBD decreases. Nine studies assessed the efficacy of raloxifene 
on MBD, with eight of these studies including only postmenopausal women. Of these nine 
studies, only three reported a statistically significant reduction in MBD. A summary of the 
results for these studies on tamoxifen and raloxifene are reported in Table 1-1.
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Table 1-1: Summary table of studies utilising SERMs to influence MBD 
Author, Year Study Design Study Population 
(age and n) 
Type of 
Intervention 
Outcome Measures Results 
Brisson, Brisson et al. 
(2000)  
RCT ≥ 35 years 
Cases (n) = 36 
Controls (n) = 33 
Tamoxifen 
20mg/day for 5 
years 
PMD and Wolfes 
Parenchymal Pattern 
Mean PMD reductions: 1.0 – 3.4 years = -6.9% ± 11.1%; 3.5 – 5 years = -
10.9% ± 12.4%. Overall PMD Reductions: Tamoxifen = -9.4%, Placebo -
3.6% P= <0.01. 
Cuzick, Warwick et al. 
(2011)  
Nested CCS 30 – 70 years 
Cases (n) = 123 
Controls (n) = 942 
Tamoxifen 
20mg/day for 5 
years 
PMD (Boyd’s SCC, 
Cumulus) 
Compared to all women in the placebo group, women in the tamoxifen 
group who experienced 10% or greater reduction in breast density had 
63% reduction in BC risk: OR = 0.37, (95% CI 0.20 to 0.69, P=0.002). 
Cuzick, Warwick et al. 
(2004)  
Nested CCS 35-75 Years 
Cases (n) = 388 
Controls (n) = 430 
Tamoxifen 
20mg/day for 5 
years 
PMD (Boyd’s method, 
visual assessment) 
BD reductions: 18 month follow up -7.9% (95% CI 6.9% to 8.9%; 
p=0.001). 54 month follow up -13.7% (95% CI 12.3% to 15.1%; 
p<0.001). 
There were reductions in the placebo group, but the reductions were 
greater in the tamoxifen group than the placebo group (p=0.001). 
Chen, Chang et al. 
(2011)  
CS 33-51 Years 




%FV, PMD (MRI: 
computer-assisted 
algorithm) 
BD reductions after 17 months = -5.8% ± 3.8% (p<0.001). 
7 subjects showed absolute reduction of %BD less than -5%; 7 were 
between -5-10%; 2 larger than -10%. 
Decensi, Robertson et 




BC women (n) = 235 
Tamoxifen 
5mg/day for 2 
years 
PMD (Boyd’s and 
Cumulus) 
MBD; Month 12 (Boyd and Cumulus) = -9.9% (95% CI -16.2 to -3.6). 
Month 24 (Boyd and Cumulus) = -16.2 (95% CI -22.6 to -9.8) 
Month 12 (analogue only) -13.8 (95% CI -20.0 to -7.6); Month 24 = -
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Outcome Measures Results 
Atkinson, Warren et 




Cases (n) = 94 
Controls (n) = 188 
Tamoxifen 




Significant change toward a less dense pattern in the case group (p = 
0.0001) after treatment with tamoxifen. 
The change was significant in the case group compared to the control 
group (p=0.0001). 
The OR associated with the denser P2 and DY patterns vs the less dense 
N1 and P1 patterns was 3.6 (95% CI 2.11 to 6.18) at the initial 
mammogram. This was significantly reduced to 1.5 (95% CI 1.32 to 
1.70) by the follow-up mammogram (p=0.019, X2 = 5.52 for the 
difference between the two ORs). 





High risk BC women 





RADs, Boyd’s SCC) 
Using the first and last digitised scores, 56% of participants showed a 
relative decrease of ≥10% mean, -10%; SD 16%). The digitised breast 
density changes were -4.3%, SD 6.60%, range -21.5 to 10.1%, P=0.0007. 
All three other criteria showed some decreases (Wolfe average -0.03, 
SD 0.4, range -1.0 to 1.5, p=0.05; BI-RADs average -0.1, SD 0.4, range -
1.5 to 0.05; p=0.12; semi-quantitative average -0.2, SD 05, range -1.2 to 
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Outcome Measures Results 





unaffected breasts of 
women following 
surgery for unilateral 
BC (n) = 27 
Tamoxifen 




19 cases (79%) showed no categorical change during or after the course 
of treatment (17 of the 19 showed fatty or minimally dense breast 
parenchyma). 3 (13%) showed a reduction in density within the first half 
of the treatment. All density changes were only by one level (e.g. 
minimally dense to fatty). Densitometer readings demonstrated a minimal 
reduction in glandular density during tamoxifen treatment in 14 cases 
(52%) within the first half and in 16 cases (60%) at the end of the course 
of treatment. Within the first half, only 4 cases showed more than 10% 
reduction in glandular density, which was noted in 7 additional cases at 
the end of the course of treatment. 




Mean age 58.5 ± 9.3 
years 
Cases (n) = 68 
Controls (n) = 80 
Tamoxifen 




Significant decrease in density (p<0.005). 
Son and Oh (1999)  RCT (post-hoc 
analysis) 
28-67 years 
152 patients with BD, 
Healthy women (n) = 
20 
Tamoxifen (n) = 102 
Control (n) = 70 
Tamoxifen 
20mg/day for 2 
years 
Visual Assessment On follow up mammograms, 61 (59.8%) of 102 patients in the tamoxifen 
group showed a decrease in breast parenchymal area, 59 (57.8%) had 
more clearly visualised Cooper's ligament, and 59 (57.8%) had clearly 
visualised ducts. A decrease in parenchyma was seen in 18 (36%) of 50 
patients in the non-tamoxifen group and two (10%) of the 20 healthy 
women. This was a significant decrease in density (p<0.005). 
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Outcome Measures Results 









PMD (BI-RADs) Null. 
Eng-Wong, Orzano-





Phase II trial of 
raloxifene (n) = 27 
Raloxifene 





No significant change, mean change at 1 year was 1% (95% CI -3 to 5), 2 
years 1% (95% CI -2 to 5). 
MRIV decreased on raloxifene – median relative change after 1 year was 
-17% (95% CI -28 to -9; p=0.0017), after 2 years -16% (95% CI -31 to -4; 
p=0.0004). 
Freedman, Martin et 
al. (2001)  
RCT 45- 60 years 
n = 168  
Placebo (n) = 45 
60mg/day raloxifene 
(n) = 45 
150mg/day raloxifene 
(n) = 42 









Results at 2 years: placebo and both raloxifene groups had PMD 
decreases. 
Placebo mean change = -1.3% (95% -2.2% to -0.4%;p=0.003) 
Raloxifene 60mg/day mean change = -1.5% (95% CI -2.7% to -0.3%; 
p=0.002). 
Raloxifene 150mg/day mean change = -1.7% (95% CI -2.8% to -0.6%; 
p<0.001). 
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Outcome Measures Results 
Harvey, Holm et al. 
(2009) 
retrospective 
subset of women 
enrolled in an RCT 
≤62 years 
Raloxifene (n) = 119 
Placebo (n) = 125 
Bazedoxifen 20mg 0r 
40mg (n) = 92, 106 
Raloxifene 
60mg/day for 2 
years 
PMD (cumulus) Results after 2 years, mean per cent change in PMD was Raloxifene -
0.5% (95% CI -1.1 to 0.1); Placebo -0.2% (95% CI -0.7 to 0.4). ANOVA 
showed no significant differences between the groups. 
Harvey, Pinkerton et 
al. (2013)  
Ancillary study of 
phase III RCT 
55.2 to 56.3 years 





60mg/day for 2 
years 
PMD (Cumulus) Mean PMD change in the raloxifene group was -0.23%; (95% CI -0.54% 
to 0.08%); placebo mean change was -0.42 (95% CI -0.72 to -0.11). 
There were no significant differences between the group. 
Jackson, San Martin et 
al. (2003)  
RCT ≥60 years – 
Raloxifene 66.9 ± 5.3; 
CCHT 66.4 ± 4.5 
Raloxifene (n) = 84 
CCHT 9n) = 109 
 
Raloxifene 
60mg/day for 1 
year 








From baseline to 12 months, 0.9% of the women in the raloxifene group 
had an increase in breast density, and 99.1% showed no change. In the 
CCHT group, 70.2% had an increase, and 29.8% showed no changes. 
There was a statistically significant difference between the treatment 
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Outcome Measures Results 
Lasco, Gaudio et al. 
(2006)  
CCS Postmenopausal 
Women with mean 
BMI 24.7, 52.4 ± 4.1 
years 
n = 70 
Raloxifene 
60mg/day 
orally for 2 
years 
Image Pro-Plus as 
hoc software 
Image Mean Index 
(IMI) 
Null – after 24 months of therapy, in the raloxifene group, there was a 
significant variation in mammary density compared with baseline. No 
significant variations were observed. The IMI value decreased 
significantly only in the raloxifene-treated women (-1.9%) p<0.05. 
IMI decreased but not significantly in the control group. 
Nielsen, Raundahl et 




n = 135 
Raloxifene 






Null – BI-RAD score did not increase significantly in either treatment 
group, and the treatment effects were not significantly different 
between the two treatment groups. The area percentage increased in 
both groups and significantly in the E2 group, which was significantly 
more than in the raloxifene group.  
Silverio, Nahas-Neto 
et al. (2007)  
RCT 61.1 years mean 
n = 80 
Raloxifene 
60mg/day for 2 
years 
PMD (BI-RADs and 
computer-assisted) 
Null – after 6 months, no alteration was observed in the MBD in 38 
women of the raloxifene group and 38 of the control group by a 
qualitative method. By a quantitative method, no alteration was 
observed in 30 women of the raloxifene group and 27 controls (p>0.05) 
Christodoulakos, 













Null – 10.7% of women in the tibolone group showed an increase in 
breast density and 6.3% showed an increase in the raloxifene group. No 
women in the control group showed an increase in breast density. 
Between-group differences did not reach statistical significance.  
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Table 1-1 continued 
Study Design Study Population 
(age and n) 




Karssemeijer et al. 
(2008)  
RCT 45-65 years 









Median reduction -4.1% (95%CI -6.9 to 2.1%) in raloxifene group 
Median reduction of 0.7% (95% CI -9.2 to 7.3%) in the tibolone group, 
both changes were statistically insignificant.  
%FV - per cent fibroglandular volume  
BC – breast cancer 
BD – breast density 
CCHT – continuous-combined hormone therapy 
CCS – case-control study 
CS – cohort study 
MRI – magnetic resonance imaging 
MRIV – magnetic resonance imaging volume 
PMD – per cent mammographic density 
RCT – randomised controlled trial 
SCC – six class categories 
SD – standard deviation 





Although tamoxifen has been shown to be efficacious at reducing MBD, as tamoxifen causes 
both a shift in breast and systemic oestrogen stimulation, it has been associated with 
significant adverse events (AEs), such as increased risk of ischemic stroke, 
uterine/endometrial cancers, vaginal discharge and hot flushes (Oncology 2009), which may 
outweigh the benefit on the therapy and reduce compliance with research stating that only 
4% of women at increased risk of breast cancer have accepted the use of tamoxifen as a 
chemopreventative therapy (Ropka, Keim et al. 2010). 
 
1.2.4.3 Aromatase Inhibitors 
Another class of pharmaceutical intervention that has been found to reduce MBD are 
aromatase inhibitors. Aromatase is an enzyme of the cytochrome P-450 superfamily and the 
product of the CYP19 gene and is expressed in several tissues including subcutaneous fat, 
liver, muscle, brain, and normal breast tissue (Nelson and Bulun 2001). The aromatase 
enzyme is responsible for the conversion of the adrenal androgen substrate androstenedione 
to oestrogen in peripheral tissues (Evans, Ledesma et al. 1986), with peripheral tissue being 
the predominant source of oestrogen in postmenopausal women (Altundag and Ibrahim 
2006). As the E/A ratio needs to be shifted to an androgen environment to benefit MBD; Ais 
reduce oestrogenic drive by blocking the conversion of androstenedione to E1 and 
testosterone to E2 decreasing both serum and breast tissue oestrogen levels (Dowsett, Jones 
et al. 1995, Miller and Dixon 2001, Geisler, Haynes et al. 2002, Ingle, Buzdar et al. 2010). 
Aromatase inhibitors are contraindicated in the treatment of breast cancer of premenopausal 
women; the rationale for this assertion is that in premenopausal women, oestrogen is 
predominately produced in the ovaries unlike postmenopausal women, where it is 
predominately produced in peripheral tissues by aromatisation of androgens. If Ais are used 
as a sole treatment in premenopausal patients, it leads to interference with the negative 
feedback mechanism between the ovaries and the pituitary gland, which can result in 
hypothalamic-pituitary inhibition, stimulating the release of Gonadotropin-releasing hormone 
(GnRH), leading to ovarian hyperstimulation (Mitwally and Casper 2001, Casper 2007). This 
ovarian hyper-stimulation being the reason that Ais are used for infertility treatment to 
induce ovarian hyper-stimulation for follicular genesis.  
 
A total of nine studies have studied the effect of Ais on MBD. Only one, an open label, 
reported a statistically significant reduction in MBD. The other two studies with reductions in 
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MBD had no significant changes from the placebo or control treatments or control 
participants. A summary of the Ai findings is reported in Table 1-2.
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women with measurable 
MBD 
50 years or greater 
Exemestane (n) = 49 








6 month follow up: Mean absolute change in PMD from baseline. 
Exemestane = -1.33 (95% CI -5.55 to 2.89; p=0.53); Placebo = 0.22 (95% CI -4.59 to 
5.02; p=0.93). 
12 Month follow up: Mean absolute change in PMD from baseline  
Exemestane = 0.56 (95% CI -3.98 to 5.11; p= 0.80); Placebo = 0.58 (95% CI -4.69 to 
5.86; p = 0.82). 
24 Month follow up: mean absolute change in PMD from baseline 
Exemestane = -0.17 (95% CI -4.34 to 4.00; p=0.93); Placebo = -2.93 (95% CI -8.70 to 
2.85; p = 0.30) the change at 12 months and 24 months did not differ significantly 








with or without a history 




occupying greater than 
25% of the breast  
Letrozole (n) = 44 








The mean (absolute) change in PD from baseline at 12 months was -1.74% (95% CI -
3.85% to 0.37%; p= 0.10) for the letrozole group; placebo was -0.24% (95% CI -4.47% 
to 4.26%). There was no statistically significant change between the two groups. 
The mean (absolute) change in PMD from baseline and 24 months was -0.01% (95% CI 
-3.89% to 3.87%; p = 0.99) for women on letrozole and -1.32% (95% CI -8.86% to 
6.22%; p = 0.71) for women on placebo. 
There was no statistically significant difference between the two groups (p=0.69) and 
after adjustment for age and BMI (p=0.61). 
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Table 1-2 continued 
Author, 
Year 






Chan et al. 
(2013) 
RCT Postmenopausal women 
with stage 0-III hormone 
receptor positive breast 
cancer 
Letrozole (n) = 139 
Exemestane (n) = 120 
Exemestane 
25mg/day for 






There was a statistically significant absolute mean decrease in PMD of -1.9% (SD 4.9%), 
which corresponded to an average percentage decrease of -5.6% (SD 34.7%). 
The baseline PMD of those subjects whose PMD decreased with Ai therapy was 19.4% 
(SD 10.9%), whereas the baseline PMD of those subjects whose MPD was stable or 
increased was 12.6% (SD 8.8%). For those subjects with baseline MPD ≥20%, the 
average absolute decrease in MPD with 2 years of Ai therapy was -4.7% (SD 5.5%), 
whereas for those subjects with baseline PMD <20%, the average absolute decrease in 
PMD was -0.6% (SD 4.0%). This difference was statistically significant (P=0.00001)  






women >60 years with 
histologically confirmed 
hormone receptor-
positive DCIS or stage I-III 
invasive breast cancer  
Anastrozole 





At 12 months compared to baseline, there was a non-statistically significant reduction 








50 years or greater  
Participants also needed 
to meet one or more 
criteria for increased risk 






total dense area 
as well as 
percentage 
density 
At 6 months, 8 women had already shown a decrease in PMD, whereas, at 12 months, 
eleven had a decrease in PMD relative to that at baseline. 3 women exhibited an 
overall absolute increase in PMD during the conduct of the study, including two who 
had decreased at 6 months. The overall difference between baseline and 12-month 
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Author, 
Year 











with increased risk of 
breast cancer 
42 subjects 






– per cent dense 
area compared 
to the entire 
breast area 

















ImageQuant showed a statistically significant reduction in PMD in women taking Ai 
plus HT. 
There were no significant changes in the control group. 
The BI-RAD system was less sensitive to change. 
Vachon, 




NCIC CTG MA-17 Study 
population 
n= 104 
Letrozole (n) = 56 (54%) 




PMD (cumulus) The change in PMD at 1-year post-randomisation was not found to differ between the 
letrozole group (unadjusted mean -0.8%) and placebo group (unadjusted mean -0.6%) 
(p=0.76). No difference between the treatment groups was found in terms of change 
in PMD after adjusting for age, BMI, nodal status, number of tumours, and time on 
tamoxifen. Longitudinal changes in PMD across time were similar in the letrozole 
groups, unadjusted mean -0.69 (95% CI -1.33 to -0.06) and adjusted group -0.68 (-1.34 
to -0.02), p=0.24 and the placebo groups, unadjusted mean -0.18 (-0.84 to 0.49) and 
adjusted group -0.12 (-0.84 to 0.59), p=0.23. 
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Table 1-2 continued 
Author, 
Year 








CCS  Postmenopausal women 
with early-stage breast 
cancer 







PMD (Cumulus) The median difference for all 369 pairs was 0.1% (with 10th percentile of 5.9% and 90th 
percentile of 5.2%). Thus, there was no evidence to conclude that the change in PMD 
over 1 year differs between a case and her matched control whether considering all 
matched pairs (n=369; p = 0.51). 
Of the 387 postmenopausal breast cancer women receiving an average of 10 months 
of adjuvant Ai therapy, 15% experienced at least a 5% decrease in their MBD. This 
increase to 20% for the 280 cases who had a baseline PMD of at least 10%. 
Multivariate analyses showed the likelihood of experiencing a reduction of at least 5% 
in PMD with Ai therapy was increased for cases with a baseline density of 15% or more 
(OR 10.4; 95% CI 4.0 to 26.9; p<0.0001) who had 12 months or more of Ai treatment 
(OR 3.18; 95% CI 1.68 to 6.03; p = 0.0004). The median difference of all 369 pairs was -
0.1% (with 10th percentile of -5.9% and 90th percentile of 5.2%). No evidence that the 
change in PMD over 1 year differs between a case and her matched controls (n=369; 
p=0.51). 
ADH – atypical ductal hyperplasia 
Ai – aromatase inhibitor  
ALH – atypical lobular hyperplasia 
BC – breast cancer 
CCS – case control study 
CI – confidence interval 
DCIS – ductal carcinoma in situ 
HT – hormone therapy 
LCIS – lobular carcinoma in situ 
MDEST – mammographic density estimator 
MPD – mammographic per cent density 
PD – per cent density 
RCT – randomised controlled trial  
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1.2.4.4 Non-steroidal Anti-inflammatory Drugs 
Another class of pharmaceutical intervention that has been examined for its influence on 
MBD are non-steroidal anti-inflammatory drugs (NSAIDs), with five studies having been 
completed analysing their influence on MBD. This class of drug works by inhibiting 
cyclooxygenase, which is an enzyme responsible for catalysing the synthesis of 
prostaglandins. Prostaglandins have been shown to increase aromatase gene expression and 
thereby also increase oestrogen production (Zhao, Agarwal et al. 1996) as well as stimulate 
progesterone synthesis (Elvin, Yan et al. 2000); with both oestrogen and progesterone driving 
cell proliferation. This increase in cell proliferation can lead to an increase in MBD. As NSAIDs 
inhibit cyclooxygenase, this results in a negative feedback loop, which is hypothesised to 
decrease oestrogen and progesterone synthesis; with this having the potential to result in 




Table 1-3: Summary of studies utilising NSAIDs to influence MBD 












26,000 women included in 
the study 
mean age 57.3 (range 40-
89) 
19.6% were under the age 
of 50 
13.9% were over the age of 
70 
 
Current Aspirin Use 
No Aspirin Use 
Use <300 mg/day 
Use >300mg/day  
Between 2012 -
2013 
BI-RADs A greater proportion of aspirin users had BI-RADs 1 and 2 densities than non-
users (72.8 vs 54.3%; p<0.001). 
After adjusting for age, BMI, and ethnicity, there was an independent, inverse 
association between aspirin use and MBD (P trend <0.001). 
Compared with women with scattered fibroglandular tissue, women with either 
heterogeneously (OR 0.84; 95% CI 0.78 – 0.92) or extremely dense (OR 0.73; 
95% CI 0.57 – 0.93) breast were less likely to be aspirin users, while women 
with entirely fat breasts were more likely to use aspirin (OR 1.15; 95% CI 1.04 – 
1.27). 
Women with dense breasts were less likely to be aspirin users than those with 
non-dense breasts (OR 0.82; 95% CI 0.76 – 0.89), this effect was also seen when 
density was analysed as a dichotomised variable (dense = BI-RAD 3 to 4 and 
non-dense BI-RAD 1 to 2). 
A lower likelihood of having dense breasts (BI-RADs 3+4) with increasing aspirin 
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Participants were part of 
two national studies in 
Australia 
Female twin pairs aged 40-
70 years 
Sister pairs aged 40-70 years 
affected by endometriosis 
3286 Participants 
Average age 54.5 (SD 8.4) 
69.2% postmenopausal 
Observed NSAID 
use for a time 
period of 0-5 years 
PMD 
(cumulus) 
After adjusting for covariates, there was no evidence of associations between 
square root PMD and any NSAIDs use, frequency, and duration (all P 
trend >0.2). 
After adjusting for all the necessary covariate, there was no evidence of an 
association between square root PMD and all the respective NSAIDs (all P 
trend >0.06). 
There was no difference in the interpretation of the separate estimates for pre- 
or postmenopausal. 
McTiernan, 




Postmenopausal aged 50 to 
75 years 
Not using menopausal 
hormone therapy, oral 
contraceptives or SERMs for 
the previous 6 months 
Aspirin group (n) = 75 








PMD decreased in women randomized to aspirin by an absolute -0.8% versus 
an absolute decrease of -1.2% in controls (P=0.84). 
There was no statistically significant difference between the two trial arms. 
No observed effect of aspirin on PMD. 
Aspirin also did not affect density differently than placebo when we looked at 
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218 from the BEAN study 
and 1247 from the NCC 
study 
Mean age from BEAN study 
was 43.0 ± 2.8 years and 
58.7 ± 8.6 years for the NCC 
subject 
Mean per cent density was 
46.9% in the BEAN study, 
whereas it was 32.5% in the 
NCC study 
NSAID use PMD 
(computer-
assisted) 
In the combined study population, no statistically significant association was 
observed between any medication use and mean PMD 
Current analysis did not show a statistically significant association between 
NSAID use and PMD in this multi-ethnic study population 
Women with long-term NSAID use had non-significantly higher PMD than non-
users although short-term users had slightly lower PMD than non-users 
Results differed by menopausal status; the trend of higher PMD with a longer 
duration of NSAIDs use was significant among postmenopausal women, PMD 





Table 1-3 continued 
Author, Year Study Design Study Population (age and n) Type of Intervention Outcome 
Measures 
Results 




Women who had two 
routine screening 
mammograms within 9 to 
28 months of each other 
between 1996 and 2006 
Women were excluded if 
they reported ever using 
raloxifene or tamoxifen, 
women with a history of 
breast cancer or women 
who had breast 
augmentation or reduction 
n = 29,284 
NSAIDs 
Continuers – 
women who had 
pharmacy 
dispensing for the 
entire period 
between the two 
mammograms 
Discontinuers were 
women who were 
dispensed a given 
class of NSAID at 
the first 
mammogram but 
had no dispensing 
within 6 months 
before the second 
mammogram 
Non-users did not 
have any pharmacy  
Bi-RADS Non-users of NSAIDs were more likely to be younger, have lower BMI, be never 
users of HRT and have dense breast tissue (BI-RADs category 3 or 4) 
Initiators and continuers of any NSAIDs were more likely to stay not dense than 
stay dense (multivariable OR 1.12; 95% CI 1.04 to 1.20; multivariable OR 1.25; 
95% CI 1.05 to1.49, respectively) 
Point estimates were the same for initiators of non-prescription and 
prescription NSAIDs for staying not dense compared with staying dense 
(multivariable OR 1.11; 95% CI 1.03 – 1.20; multivariable OR 1.11; 95% CI 0.97 
to 1.26, respectively) 
Discontinuers of non-prescription NSAIDs were more likely to decrease density 
compared with non-users (OR 1.40; 95% CI 1.10 to 1.79) compared with staying 
dense. 
There was no association with density change from discontinuation of 
prescription NSAIDs nor was there an association between continuation of 
NSAIDs (either prescription or non-prescription) and density change (increase 
or decrease) 
Continuers of non-prescription NSAIDs were more likely to stay not dense 




Table 1-3 continued 
   fills for a given class 
of NSAID within the 
6 months before 
the second 
mammogram 
 Mixed users of non-prescription NSAIDs were more likely to increase density, 
whereas mixed users of prescription NSAIDs were less likely to increase density 
(OR 1.64; 95% CI 1.08 to 2.48; OR 0.58; 95% CI 0.35 to 0.96, respectively) 
Findings show that initiators and continuers of any NSAID were more likely to 
stay not dense compared with staying dense was limited to women aged <65 
years (OR 1.24; 95% CI 1.12-1.36, OR 1.48; 95% CI 1.14 -1.93 for women ages 
<65 years compared with OR 1.02; 95% CI 0.92 -1.14; OR 1.18; 95% CI 0.93-1.48 
for women aged 65 or greater. 
Overall, there was no reduction in MBD from initiation of NSAIDs by class or 
type of NSAID. There was also no observation that on the increase in MBD from 
discontinuation of use 
CI – confidence interval 
HRT – hormone replacement therapy 
MBD – mammographic breast density 
NSAIDs – non-steroidal anti-inflammatory drugs 
OR – odds ratio 
PMD – per cent mammographic density 
RCT – randomised controlled trial 




The results from the five studies have inconsistent findings. Three of the studies (Maskarinec, 
Urano et al. 2008, McTiernan, Wang et al. 2009, Stone, Willenberg et al. 2012) show no 
association between NSAIDs and MBD, and two studies demonstrate an inverse association 
with NSAIDs and MBD, which may reflect that age and demographics of users of NSAIDs, for 
example non users are younger and have a lower BMI. To date, none of the studies show 
significant evidence that NSAIDs can be used as an intervention for reducing MBD. 
 
1.2.4.5 Metformin and Mammographic Breast Density 
Metformin is commonly prescribed as an oral antidiabetic to patients with type two diabetes, 
and its action is to target the enzyme 5’ adenosine monophosphate-activated protein kinase 
(AMPK). This enzyme induces muscles to take up glucose from the blood and increased the 
body’s insulin sensitivity and improves glycaemic control (Evans, Donnelly et al. 2005, Col, 
Ochs et al. 2012).  
 
Metformin has been found to reduce breast cancer risk (Col, Ochs et al. 2012) and It has been 
hypothesised that a possible pathway for this diabetic treatment and breast cancer risk 
reduction could be via an intermediary effect on MBD. Six studies have examined the 
association between diabetes and MBD (Roubidoux, Kaur et al. 2003, Sellers, Jensen et al. 
2007, Tehranifar, Reynolds et al. 2014, Sanderson, O’Hara et al. 2015, Buschard, Thomassen 
et al. 2017).  
 
In four of the studies, the diabetic women were found to have lower PMD compared with the 
non-diabetic women (Sellers, Jensen et al. 2007, Tehranifar, Reynolds et al. 2014, Sanderson, 
O’Hara et al. 2015, Buschard, Thomassen et al. 2017). One of the studies found a statistically 
significant inverse association between diabetes and MBD in the premenopausal participants 
but not in the postmenopausal women (Roubidoux, Kaur et al. 2003), however this study also 
found that increasing weight also lowered the odds of high MBD. Buschard, Thomassen et al. 
(2017) discovered an inverse association between MBD and diabetes for women who 
controlled their condition with diet or antidiabetic agents, while women taking insulin showed 
a positive association with having mixed/dense breasts; however, this finding was not 
statistically significant. Oskar, Engmann et al. (2018) also found that in women with type 2 
diabetes who used metformin, there was an associated average 5.7% (95% CI -10.27 to -1.19) 
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lower PMD as compared with the group without type 2 diabetes, this association was 
significantly attenuated after adjusting for BMI. 
 
From these six studies, it can be seen that there is a trend for women with diabetes to have a 
lower MBD when compared to women without diabetes. However, this result may have been 
confounded by the BMI of individuals with diabetes, as seen in the Oskar, Engmann et al. 
(2018) and Roubidoux, Kaur et al. (2003) studies.  In addition, one of the studies observed this 
trend for lower MBD in both the women on metformin and the women controlling their 
diabetes through diet. This finding shows that no definitive statements can be made. Still, 
there is potential for another cause or pathway for the decreased MBD seen in diabetic 
women, therefore more research is required to have a greater understanding of the pathways 
or processes contributing to this finding and whether it is just the effect of a larger BMI on 
lower MBD. 
 
1.3 Investigational Product 
1.3.1 Introduction 
As the tissue environment associated with MBD increases breast cancer risk, it can be 
deemed carcinogenic. For this reason, there needs to be interventions that can be provided 
to premenopausal women to reduce the lifelong exposure of the breast tissue to this 
carcinogenic environment (Boyd, Berman et al. 2018). The only widely accepted approach in 
premenopausal women is the previously described intervention of tamoxifen. As tamoxifen is 
a partial agonist of oestrogen, it causes significant alterations in both breast and systemic 
oestrogenic stimulation, the latter resulting in significant treatment-related AEs. These 
treatment-related AEs result in many women not complying with the tamoxifen treatment 
protocol; with compliance as low as 4% in women who are at increased risk of breast cancer 
accepting the use of tamoxifen for chemoprevention (Ropka, Keim et al. 2010).  
 
As reported in Section 1.2.4.3 tamoxifen is the only approach for premenopausal women due 
to the undue effects on Ai on premenopausal women concerning ovarian stimulation. 
However, raising the plasma testosterone will inhibit the rise in GnRH induced from a 
reduction in oestrogen, thus preventing this compensation. As studies suggest that 
testosterone can exert a negative feedback and an inhibitory effect on GnRH secretion 
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(Matsumoto and Bremner 1984, Pitteloud, Dwyer et al. 2008). In the literature it has been 
suggested that there are two separate, more effective approaches than tamoxifen, to achieve 
the breast tissue E/A ratio alteration required to reduce high MBD and thus reduce breast 
cancer risk. Firstly, a combination of testosterone with anastrozole, a third-generation Ai, 
patented as HAVAHT+Ai™ and secondly, anastrozole with enobosarm, a selective androgen 
receptor modulator (SARM). 
 
1.3.2 HAVAHT+Ai™  
HAVAHT+Ai™ is the brand name for the combination of testosterone and anastrozole by 
HAVAH therapeutics Pty Ltd, a South Australian based pharmaceutical company. Within the 
breast, many enzymes convert reproductive pro-hormones, including aromatase and 5α 
reductase (Suzuki, Miki et al. 2006, Vachon, Sasano et al. 2011). These enzymes convert 
testosterone to either 17 β-oestradiol or 5α-dihydrotestosterone (DHT), the latter being ten 
times more potent than testosterone as an androgenic agent. High MBD tissue has been 
shown to contain very high levels of aromatase (Vachon, Sasano et al. 2011) resulting in 
enhanced intracrine production of oestrogen, even in the premenopausal breast (Dabrosin 
2005). 
 
HAVAHT+Ai™ utilizes the overexpression of the enzymatic systems which are especially 
present in high MBD tissue. By using a pharmacological dose of testosterone combined with a 
low dose Ai, the Ai blocks the conversion of testosterone to oestrogen, thereby increasing 
available testosterone in the breast tissue. This increased testosterone is hypothesised to 
shift the E/A ratio towards an androgenic tissue environment, which, as mentioned in section 
1.2.4.1, may be favourable for reducing MBD. In addition, higher serum testosterone results 
in more of this androgen being delivered to the breast; ultimately, the consequence of these 
two actions is a high level of intramammary testosterone being made available for conversion 
to DHT and a reduction in intra-mammary E2. 
 
1.3.2.1 Clinical Rationale 
Glaser and Dimitrakakis (2013) reported using a combination of subcutaneous testosterone 
and anastrozole implant as hormonal replacement therapy in 1,268 women. They 
subsequently undertook a prospective evaluation of breast cancer incidence in this cohort. 
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After 5,642 person-years of follow-up, the incidence of breast cancer in the cohort was 142 
cases per 100,000 person-years; substantially less than the National Cancer Institute age-
specific surveillance, epidemiology, and end results program (SEER) incidence rates 
(293/100,000), the placebo arm of Women’s Health Initiative Study (300/100,000) and the 
never-users of hormone therapy from the Million Women Study (325/100,000)   (Chlebowski, 
Kuller et al. 2009, Jemal, Siegel et al. 2009, Beral, Reeves et al. 2011, Glaser and Dimitrakakis 
2013). This level of reduction in breast cancer risk is comparable to that seen in women who 
achieved a greater than 10% reduction in the MBD in the tamoxifen IBIS-I prevention trial, 
which is one of the seminal tamoxifen trials in the literature (Cuzick, Warwick et al. 2011). 
 
It has also been noted that a very small amount of anastrozole could prevent gynaecomastia 
in men abusing large amounts of anabolic steroids for bodybuilding (Coopman and 
Cordonnier 2012). Therefore, it was hypothesised that using a relatively small amount of 
testosterone, would not result in an elevation in serum E2, due to the presence of a third-
generation Ai.  
 
1.3.2.2 Summary of Rationale for HAVAHT+Ai™ 
The rationale for therapeutic intervention with combination testosterone and Ai 
(HAVAHT+Ai™) in premenopausal women with high MBD as a marker for high risk of breast 
cancer is based on both non-clinical and clinical observations. With the observed ability to 
shift the fulcrum of the E/A ratio to affect a tissue response in the premenopausal breast that 
is similar to that seen in the postmenopausal breast (i.e. a low E/A ratio), which should result 
in a protective effect against breast carcinogenesis.  
 
1.3.3 Anastrozole and Enobosarm 
The second approach that has been hypothesised to reduce oestrogenic drive is using a 
selective androgen receptor modulator (SARM) as an androgen, and again an Ai to block the 
conversion of androstenedione to E1 and testosterone to E2, decreasing both serum and 
breast tissue oestrogen levels (Dowsett, Jones et al. 1995, Miller and Dixon 2001, Geisler, 
Haynes et al. 2002, Ingle, Buzdar et al. 2010).  
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The SARM enobosarm is currently undergoing clinical trials for breast cancer treatment and 
urinary incontinence. Enobosarm appears to be tissue-selective, as it maintains the anabolic 
actions of androgens without causing the androgenic virilising side effects, such as excess hair 
growth, and male type baldness, which are both commonly seen with testosterone usage 
(Gao and Dalton 2007). In addition, it is hypothesised that high levels of SARMs can regulate 
the function of the hypothalamic-pituitary axis, which includes the GnRH from the 
hypothalamus (Gao and Dalton 2007). This regulation will inhibit the hypothalamic-pituitary 
overstimulation; therefore, allowing the Ai to function fully within the breast tissue, without 
having a meaningful impact on other peripheral tissues which are dependent on oestrogens 
action.  
 
1.4 Mammographic Breast Density as a Baseline Risk Marker and Surrogate 
Endpoint for Breast Cancer 
As there is a strong association between MBD and the risk of breast cancer, it allows MBD to 
be used as a biomarker to evaluate the efficacy of interventions that are aimed at reducing 
breast cancer risk. In the design process of clinical trials, one of the most important 
considerations needs to be the choice of outcome measure or measures. These outcome 
measures can be clinically meaningful endpoints that are direct measures of how a patient 
feels, functions and survival rates. Alternatively, indirect measures can be used, an example of 
these are biomarkers, which can include physical signs of disease, laboratory measures and 
radiological tests, which may be considered as replacement (or surrogate) endpoints for 
clinically meaningful endpoints (Fleming and Powers 2012). The changes induced by a therapy 
on a biomarker or surrogate endpoint are expected to correlate and reflect the changes in 
clinically meaningful endpoints (Temple 1995). These endpoints or biomarkers should have 
the properties of being well defined, reliable, easily measurable and interpretable, and be 
sensitive to the effects of an intervention. The sensitivity is usually a leading factor in the 
selection of an outcome measure; thus, enabling a reduction in the size and duration of 
clinical trials, to aid the achievement of significant results (if significant results are to be seen) 
(Fleming and Powers 2012). 
 
Mammographic breast density is one of the most commonly accepted biomarkers for breast 
cancer risk in the literature (Heine and Malhotra 2002, McCormack and dos Santos Silva 2006, 
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Boyd, Guo et al. 2007, Vachon, Van Gils et al. 2007). McCormack and dos Santos Silva (2006) 
found that in symptomatic women, there was little evidence of interactions between other 
risk factors for cancer and MBD. The data they combined suggests that MBD in both women 
of premenopausal and postmenopausal ages is a marker of subsequent breast cancer risk, the 
evidence of whether the strength of this association differs between the ages is not clear. In 
addition, the potential for MBD to guide breast cancer interventions, as opposed to tissue and 
circulating biomarkers (Sivasubramanian and Crew 2013), is particularly appealing since MBD 
significantly correlates with both breast cancer risk and outcomes. Specifically, MBD changes 
in response to some endocrine manipulations, it is non-invasive, and may easily be 
incorporated in the routine care already employed in screening and follow up tools for breast 
cancer; which minimises cost and effort for the patient (Shawky, Martin et al. 2016). 
 
The promise of the research utility of MBD and the lack of timely alternatives have 
encouraged researchers to consider MBD as a surrogate endpoint for risk of breast cancer 
events (Guerrieri-Gonzaga, Robertson et al. 2006). This potential of MBD as a surrogate 
endpoint has lead to MBD being used in clinical trials as a secondary endpoint (Decensi, 
Gandini et al. 2007) and as a primary endpoint (Birmingham 2000); this also including studies 
that are researching Ais in the preventative setting.  
 
1.4.1 Issues with Using Mammographic Breast Density and its Changes as a 
Breast Cancer Biomarker 
Even though there is a strong association between MBD and breast cancer, there are several 
limitations that may affect the clinical and research utility of this outcome measure. Below 
are some of the reasons why this is the case. 
 
1.4.1.1 Imaging Technique and Interpretation 
If MBD has been calculated using a subjective non-automated method (e.g. Wolfe’s system, 
BI-RAD score or breast density estimation using a quantitative area-based analysis), the 
results can have a high intra-and inter-reader variability (Ooms, Zonderland et al. 2007, 
Succurro, Arturi et al. 2010). These methods may also lack the precision to see a significant 
change in MBD, which can lead to type 2 errors (otherwise known as a false negative) and 
insignificant results in clinical trials. Furthermore, type 2 errors can lead to beneficial and 
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viable treatments being unavailable to patients, a loss of development costs and the potential 
loss of profits. The more recent, fully automated volumetric estimation methods (such as 
VolparaDensity™), which show the thickness of dense tissue at each pixel on the 
mammogram (Ng and Lau 2015), are able to show a more objective measurement and may 
reveal more sensitive and significant changes. However, these automated methods also have 
some limitations. A correlation has been established between the increasing image quality of 
mammograms, whether this being due to advancing imaging technologies or with different 
radiographers taking the image, having an effect on the generated results (Kerlikowske 2007, 
Vachon, Pankratz et al. 2007, Lokate, Stellato et al. 2013, Work, Reimers et al. 2014). This 
effect on the results can be problematic in longitudinal studies or when clinically monitoring 
MBD over a period of time, as changes seen in the image and reported on may not reflect the 
changes occurring in the breast tissue. 
 
1.4.1.2 Breast Pain with Mammography 
Breast pain is a prevalent condition amongst women (Masood, Ader et al. 1998) and several 
studies have reported that a women’s fear of pain during mammography is a significant 
barrier to attending mammography for the first time (Kee, Telford et al. 1992, Straughan and 
Seow 1995). In particular, the fear of the pain that will arise from the compression of the 
breast (Straughan and Seow 1995). In addition, two small studies found that pain during first-
round mammography is also a major barrier for re-attendance (Marshall 1994, Elwood, 
McNoe et al. 1998). In these two studies, pain was the highest reason for not re-attending 
breast screening. It could be assumed that this phenomenon may be replicated in research, 
and increase attrition rates in clinical trials, which results in incomplete data acquisition. 
 
1.4.1.3 Ionising Radiation 
A mammogram requires a woman to be exposed to ionising radiation in order to generate the 
image. Ionising radiation itself is a risk factor for breast cancer; a doubling of the risk of breast 
cancer has been observed among teenage girls who were exposed to radiation during the 
Second World War compared to women who weren’t exposed (McPherson, Steel et al. 2000). 
Ionising radiation also increases breast cancer risk later in life, and this is particularly 
problematic when exposure has occurred during rapid breast formation (McPherson, Steel et 
al. 2000). Due to powerful new imaging techniques, the per capita dose of ionising radiation 
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used for medical imaging procedures has increased six-fold between the 1980s and the 
present (Mettler Jr, Bhargavan et al. 2009). In a cohort of 100,000 women, mammographic 
screening that was conducted annually from ages 40 to 55 years and biennially until age 74 
years at a dose of 3.7 milligrays per examination would ultimately induce 86 breast cancers 
(Yaffe and Mainprize 2011). If MBD is to be utilized in premenopausal women as a biomarker 
of risk and therapeutic efficacy, frequent mammograms would be required. This increased 
frequency would also increase the ionising radiation exposure; this should ideally be avoided 
to reduce the risk of radiation-induced breast cancers. 
 
1.4.1.4 Outcome Measure Sensitivity 
The sensitivity to detect the efficacy of an intervention may be inadequate with all MBD 
measures. Cuzick, Warwick et al. (2004) reported that women taking tamoxifen, as a 
chemopreventative agent due to being classified as high breast cancer risk, had an absolute 
mean decrease in MBD of 7.9% (relative decrease of 18.9%) at 18 months and 13.7% (relative 
decrease of 32.7%) at 52 months. Chow, Venzon et al. (2000) also reported that women on 
tamoxifen therapy have an average yearly relative reduction in MBD of 4.3%. Both of these 
studies demonstrate that MBD is either slow to respond to treatment, and elicit measurable 
changes or the intervals typically used for mammography are longer in duration and may not 
show changes in a timely manner. For this reason, to adequately study MBD modifications, 
long, expensive trials are needed to determine the efficacy of chemopreventative agents or to 
determine if women are responders or non-responders to a therapeutic intervention. 
 
1.4.1.5 Conclusion 
These limitations with mammography and the measures of MBD demonstrate that it would 
be beneficial to validate a biomarker for MBD to determine the response within the breast 
tissue to therapeutic interventions. As there is a substantial number of women developing 
either benign or malignant breast disease, there needs to be a focus on research technologies 
and biomarkers that assist in determining the effectiveness in preventative and targeted 
interventions so they can be thoroughly evaluated and brought to market. This biomarker 
needs to be sensitive to detect change, which ideally would be in a timely manner, therefore, 
can benefit research and clinical uses. This timely outcome measure would allow the 
healthcare provider to modify the treatment based on whether the patients are responders 
 40 
or non-responders; which can greatly influence the patient’s management and their health-
related outcomes. Reliable and valid biomarkers are also beneficial regarding health 
economics; the ability to detect the efficacy of a drug allows resources to be applied more 
efficiently and costs to be saved if an intervention is deemed ineffective (Manton, Chaturvedi 
et al. 2006). Traditionally, especially in oncology, but across other medical fields, a patient’s 
response to their treatments have been assessed via a variety of techniques including clinical 
palpation, x-ray mammography, ultrasound and magnetic resonance imaging (Pickles, Gibbs 
et al. 2006). Unfortunately, the assessment of treatment response via these approaches can 
be considered to be a late event, since functional changes occur within the tumour before 
changes in the size of the tumours or global tissue changes (Chenevert, Meyer et al. 2002, 
Hayes, Padhani et al. 2002, Padhani 2002). 
 
1.5 Breast Tissue Elasticity 
Within this research program, it was hypothesised that breast tissue elasticity may be an 
innovative biomarker for MBD and an appropriate method to measure the changes in the 
breast tissue in response to preventative or targeted therapeutic interventions. The following 
sections will introduce the biomechanical properties of breast tissue elasticity to justify the 
reasoning behind the overarching focus of this doctorate thesis.  
 
1.5.1 Tissue Elasticity Basics 
Elasticity is the measure of the stiffness of a material. When a material is deformed, if it 
returns to its original shape, it is deemed to be elastic. The opposite of this is plastic, which is 
when the material is deformed; it maintains the deformed shape. Soft tissues and their 
biomechanical properties are dependent on the inherent molecular building blocks (fat, 
collagen, and fluid-filled sacks) and the microscopic structural organisation of these building 
blocks (Fung 1981). The notion of tissue elasticity has been present in health care for an 
extended period of time and is used in a variety of different settings and professions; the 
common practice of tissue palpation being based on the subjective assessment of tissue 
elasticity (Ophir, Alam et al. 2002). During palpation, the fingers push the tissue downwards 
(displace the tissue) and the pressure receptors on one’s finger can detect the differences in 
the local stiffness (elasticity) of the tissues (Hall 2003). The sensation felt when palpating a 
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hard lesion is due to higher elasticity values locally, which is then lower for areas overlying 
softer surrounding tissues (Hall 2003). Although this is useful in some elements of clinical 
practice, this technique is limited as it is subjective, and the examiner is unable to quantify the 
elasticity values and may not be able to accurately detect elasticity changes. 
 
The Young’s Modulus is an equation used that can describe the change in length of material 
concerning stretching or compressive forces (Garra 2007); this is the classic parameter to 










Within this equation, E is the Young’s Modulus, F is the force, A is the area over which the 
force is applied, ∆& is the change in the length in response to the force and &0 is the original 
length of the object or material (Garra 2007). This means that when an external uniform 
compression (the stress) is applied to a solid tissue, a deformation (or strain) is produced 
inside the tissue. The Young’s Modulus is stress divided by strain and can quantify the tissue 
stiffness; hard tissues have a higher Young’s Modulus and softer tissues a lesser. The unit 
used to quantify the stress and Young’s Modulus is the pascal (Pa, where one Pa= 1 Newton 
per square meter (N/m2) or more commonly the kilopascal (kPa).  
 
1.5.2 Elasticity Imaging 
The predominant method of breast elasticity quantification is a medical imaging technology 
called elastography. Elastography is an encouraging form of medical imaging in health care, as 
inevitably the biomechanical properties of soft tissues are linked to the tissues overall health 
(Sarvazyan, Rudenko et al. 1998) with pathological changes including inflammation, wound 
healing, and cancer being correlated with changes in the tissue elasticity (Ophir, Alam et al. 
2002). As mentioned, the pathological changes can be detected with clinical palpation and 
the sensation of stiffer tissue underlying the clinician’s fingers with malignant masses 
compared to ‘normal’ tissue. Elastography is currently being used for several clinical and 
health research applications for breast tissue and breast conditions. The predominate use of 
elastography for breast tissue currently being presented in the literature is the differentiation 
of benign and malignant breast lesions (Athanasiou, Tardivon et al. 2010, Chang, Moon et al. 
 42 
2011, Berg, Cosgrove et al. 2012, Au, Ghai et al. 2014) with the aim of reducing the number of 
required diagnostic biopsies. It could be argued that this lacks clinical utility as patients may 
predominately want histological findings to confirm or negate a malignant diagnosis. In 
addition, research has also shown that 6.4% to 36.6% of benign or malignant breast masses 
have elasticity values which do not conform to their histopathologic diagnosis. Therefore, 
these elasticity values may lead to false-negative results which can reduce the sensitivity of 
elastography as a diagnostic tool (Chang, Moon et al. 2011, Gweon, Youk et al. 2013, Yoon, 
Jung et al. 2013). There is currently limited research into other clinical application of breast 
elastography (these are listed in Section 1.5.2.3). Still, there is the potential that tissue 
elasticity may be able to be used as a biomarker for the efficacy, and as a prognostic guide for 
therapeutic interventions within the field of breast health. Specifically, the focus of this thesis 
is to discover if breast elasticity has the potential to be used as a biomarker for MBD.  
 
1.5.2.1 Elasticity Imaging: Shear Wave Elastography 
As introduced in Section 1.5, elastography is the term used to refer to the imaging techniques 
that aim to assess tissue elasticity. Elastography depicts the stiffness of the tissues, which 
allows for an objective, quantitative estimation of the tissue elasticity, independent of its 
morphological features. A variety of techniques and approaches have been utilised for 
advancing elastography imaging, regarding both applying the force and for measuring and 
displaying the tissue response (Nightingale, McAleavey et al. 2003, Bamber, Cosgrove et al. 
2013). One measure of elastography is shear wave elastography (SWE), which can be utilised 
to produce two or three-dimensional quantitative ultrasound images (Bamber, Cosgrove et al. 
2013) and can provide a colour coded real-time, objective measure of breast tissue elasticity 
in the unit of the kPa.  
 
Shear wave elastography is conducted by having ultrasound beams generate acoustic 
radiation force impulses, which provide the mechanical excitation through pushing beams 
that deform the underlying tissue of interest. Several of these pushing beams are transmitted 
at different depths, which results in the propagation of transient shear waves. The speed of 
these shear waves is then measured using a scanner with a very fast frame rate, allowing the 
shear waves to be followed in real-time. This is repeated for different lines; allowing a map of 
a region of interest (ROI) to be created from analysing the differences in arrival times and 
calculating the shear wave speeds. A colour-coded image is then displayed on the SWE 
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monitor, and the quantitative data is presented as a measure of shear wave speed in meters 
per second (m/s-1) or converted to the Young’s Modulus and displayed as kPa. Throughout the 
measurement, the shear wave imaging is adjunct to the B-mode image and guidance is 
possible as the same transducer that generates the shear waves also captures their 
propagation (Bercoff, Tanter et al. 2004, Sebag, Vaillant-Lombard et al. 2010, Shiina, 
Nightingale et al. 2015). 
 
1.5.2.2 Elasticity and Shear Wave Elastography in Current Clinical Practice 
It has generally been agreed upon in health care, that no other physical parameters of tissue 
change to as great an extent, with physiological and pathological influence, as does elasticity 
(Manduca, Oliphant et al. 2001). This statement suggesting that SWE has favourable 
properties as an outcome measure in clinical practice. Typical values of breast elasticity have 
been reported (Skovoroda, Klishko et al. 1995, Sarvazyan 2001, Duck 2013) and are 
summarised in Table 1-4. It could be hypothesised that breast pathologies fall within a 
spectrum of tissue elasticity values, with lower elasticity representing normal tissue and 
tissues in a pathological state become stiffer, trending with higher elasticity values.  
  
Table 1-4: Summary of typical breast elasticity values 
Area Type of Soft Tissue Elasticity in kPa 
Breast Normal Fat 18-24 
 Normal Glandular 26-66 
 Fibrous Tissue 96-244 
 Carcinoma 22-560 
 
Currently, as mentioned, the primary clinical and research focus of elastography in breast 
tissue has been differentiating lesions as being either benign or malignant. The current 
research showing that there is a statistically significant difference in elasticity values between 
these two lesions types, in which malignant lesions have a higher elasticity value (Athanasiou, 
Tardivon et al. 2010, Chang, Moon et al. 2011, Berg, Cosgrove et al. 2012, Au, Ghai et al. 
2014). However, Chang, Moon et al. 2011 determined, using a sample of 162 consecutive 
women with 186 needle biopsied or surgically excised lesions, that SWE had a sensitivity of 
88.8% and specificity of 84.9% in differentiating benign or malignant breast lesions. This 
diagnostic accuracy is too inaccurate for SWE to be used independently as a diagnostic tool. 
Additionally, some varieties of malignant tumours have differing biomechanical properties, 
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and as a consequence, elasticity values are more representative of a benign growth (Falou, 
Sadeghi-Naini et al. 2013). Furthermore, patients are becoming more adept at taking control 
of their healthcare and in cases where clinical management decisions and prognosis hinge on 
the pathology of the tissue in question, it is vital to have confidence in the diagnosis. Patient 
and families may not be satisfied with a mass being diagnosed as benign without any 
histological studies on the tissue in question. These factors have the potential to hinder its 
use as a routine clinical application within this area. There are, however, several other 
applications that SWE can be used in for the diagnosis and management of breast health.  
 
1.5.2.3 Alternative Applications of Shear Wave Elastography 
1.5.2.3.1 Shear Wave Elastography and Neoadjuvant Chemotherapy 
One encouraging area for the use of SWE is the prediction and monitoring of the tissue 
response in women undergoing neoadjuvant chemotherapy (NAC) for malignant breast 
lesions. Overall, the response to NAC is variable between patients, with approximately 77% of 
patients having a positive response (termed being a responder) to the therapy (Lee, Seo et al. 
2013). Due to this variability, early evaluation of the response is crucial to improving patient's 
health-related outcomes and decreasing the financial cost of the patient management. During 
treatment, the disease may progress which can result in a delay regarding the optimal time 
for surgical intervention (Jing, Cheng et al. 2016) and early identification of unresponsive 
tumours can lead to prompt changes in the patient management. This, in turn, can lessen the 
unwarranted side effects of unnecessary or non-beneficial drugs and improve the prognosis 
of the patient (Jing, Cheng et al. 2016). Furthermore, the formulation of a management plan 
with a validated biomarker to predict/determine an individual’s response to NAC is becoming 
a priority in breast cancer research (Cho, Im et al. 2016). Recent studies have highlighted the 
importance of early detection of patients not responding to NAC, as it has been demonstrated 
that delivering radiation and surgical intervention for chemotherapy-resistant tumours can 
result in a survival rate of 46% at five years (Huang, McNeese et al. 2002). 
 
Currently, clinical examinations in combination with traditional imaging techniques such as 
computer tomography (CT), MRI and mammography may be used to predict and evaluate the 
response of the tumour to NAC (Hylton, Blume et al. 2012, Falou, Sadeghi-Naini et al. 2013, Li, 
Arlinghaus et al. 2014, Jing, Cheng et al. 2016). These methods are often unable to provide an 
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objective evaluation of the response during the early phase of treatment, as previously 
reported in Section 1.4, functional changes relating to microscopically evident tumour death 
may occur before macroscopic or global tissue changes (Falou, Sadeghi-Naini et al. 2013). In 
addition, methods of cell death induction, such as chemotherapy, can substantially alter the 
biomechanical properties of the malignant tissues during a course of treatments (Wang, Guo 
et al. 2018). This is mainly because tumour formation and the degeneration in response to 
treatment exhibits significant interactions, e.g. fibrosis and inflammation with stromal cells 
(Mueller and Fusenig 2004, Schedin, O’Brien et al. 2007); having the ability to change the 
biomechanical properties of these cells. Furthermore, results from animal laboratory studies 
have indicated that the stiffness of a tumour is related to the tumour progression and 
chemotherapeutic resistance (Butcher, Alliston et al. 2009). Therefore, with SWE’s ability to 
objectively provide a measure of the tumour stiffness, it allows the potential for predicting 
and evaluating the response to NAC in individuals with breast cancer (Jing, Cheng et al. 2016). 
Shear wave elastography is also less expensive than other imaging techniques, and it does not 
require the use of contrast agents, which is well suited for the multiple scans that are 
necessary to monitor this form of treatment. On this basis, SWE has physiological merit to 
assess the effectiveness of NAC between responding and non-responding malignant tissues, 
with an early time frame of a few weeks, following the start of the therapy. 
 
To date, a few studies have investigated this utility for alternative elastography imaging 
techniques and in more recent times SWE. Falou, Sadeghi-Naini et al. (2013) using strain 
elastography (an alternative form of elastography), evaluated the responses to NAC in 15 
women with locally advanced breast cancer. Within this study, the authors found that the 
strain ratio of the tissue stiffness was the best predictor of the response to NAC treatment. 
The findings also revealed, that after the baseline assessment and after the second cycle of 
NAC, the tumours of those who responded to treatment were significantly softer than those 
of non-responders. However, this study also demonstrated that with a rare form of cancer 
(mucinous cancers), the SWE measurements lack sensitivity, this being due to the 
biomechanical properties of the growth; in particular the abundant extracellular mucin (Falou, 
Sadeghi-Naini et al. 2013). 
 
Fang and Yang (2019) also using strain elastography conducted a study to explore the value of 
real-time tissue elastography in predicting the efficacy of NAC. The study had two groups of 
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women; one group had a significant response to NAC (the responders) and one who did not 
have a significant response (the non-responders). The authors reported that grayscale 
ultrasound was not able to accurately evaluate the efficacy of NAC. It was also found that the 
elasticity of the tumour decreased in both groups up to 2 weeks. At 2 weeks the non-
responders tumour elasticity plateaued as did the size of the tumour, the responder's 
elasticity continued to decline. The results also showed that the elasticity changes closely 
related to the size and state of the lesion, which demonstrates that the elasticity values post 
the two-week mark may be able to assist in determining if a woman is going to be a 
responder or a non-responder to the treatment (Fang and Yang 2019). 
 
Similarly, Jing, Cheng et al. (2016) conducted a study which examined the use of SWE for the 
early prediction of the response to NAC in women with breast cancer. The authors found that 
in relation to the baseline values of the tumour stiffness following two cycles of NAC, the 
stiffness was decreased and the change was significantly different in the responders (mean 
elasticity after the second cycle: 50.18 kPa ± 25.01 kPa) but not in the non-responders (mean 
elasticity after the second cycle: 80.37 kPa ± 27.18 kPa). In addition, there was a significantly 
greater change in tumour stiffness after the second cycle of NAC in the responders (-42.19% ± 
19.99%) than in the non-responders (-23.59% ± 8.22%). Whether it was assessed at the 
baseline measurement or after the second cycle of NAC, there was a significantly lower mean 
tumour stiffness in the responders (baseline kPa 82.76 ± 47.43) compared to the non-
responders (baseline kPa 99.77 ± 45.45). The results showed that the area under the receiver-
operated curve for tumour stiffness was 0.80 (P<0.001) which indicated that within this study, 
tumour stiffness represented a useful tool for predicting and determining the neoadjuvant 
response of the breast cancer to the therapy. Ma, Zhang et al. (2017) had similar findings 
within their research with invasive breast cancers, reporting that tumours with lower stiffness 
values at baseline displayed better NAC responses and more frequently favourable 
pathological responses compared to stiffer tissues, and after the second cycle of NAC SWE 
could provide early prediction of the pathological resistance to NAC with the stiffness of the 
tumours.  
 
Supporting this finding, Evans, Armstrong et al. (2013) found that there was a statistically 
significant relationship between the baseline (pre-treatment) tissue elasticity with the 
response of the invasive breast cancer to NAC and subsequently the levels of residual cancers. 
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The findings were demonstrating that the stiffer tissues measured at baseline responded to 
NAC to a lesser extent than softer tissues. These results follow previous results by Hayashi, 
Yamamoto et al. (2012), who used strain elastography in 55 patients who received NAC for 
breast cancer and found that there was a close association between the tumour stiffness and 
the response to NAC in breast cancers. The findings demonstrating that relatively soft 
tumours were highly responsive to NAC and more frequently displayed complete resolution 
compared with stiffer tumours (complete resolution rate 50 vs 14%, respectively). 
 
Finally, Lee, Chang et al. (2015) evaluated the accuracy of SWE in the detection of residual 
breast cancer after NAC and discovered that women with residual cancers showed 
significantly higher maximum elasticity values (mean kPa 116.0 ± 74.1) than women who 
achieved complete resolution (mean kPa 26.4 ± 21.0). Additionally, Lee, Chang et al. (2015) 
found that the diagnostic performance was highest when using MRI compared to B-mode 
ultrasound and SWE; however, the difference between MRI and SWE was not statistically 
significant. In addition, SWE significantly improved the diagnostic performance of B-mode 
ultrasound regarding the detection of residual breast cancers.  
 
These studies demonstrate that responders to NAC may initially have softer tumours and 
show more significant changes in tissue elasticity values through the treatment process than 
the non-responders. Additionally, individuals with softer tumours are proving to have a higher 
likelihood of having complete resolution with treatment than those with stiffer tissues. The 
early stages of research are showing that SWE has the potential to be a viable and robust 
addition and a promising biomarker for the research and clinical practice of determining the 
prediction and response of breast tumours to NAC. 
 
1.5.2.3.2 Shear Wave Elastography in Breast Inflammation 
Mastalgia (or breast pain), is a common clinical occurrence in most women during their 
reproductive life and occasionally after menopause. In approximately 15-20% of women, 
breast pain is of a severity to impact lifestyle and requires intervention (Scurr, Hedger et al. 
2014). One of the causes of breast pain appears to be related to hormonally induced 
inflammation (Fentiman, Caleffi et al. 1988); to overcome this inflammation, the underlying 
hormonal imbalance needs to be managed. In similar clinical circumstances as NAC, SWE may 
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be a viable biomarker to monitor the inflammatory changes within the breast tissue. It is 
hypothesised that inflammation leads to a greater elasticity. Hence, as the inflammation 
decreases theoretically, the pressure within the tissue should decrease, resulting in lower 
elasticity values as recorded by SWE. 
 
To date, SWE has been used in two studies on patients with mastitis, which is an 
inflammatory condition of the breast that may either be infectious or non-infectious in origin 
(Sousaris and Barr 2016). Typically, women suffering from mastitis have oedema and breast 
pain caused by infectious or chemically induced inflammation. Sousaris and Barr (2016) 
reviewed six cases of biopsy-proven mastitis; the results indicated that the mastitis could 
either have a central soft area (the centre of an abscess) and a stiff outer region (caused by 
oedema and inflammation) or just the stiff outer region. The stiff outer region of the tissue 
has a stiffness range of 35-120 kPa with a mean value of 72.0 kPa, which is higher than the 
elasticity range of disease-free breast tissue, as stated in Section 1.5.2.2. Furthermore, Ko, 
Jung et al. (2014) within a study on non-malignant breast lesions included one case of chronic 
mastitis, again using SWE, found this tissue also had an elevated mean stiffness of 59.3 kPa.  
 
These results are based on a small sample size; therefore, correlations and the interpretation 
of the data needs to be done with caution. However, these preliminary findings demonstrate 
that elasticity values may trend higher in breast tissue where inflammation is present. With 
future research, looking at a greater sample size, it is possible that SWE could have promise to 
be used as a biomarker for mastitis or other inflammatory conditions, to determine the 
therapeutic efficacy of interventions to reduce general inflammation and hormonally driven 
breast inflammation in the clinical and research setting.  
 
1.5.2.3.3 Shear Wave Elastography in Breast Augmentation, Mastectomy and 
Reconstruction Surgery  
Shear wave elastography may also have clinical utility for the evaluation of contractures, pain 
and inflammation in relation to breast augmentation surgery. Following breast augmentation 
surgery, it is normal for a capsule to form due to the natural inflammatory response to a 
foreign object entering the body, such as a breast implant. If this happens beyond the typical 
state peri-implant fibrosis and capsular contraction may occur. This can lead to tissue 
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distortion, hardness, and pain (Basu, Leong et al. 2010). Currently, the Baker scale, which is a 
subjective scale based on a clinical evaluation of appearance, texture and tenderness, is used 
to classify the severity of the capsular contraction (Basu, Leong et al. 2010). As the 
biomechanical properties of the breast tissue changes with capsular contraction; tissue 
elasticity may be a viable method of objective evaluation for this condition. This evaluation 
could be beneficial as up to 30% of patients with the two highest grades of contractures 
potentially require surgery (Basu, Leong et al. 2010), early assessment and the ability to 
objectively detect excessive capsular formation would be of great benefit to improve clinical 
practice and patient outcomes. 
 
Three papers to date have been published in the field of SWE in the evaluation of breast 
capsular contractures. A two-person case study by Rzymski, Kubasik et al. (2011) reported 
that one of the cases, who had a Baker III contracture in their left breast and a Baker I 
contracture in their right breast, showed that post-implant replacement and capsulectomy, 
there was a decrease in tissue elasticity in the breast area (left breast 27.3 reduced to 20.5 
kPa and right breast 15.3 reduced to 14.9 kPa). The second case, who had a Baker I 
contracture in their left breast and Baker III/IV in their right showed an increase in elasticity 
values (left breast 12.5 increased to 23.5 kPa and right breast 17.6 increased to 22.4 kPa). This 
patient, however, in contrast to patient one, had an additional 85ml of fluid inserted into 
their left breast and 95ml of fluid inserted into the right; which may have influenced the 
elasticity values. These findings demonstrating that within these two subjects the Baker III 
contractures had higher elasticity values than the Baker I contractures however the findings 
indicate that post capsulectomy and implant replacement the values can be influenced by the 
fluid volume of the implant if not kept consistent. Rzymski, Kubasik et al. (2011) also reported 
that almost all tissues (fatty, glandular, fascia, and muscles) have elasticity values 2-4 times 
higher on day ten after primary breast augmentation and tend to decrease on day 20. Further 
research could be conducted to assess if the changes in elasticity with the healing process 
would allow potential tracking of this elasticity to detect complications during recovery from 
this type of surgery. 
  
Sowa, Yokota et al. (2017) also used SWE for the measurement of capsular contracture after 
breast implant reconstruction, with 20 patients (27 implants) the authors reported that 
elasticity values were strongly correlated to the Baker Score with a correlation coefficient of 
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0.81, and the reproducibility showed an intra-class correlation coefficient of 0.88, which is a 
high-reliability score. This correlation coefficient demonstrates that within this study, SWE 
was a highly reproducible method of detecting the degree of capsule contracture, deeming it 
a potentially useful clinical tool post breast reconstruction, if being done by the same 
clinician. 
 
Furthermore, Rzymski, Kubasik et al. (2011) observed that when using SWE there were 
statistically significant changes in all breast tissues with the highest values being recorded on 
day seven post-surgery; this elasticity was then found to decrease on day 14. The authors 
reported that between days four and ten there were significant correlations between the 
visual analogue scale (VAS) for pain and the capsular elasticity in the lower quadrants; this 
correlation was not found within the glandular tissues in the same quadrant. However, in the 
upper quadrants, where the glandular tissue concentration is higher, there was a significant 
correlation with the VAS for pain during days 6-10. Fatty tissue stiffness did not correlate with 
breast pain in any quadrant of the breast. Capsular contracture has been associated with a 
higher risk of reported pain; the authors have hypothesised that the cause of the pain was 
likely to be inflammatory. An objective tool, whether elasticity imaging or histological findings 
of inflammation, could demonstrate the bridging link between the two (Sperlingl, Høimyrl et 
al. 2011).  
 
In addition to capsular contraction, SWE has been used in a small study by Sowa, Numajiri et 
al. (2015) to investigate fatty stiffness post breast reconstruction following a mastectomy, as 
fatty induration is associated with necrosis and is a common complication in breast 
reconstruction with autologous flaps after mastectomy (Kroll 2000, Casey, Rebecca et al. 
2013). Currently, within the clinical setting, palpation is used, which is a subjective measure 
and, as previously mentioned, is unable to be quantified. The authors found that in one case 
study, in the superior medial area of the breast, fatty tissue showed increased stiffness (mean 
22.3 kPa) when compared to the lateral area (mean 6.6kPa). Furthermore, another case who 
complained of a breast mass with pain and stiffness had a significantly higher SWE reading 
(mean 107.4 kPa) in the superior medial area compared to the lateral area (13.9kPa) finding 
that the breast mass was associated with fat necrosis.  
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These preliminary results based on small sample size suggest that with further research SWE 
may be able to facilitate post-surgical care and management and may be accepted into 
clinical practice post breast augmentation or reconstruction. Although still in the early phase 
of research, there is potential that SWE will be able to be used to offer new possibilities of 
postoperative follow up; determining if elasticity values fall in the expected timeline or 
remain stagnant or continue to increase can provide clinicians with valuable information 
leading to the prediction that unwanted complications may be occurring and provide the 
opportunity for early intervention. 
 
1.5.2.3.4 Breast Elasticity as an Alternative Biomarker of Mammographic Breast 
Density 
Breast elasticity, as measured by SWE, may have the potential to be used as a biomarker to 
determine the effectiveness of therapeutic and preventative interventions which are aimed at 
reducing breast cancer risk. Breast elasticity also has the potential to be a correlated measure 
of baseline MBD, which may be beneficial to guide clinical reasoning and decision making for 
referring a patient to begin mammography screening. It is presently known that breasts that 
have a high MBD are associated with extensive collagen, a greater number of cells, increased 
extracellular matrix (ECM), including the increased expression of the proteoglycan lumican 
and decorin (Alowami, Troup et al. 2003, Li, Sun et al. 2005, DeFilippis, Chang et al. 2012). 
These proteoglycans can bind growth factors, which contribute to the mechanical integrity of 
tissues; influencing the elasticity and the behaviour of the breast tissue (Butcher, Alliston et 
al. 2009). It has also previously been reported that high MBD tissue shares similar 
characteristics to malignant breast tissue, specifically fibrodense areas having high ECM 
content and low adipocytes (DeFilippis, Chang et al. 2012). This abnormal ECM deposition can 
lead to tissue stiffening, causing greater tissue elasticity as seen in breast cancer (Bonnans, 
Chou et al. 2014).  
 
Additionally, the tissue associated with increased MBD has some similar properties to 
individuals with hepatic fibrosis; a resultant condition of the healing response to repeated 
liver injury (Friedman 2003). The process of hepatic fibrosis is associated with the liver’s 
inflammatory response and the deposition of ECM. If the hepatic injury persists, the liver's 
ability to regenerate begins to fail, and the usual generation of hepatocytes are substituted 
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with abundant ECM, including fibrillary collagen (Bataller and Brenner 2005). The 
accumulation of the abundant ECM in hepatic fibrosis can result from two pathways; an 
increased synthesis and from decreased degradation of ECM (Arthur 2000); with the 
decreased activity of ECM-removing matrix metalloproteinases (MMPs) mainly being due to 
an overexpression of their specific inhibitors (tissue inhibitors of metalloproteinase (TIMP) 
(Bataller and Brenner 2005). Both of these pathways have also been seen in 
mammographically dense tissue with Guo, Martin et al. (2001) demonstrating that within high 
MBD tissue, there is increased TIMP-3 expression and a positive association with 
metalloproteinase-3 (MMP-3).  
 
Additionally, isoprostanes and malondialdehyde (MDA), both of which are in vivo biomarkers 
for oxidative stress, have demonstrated to be mediators for the increased cell proliferation 
and collagen production in hepatic fibrosis (Comporti, Arezzini et al. 2005). Oxidative stress 
occurs when there is an imbalance between reactive oxygen species (a collective term for 
oxygen free radicals or non-radical oxidising agents that can be converted easily into radicals 
(Halliwell and Gutridge 1989)) production and the antioxidant defences, which can lead to 
damaged DNA, protein and lipid molecules. Mutagenesis can occur due to DNA damage, and 
this can increase the risk of cancer (Valko, Izakovic et al. 2004). Inflammation has also been 
linked to reactive oxygen species, and maybe another reason oxidative stress relates to 
cancer (Pathak, Sharma et al. 2005). In three independent studies (Boyd and McGuire 1990, 
Boyd, Connelly et al. 1995, Hong, Tang et al. 2004), a positive association was found between 
MBD and 24-hour urinary MDA excretion. Additionally, in both pre- and postmenopausal 
women, representing a range of MBDs (Boyd, Connelly et al. 1995, Hong, Tang et al. 2004), 
adjusting for differences in age, BMI and waist circumference, urinary MDA excretion was 
23% to 30% higher in the highest quartile of MBD when compared with the lowest MBD 
quartile.  
 
Liver fibrosis is a response to tissue injury and the inflammation associated with the injury 
(which as mentioned previously increases oxidative stress). The processes involved are the 
proliferation and activation of fibroblasts, with an accumulation of ECM the resultant effect 
(Hinz 2007). As there are strong similarities between hepatic fibrosis and MBD, it could be 
hypothesised that breast elasticity may be increased in women with high MBD. As the 
FibroScan® (transient elastography) began as a biomarker and then a diagnostic tool for liver 
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fibrosis, there is potential that breast elasticity may be able to do the same for MBD. If this 
research does find an association between the two, breast elasticity as measured by SWE may 
be able to be used as a biomarker and detect changes in the breast tissue, which may also be 
at an earlier time, than mammographic imagery. Thus, potentially providing useful 
information again concerning treatment responses and monitoring breast cancer risk. 
 
1.6 Introduction Summary 
Through this research program, the performance characteristics of using SWE to measure 
whole breast elasticity, in relation to the clinical utility and psychometric properties for the 
use of breast elasticity as a biomarker for MBD, will be examined. This research program will 
also establish and describe a user-friendly, reliable method for using the SWE ultrasound for 
this indication. The benefits of conducting and reporting this evidence are firstly; it will begin 
to develop the body of evidence regarding the validation of breast elasticity as a biomarker in 
health research, in particularly pharmacology research. In addition, by providing the 
methodology for using SWE for this indication, researchers who wish to conduct future 
research in this field will not need to establish a reliable method for collecting the SWE data, 
which can save time and resources. Furthermore, by using a consistent methodology for SWE, 
evidence can be easily compared and synthesised to further validate breast elasticity as a 





Chapter 2 Research Aims, Objectives and Structure 
2.1 Aims 
The primary aim of this research program is to determine if whole breast elasticity, as 
measured by SWE, can be used as a biomarker for MBD.  
A secondary aim of this research is to determine a reliable and valid protocol when using SWE 
to measure whole breast elasticity in order to increase research and clinical implementation. 
 
2.2 Objectives 
1. Determine the efficacy of hormonal interventions to reduce mammographic breast 
density 
The initial objective of this research was to determine the efficacy of HAVAHT+Ai™ and the 
combination of enobosarm and anastrozole in their ability to reduce MBD. This was 
conducted to provide baseline data regarding the effect of these interventions on the breast 
tissue, to show that there are physiological changes occurring in the primary endpoint of 
interest.  
 
2. Determine the effect of these two, hormonal combination on breast elasticity and 
whether these correlate with changes to mammographic breast density 
The second objective of this research was to determine if the two hormonal combinations 
(HAVAHT+Ai™ and the combination of enobosarm and anastrozole) can influenced breast 
elasticity, as measured by SWE. 
 
3. Determine the normative values and behaviour of breast elasticity in healthy women 
not on any form of hormonal intervention 
The third objective was to analyse the average breast elasticity of healthy women who were 
not on hormonal interventions that may influence the elasticity values. This was done with 
repeat measures to analyse the behaviour and fluctuations of the breast elasticity and 




4. Determine a valid and reliable protocol for the shear wave elastography machine to 
measure whole breast elasticity 
The fourth objective was to determine if there is a reliable and precise method to determine 
the whole breast elasticity as measured by SWE as to date there is no consistent protocol to 
be used in clinical and research purposes. 
 
2.3 Research Plan with Associated Objectives 
The research plan and associated objectives are presented in Figure 2-1 below.  
 
Study 1 
The effect of a subcutaneous combination 
of Testosterone (T) and anastrozole (Ai) 
(HAVAHT+Ai™) on volumetric 
mammographic breast density (MBD); an 
open labelled cohort study 
 
Study Design: Cohort analysis of patient database of women  
Intervention: HAVAHT+Ai™ 




Pharmacodynamics (breast tissue 
elasticity) of combination subcutaneous 
Testosterone (T) and anastrozole (Ai) 
(HAVAHT+Ai™) in premenopausal women 
with high Mammographic Breast Density 
Study Design: Nestled study within a single dose, single 
centre, open label non-randomised pharmacokinetic trial of 
HAVAHT+Ai™ 
Intervention: HAVAHT+Ai™ 
Outcomes: %VBD and TFV as determine by VolparaDensity 
and breast elasticity (kPa) measured by SWE 
Study 3 
Anastrozole and GTx-024: The effect of an 
aromatase inhibitor and selective 
androgen receptor modulator on 
Mammographic Breast Density and Breast 
Elasticity in premenopausal women 
Study Design: 12 month, single centre, open label, pilot trial 
of women with high MBD 
Intervention: anastrozole and GTx-024 (enobosarm) daily 
Outcomes: %VBD and TFV as measured by VolparaDensity™ 
and breast elasticity (kPa) measured by SWE 
Objectives: 1,2  
Study 4 
Does region of interest (ROI) size affect 
the breast elasticity and coefficient of 
variation (CV) of a dataset analysing the 
average breast elasticity of women on a 
hormonal chemopreventative therapy 
Study Design: secondary analysis using data from Study 2 
Intervention: N/A 
Outcomes: breast elasticity (kPa) as measured by SWE, 
coefficient of variation 
Objectives: 4 
Study 5 
The behaviour of breast elasticity as 
measured by Shear Wave Elastography in 
healthy women in regard to menstrual 
cycle changes, repeatability and intra-
rater reliability 
Study Design: 1.5 month reliability study with 4 repeat 
measures, monitoring stage of menstrual cycle with healthy 
women not on hormonal interventions 
Intervention: N/A 
Outcomes: Breast Elasticity (kPa) as measured by SWE, intra-
rater reliability of SWE 
Objectives: 3,4  
Figure 2-1: Research plan and associated objectives 
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Chapter 3 The Effect of a Subcutaneous Combination of 
Testosterone (T) and Anastrozole (Ai) (HAVAHT+Ai™) on Volumetric 
Mammographic Breast Density (MBD); an Open Labelled Cohort 
Study. 
3.1 Background 
As reported in section 1.2, MBD is a major, independent risk factor for breast cancer and 
there are limited interventions that have shown to be efficacious at reducing MBD, 
particularly in a premenopausal cohort as Ai's are contraindicated in this population. The 
overall primary aim of this thesis is to determine if breast elasticity can be used as a 
biomarker for MBD, especially in clinical trials due to its hypothesised sensitivity and clinical 
utility. In order to determine if the breast elasticity changes are correlating with the changes 
in MBD, it needs to be established that the hormonal interventions we are using in the 
subsequent clinical trials in this thesis are effective are reducing MBD.  
 
This chapter is an analysis of clinical practice records of women who have been given the 
investigational product of HAVAHT+Ai™. Six hundred fifty-two women who attended Wellend 
Health Pty Ltd, Adelaide, South Australia, received HAVAHT+Ai™ as a subcutaneous implant 
every three to four months, were evaluated for MBD changes, as determined by 
VolparaDensity™ analysis software. One hundred forty-two of these women had two or more 
mammograms within the analysis, and a restricted analysis set (RAS) of 89 of these women 
were compared with a matched cohort 65 women undergoing mammographic screening for 
high risk of breast cancer but did not receive any hormonal therapy. 
 
3.2 Objectives 
The primary objective of this cohort analysis is to determine whether the administered 





3.3 Publication Manuscript 
The statement of authorship for the following publication manuscript is presented in 
Appendix 1.  
 
The Effect of a Subcutaneous Combination of Testosterone (T) and Anastrozole (Ai) 
(HAVAHT+Ai™) on VolparaDensity™ Automated Volumetric Mammographic Breast Density 
(MBD); an Open Labelled Analysis of Clinical Practice Records. 
 
1st author: Daniella Dougherty, The University of Adelaide 
2nd author: Suzanne B Good, Wellend Health Pty Ltd 
4th author: Professor Paul Rolan, The University of Adelaide 
5th author: Nicholas J Birrell, HAVAH Therapeutics Pty Ltd; Wellend Health Pty Ltd 
6th author: Dr Stephen Birrell, Havah Therapeutics Pty Ltd; Wellend Health Pty Ltd 
sb@havahtx.com 
 
All correspondence will be through Stephen Birrell 
Email: sb@havahtx.com 




Mammographic breast density (MBD) is a modifiable risk factor for the development of breast 
cancer. An alteration in the oestrogen/androgen (E/A) ratio in favour of an androgenic 
environment may reduce MBD. It is hypothesised that HAVAHT+Ai™ may cause this 




Women who received HAVAHT+Ai™ subcutaneous implant had their percentage volumetric 
breast density (%VBD) and absolute fibroglandular volume (FGV) measured by 
VolparaDensity™. Mixed model analyses were used to examine the drug dose relationship 
with %VBD and FGV. A restricted analysis set (RAS) of 89 women were compared with a 
matched control cohort of 65 women, their change from baseline in %VBD and FGV were 





142 women were included in the analysis. Larger decreases in MBD were observed with 
accumulated testosterone (T) dosing of over 500mg compared with patients with <500mg. 
Change from baseline in %VBD by cumulative T dose, the largest reductions were -2.26% 
(95% CI -4.23% to -0.29%; p=0.00251) to -2.80% (95% CI -4.66% to -0.95%; p=0.0035) for the 
500 – 700mg and 700mg+ strata, respectively. For change in baseline in FGV a cumulative T 
dose of 700mg+ demonstrated a reduction of -22cm3 (95% CI -39.48 to -4.51; p=0.0142) and -
36.21cm3 (95% CI -59,71 to -12.71; p=0.0029), at years 2 and 3 respectively. No significant 




A cumulative dose of greater than 700mg of T and 30mg of Ai over 2 to 3 years, achieved a 
similar reduction in MBD as has been demonstrated with tamoxifen with better tolerability. 
 
Introduction 
Breast cancer is the most commonly diagnosed cancer and the leading cause of cancer death 
in women (Bray, Ferlay et al. 2018). Worldwide, there were approximately 2.1 million newly 
diagnosed female breast cancer cases in 2018, accounting for almost 1 in 4 cancer cases 
(Bray, Ferlay et al. 2018). In 2020, it has been estimated that there will be 279,100 new breast 
cancer cases in the United States alone (Siegel, Miller et al. 2020). The initiation and 
promotion of most, if not all, breast cancers are highly dependent on female reproductive 
hormones. Thus, manipulation of these hormonal pathways has been used to improve 
therapeutic outcome since the 1890s. Subsequently, anti-oestrogen therapies used for the 
treatment of breast cancer were shown to reduce the incidence of new breast cancers in the 
contralateral breast (Group 2005, Group 2011). Oral tamoxifen is the only widely accepted 
intervention registered for chemoprevention of breast cancer. However, tamoxifen has both 
agonistic and antagonistic impact on tissue-specific estrogenic effects, which results in 
significant adverse effects and contributes to a poor compliance rate.  Approximately just 4% 
of women at increased risk of developing breast cancer utilise tamoxifen intervention (Ropka, 
Keim et al. 2010). Other treatments which appear to reduce the incidence of breast cancer, 
but have not achieved registration for this indication, include raloxifene, anastrozole and 
retinoids. Thus, there is an urgent need for new hormonal strategies to make 
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Mammographic breast density (MBD) is the ratio of glandular/stromal to fatty tissue within 
the breast and is a major modifiable risk factor for breast cancer. In a meta-analysis of 42 
studies, McCormack and dos Santos Silva (2006) found that MBD was strongly associated with 
an individual’s breast cancer risk, and MBD has been proposed as a potential surrogate 
endpoint of the efficacy of hormonal interventions (Shawky, Martin et al. 2016). It has been 
demonstrated that accumulative exposure of the breast to high MBD tissue is directly 
correlated with breast cancer risk (Cuzick 2003, Boyd, Berman et al. 2018), one prevention 
trial has demonstrated that reducing MBD can lead to a decrease in breast cancer risk. Cuzick, 
Warwick et al. (2011) reported that women treated with tamoxifen who had more than 10% 
absolute reduction in breast density (as visually assessed by reporting total breast area 
composed of dense tissue on an 0-100% scale) experienced a 63% decrease in breast cancer 
risk, as compared to no change in breast cancer risk in the placebo group and the women 
who did not respond to tamoxifen. Furthermore, many studies have evaluated the influence 
of tamoxifen associated MBD declines on breast cancer outcomes in the adjuvant setting (Li, 
Humphreys et al. 2013, Nyante, Sherman et al. 2015, Mullooly, Pfeiffer et al. 2016, Shawky, 
Martin et al. 2016). In particular, Li, Humphreys et al. (2013) reported, after a 15 year follow 
up, that women with breast cancer treated with tamoxifen as adjuvant therapy who 
experienced a reduction of more than a 20% relative reduction in absolute dense area in cm3 
had a 50% reduction in their breast cancer mortality, again compared to women who didn’t 
respond to tamoxifen. 
 
Therefore, reducing MBD in women at high risk of breast cancer may be of considerable 
benefit. There is usually a substantial reduction in MBD following menopause (Boyd, Martin et 
al. 2002) and this reduction correlates with the alteration in the oestrogen/androgen (E/A) 
ratio. The breast responds to this alteration in the E/A ratio (McNally and Stein 2017), such 
that when there is a shift towards a more androgenic environment, there is a substantial 
reduction in MBD. Therefore, it is hypothesised that pharmacologically enhancing this natural 
trend towards a more androgenic environment will result in a greater reduction in MBD, and 
this can be an effective way of lowering breast cancer risk. 
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A subcutaneous implant (HAVAHT+Ai™) containing testosterone (T) (80mg to 120mg), and the 
aromatase inhibitor (Ai) anastrozole in the dose range of 2 to 8mg, has been used in clinical 
practice as a custom pharmaceutical in Australia and the United States (Birrell, Butler et al. 
2007, Glaser 2010). Combining T and anastrozole was initially used as a non-estrogenic 
treatment for the management of anastrozole-induced arthralgia and menopausal symptoms 
in women with breast cancer (Birrell and Tilley 2009, Glaser, York et al. 2014). The 
observation was made that this combination significantly reduced breast pain, which is closely 
linked to MBD (Birrell and Tilley 2009). As high MBD tissue has been demonstrated to have 
very high levels of aromatase (Vachon, Sasano et al. 2011), which results in high levels of 
tissue estradiol (even in the premenopausal breast) (Dabrosin 2005), the authors 
hypothesised that combining a pharmacological dose of T with an ultra-low dose of 
anastrozole would be adequate to shift the E/A ratio towards an androgenic environment. 
Subsequently higher levels of T would be made available for the 5α-reductase shift to the 
potent androgen 5α- dihydrotestosterone (5α-DHT). This intra tissue dynamic, would 
substantially change the tissue environment from an estrogenic to an androgenic 
environment milieu and drive down MBD.   
 
This study aimed at utilising a subcutaneous combination of a pharmacological dose of T and 
a very low dose of anastrozole in a subcutaneous pellet to evaluate the impact of this therapy 
on MBD in addition to safety and acceptability of this treatment. 
 
Method 
This study was a single centre cohort study based at Wellend Health Pty Ltd, Toorak Gardens, 
South Australia. Patients were referred to the Wellend Health Pty Ltd for either high MBD, the 
management of menopausal symptoms, the treatment of breast pain or a combination of 
these factors. All patients gave written consent for their clinical data to be used for research. 
 
All patients in the study cohort received a combination of T and anastrozole implants 
(HAVAHT+Ai™). The formulation consisted of a compressed implant containing crystalline T, 
anastrozole and magnesium stearate. A T dose of approximately 1mg per kilogram along with 
2mg-8mg of anastrozole per subcutaneous implant was used in the first dosing. Dosing was 
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altered in subsequent implants depending on either symptomatic response or lack of breast 
tissue response.  
 
Patients were started on the therapy following baseline evaluation consisting of medical 
history, mammography and biochemical and haematological testing, including reproductive 
hormone levels. The patients underwent repeat blood evaluations at four weeks, and 12 
weeks after initiation of treatment, the included serum T and Sex Hormone Binding Globulin 
(SHBG) to allow the generation of Free Androgen Index (FAI). A clinical review occurred at six 
weeks, consisting of clinical examination and reporting of adverse events (AEs). The MedDRA 
coding dictionary (version 20.0) was used to standardise events named into preferred terms 
(PT) and place within system organ class (SOC). A new pellet was inserted at three to four 
months. This clinical process was repeated after each dosing, for the duration of each 
patient’s therapy. 
 
The primary efficacy measurement for patients treated for high MBD was a reduction in MBD. 
During the treatment period patients generally had a mammogram on an annual basis. 
Measurements of MBD were undertaken utilising automated MBD analysis software 
(VolparaDensity™) generating the following variables: percentage volumetric breast density 
(%VBD), the absolute volume of fibroglandular tissue in cm3 (FGV), the volume of both breasts 
and BI-RADs score. As mammograms were not scheduled for specific time-points, a visiting 
windowing system was applied to the data in order to provide a specific data value to a 
specific time point. The windows were as follows; six months (180 days after first 
HAVAHT+Ai™ implant +/- 60 days), one year (365 days after first HAVAHT+Ai™ implant +/- 180 
days), two years (730 days after first HAVAHT+Ai™ implant +/- 180 days), three years (1095 
days after first HAVAHT+Ai™ implant +/- 180 days) and four years (1460 days after first 
HAVAHT+Ai™ implant +/- 180 days). Mammography variables were compared with the date 
of the first HAVAHT+Ai™ implant. If more than one mammogram was taken within a window, 
the results closest to the mid-point of the window were used. No windows were applied to 
the baseline value, that is, the baseline value could occur at any point prior to first 
HAVAHT+Ai™ implant date (the average number of days prior to the first implant for the 
baseline mammogram was 60 days). 
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In addition to the treatment group, mammographic data (%VBD and FGV) from an aged-
matched control cohort of perimenopausal women at high risk of breast cancer who did not 
receive HAVAHT+Ai™ treatment were obtained from Wellend Health Pty Ltd clinic records. 
These women were not treated with HAVAHT+Ai™ due to personal preference as it is an 
experimental therapy and not covered by the Australian Governments Pharmaceutical 
Benefits Scheme. Each of the 65 women had data from two sequential breast cancer 
screening mammograms. A group of participants that had a mammogram both prior to and 
after HAVAHT+Ai™ implant were identified for comparison against the control cohort. This 
group was referred to as the restricted analysis set (RAS). 
 
Statistical Analysis 
Excel (Microsoft, USA) was used to collate and tabulate the data. SAS® for Windows Version 
9.3 (SAS Institute) was used for the statistical analysis. To examine the drug dose relationship 
with the %VBD response, the change from baseline MBD was used as the outcome measure 
in a mixed model analysis using SAS PROC Mixed. This procedure allows for the potential of 
individual patients to contribute more than one mammogram following commencement of 
HAVAHT+Ai™ treatment (repeated measures analysis), as well as examining different 
covariance patterns amongst the data. From the data set provided for analysis, the following 
independent (explanatory) variables were used to examine their impact on the change in 
MBD: days since first implant, baseline %VBD MBD measurement (the value closest to, but 
not later than, the first HAVAHT+Ai™ implant), cumulative testosterone dose (mg) across the 
entire study (stratified into <500mg, 500mg to <700mg, and 700mg+), cumulative anastrozole 
dose (mg) across the entire study (as a continuous covariate), age (in years) at first implant, 
machine type (GE Healthcare or Hologic Inc mammography machine), the radiation dose at 
the mammogram, compression pressure at the mammogram, history of breast cancer (yes or 
no), the interaction term between days since the first implant and cumulative dose of 
testosterone strata. The last interaction term listed above allows for the fitting of different 
slopes to each of the T dose strata to see if any potential differences exist across the strata. In 
addition to the analysis conducted using %VBD MBD measurements, a complementary 
analysis was undertaken using a similar model, with the change from baseline FGV as the 
dependent variable. The only other change to the list of dependent variables was to replace 
baseline %VBD with absolute baseline FGV. 
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With the control cohort and RAS group, the ‘change from baseline’ in %VBD and in FGV were 
analysed using a mixed model approach, modelled controlling for the following items: age (for 
control cohort, age at first recorded mammogram and for RAS age at first HAVAHT+Ai™ 
implant), baseline %VBD/FGV (for control cohort, %VBD/FGV at first mammogram and for 
RAS, %VBD/FGV at mammogram closest to, but not after, first HAVAHT+Ai™ implant) and 
reference day (for control cohort, number of days between first and second mammogram 




In total, HAVAHT+Ai™ dosing information from 652 women was provided for analysis. 142 
patients had both pre-intervention baseline and subsequent mammograms. 65 patients were 
included in the control cohort with an average age of 49.6 (SD 7.24) years. 89 patients were 
included in the RAS group, with an average age of 51.3 (SD 6.89) years. Demographic and 
baseline summary information is provided in Table 3-1. All 652 patients were female, with an 
average age at the time of first HAVAHT+Ai™ implant of 52 years (range 23 to 79 years).  
 
Table 3-1: Participant Characteristics 
Characteristics All Patients Restricted Analysis Set Control Cohort 
Age at first implant – Years (SD) n = 652 52.3 (7.66) n = 142 51.7 (7.26) n = 65 49.6 (7.24) 
Pre-implant %VBD - % (SD)  13.89 (7.89)  16.14 (8.14)   
Pre-implant FGV – cm3 (SD)  156.26 (88.16)  170.77 (92.34)   
Indications   
Reduce BC risk (%) n = 89 13.7% n = 40 28.2%   
Hormonal Dysfunction n = 334 51.2% n = 43 30.3%   
Both n = 177 27.1% n = 58 40.8%   
Breast Cancer History   
Yes n = 560 85.9% n = 124 87.3%   
No n = 90 13.8% n = 18 12.7%   
Invasive Type BC   
Yes n = 6 0.9% n = 0 0.00%   
In-situ type BC   
Yes n = 14 2.1% n = 3 2.1%   
Reason for Stopping   
Ongoing Treatment n = 365 56.0% n = 107 75.4%   
Experienced adverse effects n = 14 2.1% n = 2 1.4%   




Table 3-1 continued 
Subject decided to cease 
HAVAHT+Ai™ treatment 
n = 46 7.1% n = 7 4.9%   
Subject felt HAVAHT+Ai™ treatment 
was not working 
n = 28 4.3% n = 5 3.5%   
Unexplained n = 123 18.9% n = 9 6.3%   
Doctor advised HAVAHT+Ai™ 
treatment is no longer required 
n = 16 2.5% n = 4 2.8%   
Doctor advised HAVAHT+Ai™ 
treatment is complete 
n = 25 3.8% n = 5 3.5%   
Subject was relocating n = 4 0.6% n = 0 0.0%   
Concomitant Medications   
Oestrogen-based Concomitant Medications Used   
No n = 430 66.0% n = 100 70.4%   
Yes n = 222 34.9% n = 42 29.6%   
Oral Concomitant Medications   
Yes n = 10 1.5% n = 2 1.4%   
Topical Concomitant Medications   
Yes n = 192 29.4% n = 34 23.9%   
Subcutaneous Concomitant Medications   
Yes n = 13 2.0% n = 4 2.8%   




Measurement of Efficacy 
Table 3-2 provides descriptive statistics for the change from pre-implant (baseline) 
mammography results. Although these values are unadjusted for other potential factors, 
both %VBD and FGV show a reduction following intervention with HAVAHT+Ai™ therapy. No 
data with a baseline pair was available for the 4-year post-implant window.  
 




6-month Window n 12 
 Mean (SD) -0.56% (3.02) 
1-year Window n 94 
 Mean (SD) -1.77% (3.57) 
2-year Window n 48 
 Mean (SD) -1.44% (2.41) 
3-year Window n 13 




Drug Dose and Relationship to %VBD Response 
To examine more closely, the impact of HAVAHT+Ai™ intervention on MBD as measured 
by %VBD, the subsets of patients who had mammograms both before and after the 
commencement of treatment were considered. The mixed model estimates for change from 
baseline in %VBD are shown in Table 3-3. Statistically significant findings were noted for days 
since first HAVAHT+Ai™ implant and the interaction between days since first HAVAHT+Ai™ 
implant and cumulative testosterone strata. Specifically, larger decreases in %VBD were 
noted over time for patients with accumulated testosterone dosing of over 500mg compared 
with patients with <500mg. Baseline %VBD was also statistically significant, with higher 
baseline scores having larger observed changes (reduction in %VBD).  
 
Efficacy of HAVAHT+Ai™ in the Reduction of MBD as Measured by %VBD and FGV 
Table 3-3 presents the least square mean estimate of the change from baseline in %VBD, by 
cumulative T strata and time since the first implant. The largest reductions from baseline in 
MBD observed were for the 500-700mg strata, -1.69% (95% CI -3.01% to -0.38%; p=0.0121) at 
2 years and -2.26% (95% CI -4.23% to -0.29%; p=0.0251) at 3 years and the 700+mg 
cumulative T strata with a reduction of -1.87% (95% CI -3.62 to -0.12; p=0.032) at 1 year, -
2.36% (95% CI -3.88% to -0.79%; p=0.0034) at 2 years and -2.80 (95% CI -4.66% to -0.95%; 
p=0.0035) at 3 years. Table 3-4 presents the least square mean estimates of the change from 
baseline in FGV, by cumulative T strata and time since the first implant. The only values of 
significance were those in the 700+mg cumulative T strata with reductions of -22.00cm3 (95% 
CI -39.48cm3 to -4.51cm3; p=0.0142) at 2 years and -36.21cm3 (95% CI -59.71cm3 to 












Lower 95% CI Upper 95% CI p-value 
<500mg 1 year -1.6085 -2.8628 -0.3542 0.0123 
<500mg 2 years -1.2130 -2.6838 0.2579 0.1053 
<500mg 3 years -0.8174 -2.8829 1.2480 0.4349 
500 to <700mg 1 year -1.1249 -2.4165 0.1668 0.0872 
500 to <700mg 2 years -1.6916 -3.0057 -0.3775 0.0121 
500 to <700mg 3 years -2.2584 -4.2275 -0.2893 0.0251 
700+mg 1 year -1.8688 -3.6155 -0.1222 0.0362 
700+mg 2 years -2.3358 -3.8817 -0.7899 0.0034 
700+mg 3 years -2.8028 -4.6566 -0.9490 0.0035 
 
 








Lower 95% CI Upper 95% CI p-value 
<500mg 1 year -12.6001 -25.7233 0.5230 0.0597 
<500mg 2 years -11.2073 -28.3175 5.9029 0.1975 
<500mg 3 years -9.8144 -35.6603 16.0314 0.4537 
500 to <700mg 1 year 0.2747 -12.2756 12.8251 0.9652 
500 to <700mg 2 years -4.1993 -19.8209 11.4223 0.5950 
500 to <700mg 3 years -8.6734 -34.0633 16.7166 0.4985 
700+mg 1 year -7.7803 -26.2516 10.6910 0.4052 
700+mg 2 years -21.9964 -39.4828 -4.5101 0.0142 
700+mg 3 years -36.2126 -59.7196 -12.7056 0.0029 
 
Laboratory Tests 
The prevalence of laboratory values out of the normal range is presented in Figure 3-1. Only 
patients with a pre-HAVAHT+Ai™ lab assessment are included in the figure to gauge the 




Figure 3-1: Prevalence of lab values out of normal range 
 
Out of range FAI values were noted for 29% of patient’s pre-HAVAHT+Ai™ (with denominator 
n= 279). The out of range FAI values increased to 78% of patients following the first implant 
with HAVAHT+Ai™ and then increased steadily over time, with over 90% of patients assessed 
(n= 54) at implant occasion 6 having values out of range. Out of range SHBG values were 
noted for 11% of patients pre-HAVAHT+Ai™ (with denominator n= 287) with the prevalence 
of out-of-range values remained relatively constant over the course of subsequent implants. 
Out of range testosterone values were noted for 9% of patient’s pre-HAVAHT+Ai™ (with 
denominator n= 303). The prevalence of out of range values remained relatively constant 
over the course of subsequent implants with HAVAHT+Ai™.  
 
Adverse Events 
The most prevalent AEs were those seen in the skin and subcutaneous conditions SOC. Within 
this SOC, 58 (9%) patients reported hirsutism and 37 (6%) reported acne; this did not result in 
early termination of therapy. Other events with a prevalence of 4% or more included fatigue 
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(n=37 patients 6%), malaise (n=27 patients, 4%), weight increase (n=27 patients, 4%) and hot 
flushes (n=76 patients, 12%). Treatment-related AEs reported by five or more patients are 
displayed in Table 3-5. No deaths or serious adverse events that were related to HAVAHT+Ai™ 
occurred during the study time frame.  
 
Table 3-5: Treatment related adverse events experienced by at least two patients, by average testosterone dose per implant 


















Subjects with at least one AE 8 (4.4%) 19 10 (3.7%) 31 7 (6.6%) 15 4 (5.6%) 7 29 (4.4%) 72 
Skin and subcutaneous tissue disorders 6 (3.3%) 8 9 (3.3%) 12 6 (5.7%) 7 3 (4.2%) 3 24 (3.7%) 30 
Hirsutism 3 (1.6%) 3 5 (1.8%) 5 2 (1.9%) 2 1 (1.4%) 1 11 (1.7%) 11 
Acne 4 (2.2%) 4 2 (0.7%) 2 3 (2.8%) 3 0 (0.0%) 0 9 (1.4) 9 
Alopecia 0 (0.0%) 0 4 (1.5%) 4 1 (0.9%) 1 2 (2.8%) 2 7 (1.1%) 7 
Psychiatric disorders 3 (1.6%) 3 3 (1.1%) 5 1 (0.9%) 3 1 (1.4%) 1 8 (1.2%) 12 
Anxiety 2 (1.1%) 2 0 (0.0%) 0 (0.0%) 0 0 (0.0%) 0 2 (0.3%) 2 
Depression 0 (0.0%) 0 2 (0.7%) 2 0 (0.0%) 0 0 (0.0%) 0 2 (0.3%) 2 
Mood Swings 1 (0.5%) 1 1 (0.4%) 1 0 (0.0%) 0 0 (0.0%) 0 2 (0.3%) 2 
Gastrointestinal disorders 2 (1.1%) 3 2 (0.7%) 2 0 (0.0%) 0 0 (0.0%) 0 4 (0.6%) 5 
Nausea 1 (0.5%) 1 1 (0.4%) 1 0 (0.0%) 0 0 (0.0%) 0 2 (0.3%) 2 
General disorders and administration site conditions 0 (0.0%) 0 2 (0.7%) 2 2 (1.9%) 2 0 (0.0%) 0 4 (0.6%) 4 
Feeling abnormal 0 (0.0%) 0 1 (0.4%) 1 1 (0.9%) 1 0 (0.0%) 0 2 (0.3%) 2 
Investigations 0 (0.0%) 0 3 (1.1%) 3 0 (0.0%) 0 1 (1.4%) 1 4 (0.6%) 4 
Blood pressure increased 0 (0.0%) 0 2 (0.7%) 2 0 (0.0%) 0 0 (0.0%) 0 2 (0.3%) 2 
Weight increased 0 (0.0%) 0 1 (0.4%) 1 0 (0.0%) 0 1 (1.4%) 1 2 (0.3%) 2 
Injury, poisoning and procedural complications [a] 0 (0.0%) 0 1 (0.4%) 1 2 (1.9%) 2 0 (0.0%) 0 3 (0.5%) 3 
Nervous system disorders 1 (0.5%) 1 2 (0.7%) 2 0 (0.0%) 0 0 (0.0%) 0 3 (0.5%) 3 
Vascular disorders 1 (0.5%) 1 1 (04%) 1 1 (0.9%) 1 0 (0.0%) 0 3 (0.5%) 3 
Hot flush 1 (0.5%) 1 1 (0.4%) 1 1 (0.9%) 1 0 (0.0%) 0 3 (0.5%) 3 
Reproductive system and breast disorders [a] 1 (0.5%) 1 1 (0.4%) 1 0 (0.0%) 0 0 (0.0%) 0 2 (0.3%) 2 
Respiratory, thoracic and mediastinal disorders [a] 1 (0.5%) 1 0 (0.0%) 0 0 (0.0%) 0 1 (1.4%) 1 2 (0.3%) 2 
[a] These are represented only at SOC level. There were no specific preferred terms within the SOC that occurred in two or more patients. 
S (%) E – the number of patients with at least one event (percentage of patients with N as defined in the column heading), followed by 
number of events. 
 
Control Cohort and Restricted Analysis Set 
The results for the estimated change in %VBD and FGV after 2 years are presented in Table 3-
6. For %VBD, after adjusting for age and baseline values, control cohort patients on average 
had an increase of 0.60% after two years, compared with a decrease of -1.76% in the RAS 
group. These findings represented a difference between the two groups of -2.36%, which was 
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a statistically significant difference from zero (95% CI -3.56% to -1.15%). For FGV, after 
adjusting for age and baseline values, control cohort patients on average had an increase of 
6.4cm3 after two years, compared with a decrease of -11.6cm3 in the RAS group. These FGV 
values represent a difference between the two groups of -18.0cm3, which was a statistically 
significant difference from zero (95% CI -31.1cm3 to -4.8 cm3). Based on the limited 
demographic information available from the control cohort, the modelling suggests that the 
intervention of HAVAHT+Ai™ therapy has a significant effect on MBD outcome measures 
of %VBD and FGV compared to the control cohort.  
 
Table 3-6: The estimated change in %VBD and FGV after 2 years in Control Cohort and RAS group 
 Estimated Change 
in %VBD (95% CI) After 2 
Years 
Estimated Change in FGV 
(cm3) (95%CI) After 2 
Years 
Control Cohort 0.60 (-0.27, 1.47) 6.4 (-2.8, 15.5) 
RAS -1.76 (-2.52, -1.00) -11.6 (-20.9, -2.3) 




It has been demonstrated that the maximal reduction in MBD with tamoxifen is seen at 2 
years following initiation of therapy (Cuzick, Warwick et al. 2011). Unlike cancer therapy, 
where dose maximisation frequently is traded off against AEs, prevention therapy needs to be 
the lowest dose possible to affect a response and ensure that the side effect profile provides 
a clear benefit over the AE relationship. This patient cohort analysis using VolparaDensity™ 
obtained from 142 patients with mammograms taken both pre- and post-commencement of 
HAVAHT+Ai™ therapy showed there were statistically significant changes from baseline MBD 
measurements of both %VBD and FGV following intervention with HAVAHT+Ai™ therapy. 
 
When MBD was measured by %VBD, patients with cumulative T dosing of 700mg+, the one-
year post-commencement of therapy estimated change was -1.87%, the two-year post-
commencement of therapy estimated change was -2.34%, and the three-year post 
commencement point of therapy had an estimated change of -2.82%. These figures result in a 
relative %VBD change of -11.6%, -14.5% and -17.5% respectively. For patients with cumulative 
T dosing of 500-<700mg+, the one-year post-commencement estimated change was -1.12% 
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(p=0.09), the two-year post-commencement estimated change was -1.69%, and the three-
year post commencement of therapy estimated change was -2.26%. These results equated to 
a -6.9%, -10.5% and -14% relative %VBD decrease, respectively.  
 
When the MBD variable of interest was FGV, the only values of significance were those in the 
700mg+ cumulative T group, at 2 and 3 years post-first HAVAHT+Ai™ implant. The absolute 
change from FGV estimates were -22cm3 and -60cm3 at 2 and 3 years, respectively. These 
results equate to a -12.9% and -35.1% relative decrease. Both results demonstrate clinically 
significant findings as per the previous research reported in the literature. As discussed in the 
introduction for this paper, Cuzick, Warwick et al. (2011) reported that a 10% reduction on a 
0-100% scale is required for a 63% decrease in breast cancer risk, which was reached in the 
first year with 700mg+ T cumulative dosing and at the third year on 500-700mg+ T cumulative 
dosing. In addition, a 20% decrease in FGV has been reported in the literature to lead to a 
50% reduction in breast cancer mortality which was accomplished at the third year with 
700mg+ cumulative T dosing (Li, Humphreys et al. 2013). The model fitted also suggested that 
cumulative anastrozole dosing is a variable of interest when assessing change in MBD 
(p=0.06). Larger values of cumulative anastrozole doses were associated with larger changes 
from baseline (decrease from baseline) in MBD.  
 
The other clinically meaningful benefit of HAVAHT+Ai™ was that there was a favourable AE 
profile of the therapy. Factors that are known to be associated with oral T (elevated 
haematocrit, elevated liver enzymes, elevated adverse lipid profile) were not observed. There 
were some increases in androgenic effects such as hirsutism, but these were not enough to 
cause a cessation of therapy. Local AEs were infrequent and were not graded for severity, but 
most of those that were listed as site haemorrhage were bruising rather than overt bleeding.  
 
This cohort patient analysis has exhibited findings that combination therapy of T and 
anastrozole (HAVAHT+Ai™) results in a statistically and clinically significant reduction of %VBD 
and FGV. To achieve the clinically significant level of MBD reduction that was seen in the IBIS-
1 tamoxifen breast cancer prevention study (Cuzick, Warwick et al. 2011), a minimum 
cumulative dose inclusive of 700mg of T in combination with anastrozole needs to be given. 
Although dosing of less than 700mg of cumulative T exposure in combination with 
anastrozole was shown to affect significant changes in %VBD as a measure of MBD. FGV is a 
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more robust measurement of breast tissue response as it is the least likely of the measures to 
fluctuate with changes in BMI (Krishnan, Baglietto et al. 2017). %VBD needs to be corrected 
over time for the change in BMI, and this was not captured in this cohort analysis; this may be 
the reason for greater heterogeneity in the dose-response seen when measuring %VBD 
compared with FGV. 
 
However, the most significant response in FGV and %VBD was when there was greater than 
700mg of T given in combination with anastrozole over a two to three-year period. Larger 
values of cumulative anastrozole dose were associated with greater changes from baseline 
(decrease from baseline) in %VBD (p=0.06 when the significance level was set at p=0.05). It 
was demonstrated that the average anastrozole dose in this cohort of 2mg per implant was 
not adequate. Based on these observations, suggested dosing for reduction of MBD should 
include a mid-range dose of T (80mg per implant) and an upper-end range of anastrozole 
(4mg per implant). Therefore, a treatment regimen of 10 implants administered over 2.5 
years, delivering a cumulative dose of 800mg of T in combination with 40mg of anastrozole 
should achieve the target clinical effort on MBD (in line with tamoxifen) while maintaining a 
low incidence of AEs and good patient tolerability.  
 
Due to the nature of this research, there needs to be some consideration with the 
interpretation of these findings. Firstly, as this was an analysis of patient records the results 
may be affected by selection bias, the participants that are returning for repeat implant 
dosages might be the patients who responded well to the treatment in regard to decreasing 
MBD variables and the interventions side effect profile. Therefore, the decreasing %VBD and 
FGV values with the increasing cumulative T dosing may not represent the true results that 
would be present in the intended population. Furthermore, limited demographic information 
was documented for the control cohort; therefore, we were unable to determine if the 
baseline characteristics were significantly different from the intervention group. This 
discrepancy may lead to a different outcome occurring if the research was to be replicated. 
With the information presented, it would be feasible and beneficial to conduct further 
research of a more rigorous design, using the knowledge that HAVAHT+Ai™ has signs of effect 
of being able to reduce %VBD and FGV in women at increased risk of breast cancer.  
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Overall, this patient cohort analysis demonstrated that the hormonal intervention of T and 
anastrozole (HAVAHT+Ai™) was efficacious at reducing MBD, with no suggestion of increasing 
AE prevalence with increasing T dose, in a perimenopausal patient population with high MBD. 
This analysis has produced the first report of the impact of combining a pharmacological dose 
of T with a low dose of anastrozole on MBD; these results suggest a larger study should be 
undertaken to confirm the efficacy and safety of this therapy as a chemopreventative 
intervention for breast cancer. 
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3.4 Publication Summary 
To date, clinical observations of subcutaneous testosterone and an anastrozole implant as a 
hormonal replacement have shown favourable results. Compared to previously conducted 
studies, the incidence of breast cancer in the treated women (142/100,000) is substantially 
lower than it is in SEER age-specific incidence rates (293/100,000), the placebo arm of the 
Women's Health Initiative (300/100,000), and the never users of hormonal therapy from the 
Million Women's Study (325/100,000) (Glaser and Dimitrakakis 2013). Glaser and Dimitrakakis 
(2013) originally stated that breast cancer is preventable by maintaining an androgenic 
environment concerning the testosterone/oestrogen ratio. It has previously been 
demonstrated that there is an association between hormone exposure, MBD, and future risk 
of breast cancer (Boyd, Melnichouk et al. 2011). This cohort analysis contributes to previous 
research by Glaser and Dimitrakakis (2013) demonstrating a potential association with 
HAVAHT+Ai™ therapy, the shift to an androgenic breast tissue environment, a reduction in 
MBD variables, and a possible reduction in breast cancer risk.  
 
Although there is evidence to show the previously stated associations, the study did have 
some significant limitations that require further discussion. Firstly, the main limitation of this 
analysis is the study design itself. As it was an open-label uncontrolled record of clinical 
practice rather than a double-blind, randomised controlled trial (RCT), we were unable to 
establish a direct causal link between HAVAHT+Ai™ and the reduction of MBD and TFV in this 
patient cohort. However, the observations reported met some criteria of the Bradford Hill 
criteria for causality (Hill 1965), specifically temporality, biological gradient and plausibility as 
the reductions in mammography variables occurred after the commencement of 
HAVAHT+Ai™ therapy, showed greater reductions with increasing dose and aligned with the 
hypothesised changes based on the current body of evidence, so a causal link between the 
therapy and a reduction in MBD and TGV is likely. More rigorous research designs, such as the 
RCT mentioned above are required to be undertaken to determine if HAVAHT+Ai™ is the 
causal reason for the reduction in the mammography variables and the subsequent potential 
breast cancer reduction.  
 
A further limitation of this study was that HAVAHT+Ai™ is currently being used for numerous 
indications such as menopausal symptom and breast pain management. Due to this reason, 
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within the cohort of 652 women, only 89 patients (14%) were given the therapeutic 
intervention for an indication of a reduction in MBD/breast cancer risk. As there was limited 
baseline MBD data, and we analysed the correlation between dosage and MBD, this could be 
a confounder as the patients in this cohort may have had a lower MBD at baseline. In saying 
this, the patients that had a baseline mammogram, although unadjusted for other potential 
factors, showed a reduction in %VBD and TFV MBD measurements, following the 
HAVAHT+Ai™ intervention irrespective of baseline MBD.  Another limitation within this 
analysis was the limited data regarding the tolerance of HAVAHT+Ai™; 123 women were lost 
to follow up, 46 decided to cease therapy, and 28 felt that HAVAHT+Ai™ was not working. It is 
important that for future studies the drug tolerance is analysed and any reasoning for the 
cessation of the therapeutic intervention is understood and documented.  
 
3.5 Conclusion 
Regarding the overall aims and objectives of this analysis of clinical practice records, there is 
evidence that HAVAHT+Ai™ has signs of effect concerning reducing MBD in a patient cohort 
with measures high MBD. Future research needs to be conducted with more rigorous, 
statistically powered, placebo-controlled, double-blind RCT. Within these studies, there will 
also need to be a more specific inclusion and exclusion criteria which incorporates women 
with high MBD. This eligibility criterion will allow the study population to be an accurate 
representation of the population of interest. Also, any study of this nature will need to 
incorporate baseline measures and repeat measures of the mammography variables, in 
addition to safety and tolerability data. Utilising this study design will allow the effect size of 
the intervention on the MBD variables to be calculated and evidence to be presented 
regarding the safety and overall tolerability of the drug. 
 
3.6  Future Research 
The initial hypothesis was that breast elasticity might be a viable biomarker for MBD and the 
associated aims and objectives, as reported in Section 2, were trying to establish whether this 
is the case. The results from this study were produced so they could be applied to the 
subsequent studies within this thesis. The findings from this chapter demonstrate that 
HAVAHT+Ai™ was associated with a reduction in %VBD and TFV. The future studies within this 
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doctoral thesis can incorporate the breast elasticity outcome measure with the use of the 
SWE ultrasound machine. The breast elasticity can be measured at more frequent intervals 
than mammography. This study design will allow us to determine if breast elasticity also 
changes in response to this hormonal intervention, if these changes correlate with the 
changes occurring in the mammography variables and whether the breast elasticity is more 
sensitive to detect changes. 
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Chapter 4 Pharmacodynamics (breast tissue elasticity) of 
Combination Subcutaneous Testosterone and Anastrozole 
(HAVAHT+Ai™) in Premenopausal Women with High 
Mammographic Breast Density  
4.1 Introduction 
As reported in Chapter 3, HAVAHT+Ai™ has demonstrated the potential to be efficacious at 
reducing %VBD and TFV within a cohort of women with high MBD and therefore increased 
breast cancer risk. This study is the initial study within this research program for which we 
have incorporated the measure of breast elasticity to evaluate the response of the breast 
tissue to the investigational product. The study within this chapter is a sub-study analysis 
within a single-dose pharmacokinetic trial of HAVAHT+Ai™. As the results in Study 1 (Chapter 
3) suggest, repeat dosages of HAVAHT+Ai™, which led to a cumulative testosterone dosage of 
500 to 700mg+, were found to be the most efficacious for reducing MBD. Therefore, as this is 
a single-dose study, it is not hypothesised that MBD and its associated variables will change in 
response to the investigational product; however, there may be a short-term response seen 
in the breast elasticity. 
 
As mentioned in Section 1.2.4, the breast is embryologically a modified sweat gland, and it 
responds like a sweat gland to any alteration to its E/A ratio (McNally and Stein 2017). When 
there is a shift in this ratio towards an androgenic tissue environment in the breast, there is a 
substantial change in MBD (as is seen following menopause) (Boyd, Martin et al. 2002). The 
only widely accepted intervention shown to achieve this effect in premenopausal women is 
oral tamoxifen. As a partial agonist of oestrogen, tamoxifen causes significant alterations in 
both breast and systemic oestrogenic stimulation; this systemic oestrogenic stimulation can 
result in significant treatment-related side effects that reduce the compliance with tamoxifen 
as a breast cancer chemopreventative agent (Peres 2014). 
 
Within the breast, there are many enzymes that convert reproductive pro-hormones, 
including aromatase (Vachon, Sasano et al. 2011) and 5α-reductase (Suzuki, Miki et al. 2006). 
These enzymes convert testosterone to either E2 or DHT, the latter being ten times more 
potent than testosterone as an androgenic agent. High MBD tissue has been shown to 
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contain very high levels of aromatase (Vachon, Sasano et al. 2011), resulting in enhanced 
intracrine production of oestrogen. Aromatisation of testosterone is important in both the 
pre-and postmenopausal breast (Dabrosin 2005). 
  
By using HAVAHT+Ai™, we intend to utilise the overexpression of these enzymatic systems in 
high MBD breast tissue by treating with a pharmacological dose of testosterone combined 
with a low dose of an Ai, thus shifting the E/A ratio towards an androgenic tissue 
environment. This androgenic environment results from the Ai blocking the conversion of 
testosterone to oestradiol, thus increasing bioavailable testosterone in the breast tissue. In 
addition, higher serum testosterone results in more of this androgen being delivered to the 
breast. Ultimately, the consequence of these two actions is a high level of intra-mammary 
testosterone being made available for conversion to DHT and a reduction in intra-mammary 
E2. 
 
As previously mentioned in Section 1.5, within the tissue of high MBD, there is decreased 
activity of the extracellular matrix-degrading enzymes, MMPs and an overexpression of their 
specific inhibitors (TIMPs). The organisation of the extracellular matrix is likely to play a role in 
mediating the mechanical properties of tissues and may influence the elasticity of the tissue. 
Nilsson, Garvin et al. (2007) conducted research into the effect of oestrogen and tamoxifen 
on the secretion and activity of MMP-2 and MMP-9 and TIMP-1 and TIMP-2, finding that 
tamoxifen treatment induced a significant increase in MMP-2/MMP-9 activity (P<0.001 as 
compared to control cells) and that oestradiol significantly decreased MMP-2/MMP-9 activity 
(P<0.05 as compared to control cells) and this decrease was in part reversed by addition of 
tamoxifen to the oestradiol treatment (P<0.01). Nilsson, Garvin et al. (2007) also reported 
that tamoxifen significantly increased TIMP-1 levels (P<0.05 as compared to control) whereas 
oestradiol significantly lowered the amounts (P<0.01 as compared to control cells). We 
hypothesised that by using HAVAHT+Ai™ to decrease the oestradiol levels within the breast, 
there will be an increase in the extracellular matrix degrading proteins of MMP-2 and MMP-9 
and an increase in the TIMP-1 and TIMP-2 tissue inhibitors, which would lead to greater 
extracellular matrix regulation. Therefore, breast tissue elasticity may change in response to 
the HAVAHT+Ai™ intervention, and this could be detected earlier than the global tissues as 




This is the first study within this thesis that directly measures the effect of a 
chemopreventative agent (HAVAHT+Ai™), that has been shown to reduce MBD (as per 
Chapter 3), on breast tissue elasticity. This study evaluates the potential effect on 
HAVAHT+Ai™ on breast tissue elasticity, as measured by SWE and whether these changes 
correlate with changes (if occurring) in MBD, as measured by VolparaDensity™. 
 
4.3 Method 
This pharmacodynamic analysis was a sub-study study within a single-dose, single-centre, 
open-label non-randomised pharmacokinetic trial of HAVAHT+Ai™ in premenopausal women 
conducted at Wellend Health Pty Ltd, Toorak Gardens, South Australia. This trial was 
approved by the Bellberry Limited Human Research Ethics Committee (HREC) (approval 
number 2017-06-434). As the purpose of the trial was descriptive, a formal sample size 
calculation was not appropriate. A planned sample size of 12 participants was based on 
feasibility, and it was anticipated that sufficient information would be obtained to achieve the 
primary pharmacokinetic objective of the trial. 
 
4.3.1 Patient Population 
The trial population consisted of premenopausal women. Potential participants were those 
either referred by their medical practitioners or self-referred to the Wellend Health Pty Ltd 
clinic for HAVAHT+Ai™ therapy for the reduction of high MBD. Potential patients were 
screened for their eligibility to be included in the study during the 21 days prior to the 
scheduled dosing date. Participants were eligible for the study if the following criteria were 
met; premenopausal levels of follicular stimulating hormone, luteinizing hormone and 
oestradiol (FSH/LH/E2) according to the definition of “premenopausal range”, 
VolparaDensity™ volumetric breast density of ≥ 15.5% (combined average both breasts), aged 
between 33-55 years inclusive, body weight between 50 and 90kg inclusive, in good general 
health without clinically significant cardiac, respiratory, or psychiatric disease and a negative 
pregnancy test. Participants were excluded from the trial if there was the presence of breast 
cancer, had a previous or concomitant other malignancy (non-breast, other than skin) within 
the previous five years, diabetes mellitus or glucose intolerance, history of coronary artery 
 81 
disease, existing testosterone, oestrogen and/or anastrozole treatment or systemic hormonal 
contraception. Participants who prematurely withdrew post-dosing were to be replaced to 
ensure that at least 11 participants completed the trial. Prior to dosing, the participants were 
confirmed to be in the luteal phase of their menstrual cycle, as based on progesterone levels 
of >4nmol/L. 
 
4.3.2 Investigational Product 
All participants received the same active treatment of HAVAHT+Ai™, a subcutaneous pellet 
with 80mg of testosterone and 4mg of anastrozole. This dosing regimen of HAVAHT+Ai™ is 
appropriate for a population of the age and BMI set out in the inclusion criteria. The 
participants were advised to place a patch of EMLA local anaesthetic cream (a combination of 
lidocaine and prilocaine) at least one hour before the planned administration of the 
HAVAHT+Ai™ at the site of the proposed insertion. The investigational product was 
administered to each participant by Dr Stephen Birrell, The Medical Director of Wellend 
Health Pty Ltd. Prior to administration, a standard sterile procedure was undertaken, and 5ml 
of xylocaine was injected with a 25-gauge needle on the right gluteal region midway between 
the greater tuberosity of the hip and the superior tuberosity of the pelvis. A 4mm incision was 
made through the skin, and a 4mm trochar was inserted at an angle of 45˚ into the 
subcutaneous tissue for a length of 5cm. The implant was inserted to the end of the trochar, 
after the withdrawal of the trochar, the wound was closed with a butterfly closure such as 
steri-strips and covered with a waterproof dressing.  The pellet was inserted between 8 am 
and 10 am on the day of dosing.  
 
4.3.3 Outcome Measures 
All participants had a baseline mammogram conducted by Dr Jones and Partners Medical 
Imaging at Burnside Hospital. These mammography images were analysed by 
VolparaDensity™ software, which provided the variables of %VBD, TFV and total breast 
volume in cm3 (TBV). The participants also consented for their 12-month annual follow-up 
mammogram to be analysed as part of this study. 
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Breast elasticity was measured with SWE and was conducted using the SuperSonic™ Imagine 
Aixplorer® ShearWave™ ultrasound (Aixplorer®, France) (Figure 4-1). A linear transducer head 
with ample ultrasound gel (Figure 4-2) was placed on the breast, parallel from the nipple, two 
centimetres away from the nipple in a diagonal direction (Figure 4-3).  
 
 
Figure 4-1: SuperSonic™ Imagine Aixplorer® ShearWave™ Elastography ultrasound device 
 
 
Figure 4-2: Linear transducer head with ultrasound gel 
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Figure 4-3: Diagram of the location and direction of the linear transducer head on the breast 
 
The breast was visually divided into eight quadrants (Figure 4-4), in reference to Figure 4-4, 
number one is the right outer lower quadrant, number two is the right outer upper quadrant, 
three was the right inner upper quadrant, four is the right inner lower quadrant, five is the 
left inner lower quadrant, six is the left inner upper quadrant, seven is the left outer upper 
quadrant and eight is the left outer lower quadrant. Once the images were captured, they 
were analysed post-hoc on the SWE machine. To analyse the image and generate the 
elasticity data, a single or multiple pre-defined circular Q-Box™ were placed on the image 
(Figure 4-5), within this Q-Box™ a ROI was created and the minimum, maximum, mean and 
standard deviation (SD) of the tissue elasticity in kilopascals (kPa) and the depth of the tissue 
was calculated from this ROI. For this study, six 3mm (6 x 3mm) Q-Box™ were placed on the 
image (Figure 4-5). 
 
 
Figure 4-4: Image sequence of the breast quadrants used in shear wave elastography 
 
The average of all six Q-Box™ per image were combined to determine the average elasticity of 
both breasts combined per participant. The Medical Director at Wellend Health Pty Ltd 
advised the method of using 6 x 3mm Q-Box™ as the best method for acquiring the elasticity 
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data and therefore was used within this study. Once the images had the Q-Box™ and elasticity 
measurements generated, a report was made with all the images and all the corresponding 
data which was exported from the machine. Breast elasticity was assessed at baseline, and on 
days 29, 57 and 85. 
 
 
Figure 4-5: Shear wave ultrasound output with six 3mm Q-Box™ and the elasticity measurements 
 
4.3.4 Statistical Analyses 
All collected data was collated and tabulated using Microsoft Excel (Microsoft, USA). All 
statistical analyses were conducted using IBM SPSS version 25 (IBM, Amarok, USA). The 
statistical model chosen for each analysis is described in the corresponding result section. 
4.4  Results 
4.4.1 Patient Demographic 
11 participant datasets were included in this analysis. The average age of the participants was 
41.5 (SD 3.7) years; a full summary of the participant demographics is presented in Table 4-1. 
All participants had their data included in all the analyses.  




Table 4-1: Participant characteristics 
Demographic Parameters (Units) Average (SD) 
Age (years) 41.4 (3.7) 
Weight (kg) 67.87 (10.27) 
Height (m) 1.673 (0.066) 
BMI (kg/m2) 24.14 (2.26) 
 Number of Participants (%) 
Race (white) 10 (90.9%) 
Race (white/Asian) 1 (9.1%) 
Ethnicity (not Hispanic or Latino) 11 (100%) 
 
4.4.2 Changes in Breast Elasticity from Baseline to Month 3 
The descriptive summary of the breast elasticity values and the change in breast elasticity are 
presented in Table 4-2. 
Table 4-2: Mean Breast elasticity summary and change from baseline 
Timepoint Breast Elasticity 
(SD) in kPa 
Change from 
Baseline (kPa) 
Baseline 13.67 (7.89)  
Month 1 11.68 (5.58) -1.99 
Month 2 9.86 (5.63) -3.80 
Month 3 8.63 (3.96) -5.04 
 
Due to the small sample size of this study, a spaghetti plot was created to visualise the 
patterns for each study participant (Figure 4-6). This plot shows that there is significant 
variation within each individual dataset. The most common trajectory was a breast elasticity 
decrease from baseline, however there were two participants whose breast elasticity 
increased over the three weeks.  
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Figure 4-6: Breast elasticity for each individual participant, at each timepoint 
 
Upon analysing the data, it was observed that there were outliers present in each data set. All 
of these data points were assessed and deemed to be true values and were left within the 
analysis. The original data were not normally distributed as determined by the Shapiro-Wilk 
test; for this reason, the Friedman test, a non-parametric statistical model, was used to 
analyse the data. 
 
The results show that breast tissue elasticity was statistically significantly different at the 
different time points during the intervention X2(3) = 30.835, p<0.0005. The median values of 
the breast tissue elasticity at each time point are presented in Table 4-3. Pairwise 
comparisons were performed with Bonferroni corrections for multiple comparisons. The 
breast elasticity was statistically significantly different between baseline and month 2 
(p=0.002) and baseline and month 3 (p<0.0005). There were no statistically significant 




Table 4-3: Median breast elasticity values 




Baseline 13.10  
Month 1 10.80 1.000 
Month 2 8.39 0.002 
Month 3 7.98 <0.0005 
 
4.4.3 Changes Between Percentage Volumetric Breast Density from Baseline 
to Month 12 
Within the study protocol, the participants were scheduled to have a mammogram after 12-
months. From this data, it enabled us to determine the effect of HAVAHT+Ai™ on %VBD 
across 12 months. The women all had differing dosages levels, due to the small sample sizes, 
the results will be provided as the overall changes and then descriptive statistics regarding the 
different dosage groups. 
 
Upon looking at the data sets, the data were normally distributed, and there were no outliers 
present in either data set. The mean %VBD of the baseline data was 19.41% (SD 3.07), and 
the 12-month data was 18.08% (SD 4.91%). The results of a paired-samples T-Test showed 
that there was a statistically insignificant mean difference of -1.33% (95% -1.61% to 4.26%; p= 
0.34). As mentioned, that treatment doses varied between participants; Table 4-5 shows the 


















1 2 18.4% 16.5% -1.9% 
2 1 17.5% 18.3% 0.8% 
3 5 18.9% 16.36% -2.54% 
4 2 20.0% 21.2% 1.2% 
5 1 24.7% 23.4% -1.3% 
a The number of pellets varied due to the participants having the choice of continuing therapy or 
discontinuing therapy once the 3-month study had reached completion 
 
4.4.4 Changes in Total Fibroglandular Volume from Baseline to Month 12 
 
The TFV (cm3) is a mammography variable that calculates the volume of fibroglandular (or 
dense) tissue within the breast. The data of the baseline TFV was not normally distributed, 
and there was one outlier present in the baseline dataset, which was assessed and deemed to 
be a correct figure and was left in the analysis. As the data was not normally distributed, a 
non-parametric statistical model was chosen to analyse the data. Table 4-6 shows the mean 
descriptive statistics for the dose-specific changes.  
 
The mean fibroglandular volume of the baseline dataset was 197.4cm3 (SD 118.7cm3) and 
184.4cm3 (SD 125.1cm3) for the 12-month dataset, this was a mean difference of -13.02cm3 
(SD 29.55). 
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1 2 214.55 197 -17.55 
2 1 196.3 254.4 58.1 
3 5 137.32 107.24 -30.08 
4 2 389.6 386.8 -2.8 
5 1 80 69.8 -10.2 
 
When using the non-parametric statistical models, the median values and median differences 
are the data used unless otherwise stated. The distribution of the differences between the 
two groups was not symmetrical in shape; for this reason, the Sign test was chosen as it does 
not require the assumption of symmetry within the differences. 
 
Eleven participants were recruited into the pharmacokinetic study, and all 11 had a baseline 
and 12-month follow-up data recorded. All data are median values unless otherwise stated. In 
the analysis, when comparing the baseline and TFV at baseline and month 12; participants 
had a lower TFV at 12-months (126.90cm3) compared to the baseline data (154.10cm3) with a 
median difference of -22cm3, this result had a p-value of 0.065. From the 11 participants, two 
had increased, and nine had decreased TFV, there were zero ties within the dataset. 
 
4.4.5 Correlations Between Per Cent Volumetric Breast Density and Breast 
Elasticity  
This section contains three different statistical analyses to determine if; 
1. The baseline %VBD were correlated with the breast elasticity 
2. The 12-month %VBD measures were correlated with the 3-month breast elasticity measures 
3. The changes in %VBD were correlated with the change in elasticity from baseline to the final 
measures 
 
For parametric data, the Pearson’s correlation coefficient and for non-parametric data, the 
Spearman Rank Order correlation was used to determine if there was a relationship between 
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the %VBD and the breast elasticity. The correlation thresholds that were used were in 
accordance with the recommended medical research thresholds (Mukaka 2012) and are 
presented in Table 4-6. 
                              
Table 4-6: Pearson's correlation coefficient correlation thresholds 
Size of Correlation Interpretation 
.90 to 1.00 (-.90 to -1.00) Very high positive (negative) correlation  
.70 to .90 (-.70 to -.90) High positive (negative) correlation 
.50 to .70 (-.50 to -.70) Moderate positive (negative) correlation 
.30 to .50 (-.30 to -.50) Low positive (negative) correlation 
.00 to .30 (.00 to -.30) Negligible correlation 
 
Both the baseline %VBD and the breast elasticity data, according to the Shapiro-Wilks test, 
were normally distributed, and there were no outliers present in either dataset. Using 
Pearson’s correlation coefficient, the results showed an r-value of 0.184 (p=0.589), this is a 
statistically insignificant negligible correlation between the two variables. The correlation is 
presented in Figure 4-7. 
 
 
Figure 4-7: Correlation between %VBD and breast elasticity at baseline  
 
Both the 12-month %VBD and three-month elasticity data, according to the Shapiro-Wilks 
test, was normally distributed. Using Pearson’s correlation coefficient, the results showed an 
r-value = 0.184 
p=0.589 
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r-value of 0.233 (p = 0.491), this is a statistically insignificant negligible correlation between 




Figure 4-8: Correlation between %VBD at 12 months and breast elasticity at 3 months 
 
When determining if there is a correlation between change in %VBD and the change in the 
elasticity values, the correlation analysis was conducted on the difference values between the 
baseline %VBD and 12-month %VBD results, and the difference values between the baseline 
elasticity and the 3-month elasticity values. The Shapiro-Wilk test for normality showed that 
the data were normally distributed; there were no outliers present within the data. Pearson’s 
correlation for the change in the variables had an r-value of 0.315 (p=0.345); this was a 
statistically insignificant low positive correlation between the change in the variables across 
the study. The correlation is presented in Figure 4-9. 
 




Figure 4-9: Correlation between change in %VBD (baseline to month 12) and change in breast elasticity (baseline to month 
3) 
 
4.4.6 Correlations Between the Total Fibroglandular Volume and Breast 
Elasticity  
The TFV is the recorded volume of dense tissue within the mammogram, this is a variable of 
interest as the %VBD is influenced by both the fibroglandular volume and the TBV, so if a 
therapeutic intervention reduces both variables, the %VBD may remain unchanged. The TFV 
is the outcome measure that can quantify the extent of the changes occurring in the actual 
dense tissue itself; this being the tissue of interest in regard to interventions being used to 
reduce MBD. 
 
Within the baseline TFV and the baseline breast elasticity values, the Shapiro-Wilks test 
showed that the baseline fibroglandular data were not normally distributed. There was a 
single outlier present within the data, and upon further analysis, this was deemed a correct 
figure and therefore was left in the analysis. Spearman’s rank-order correlation was used as 
the statistical model. The results produced a rs value of -0.118 (p=0.729); this was a 
statistically insignificant negligible correlation between the baseline fibroglandular volume 
values and the baseline breast elasticity values. The correlation is presented in Figure 4-10. 
 
 




Figure 4-10: Correlation between total fibroglandular volume and breast elasticity at baseline 
 
About the 12-month fibroglandular volume and 3-month elasticity data, the fibroglandular 
data, according to the Shapiro-Wilks test, was not normally distributed. No outliers were 
present within either dataset. Spearman rank-order correlation was used as the statistical 
model for the analysis. The results showed a rs value of -0.436 (p=0.180) this was a statistically 
insignificant moderate negative correlation between the variables. The correlation is 
presented in Figure 4-11. 
 
 
Figure 4-11: Correlation between total fibroglandular volume (month 12) and breast elasticity (month 3) 
 
Rs value = -0.118 
p=0.729 
Rs value = -0.436 
p=0.180 
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When determining if there was a correlation between change in TFV and the change in the 
elasticity values, the correlation analysis was conducted on the difference values of the 
baseline TFV and the 12-month TFV and the difference values of the baseline elasticity and 
the 3-month elasticity values. The Shapiro-Wilks test showed that the data were normally 
distributed. There was an outlier within the fibroglandular volume dataset, and with further 
analysis, this was deemed a true value and left in the analysis. Pearson correlation coefficient 
demonstrated that the r-value was 0.689 (p=0.019); this was a statistically significant 




Figure 4-12: Correlation between change in total fibroglandular volume (baseline to month 12) and change in breast 
elasticity (baseline to month 3) 
 
In addition to the elasticity changes across the three months, two additional analyses were 
conducted for the one-month data and the two-month data elasticity change with the TFV 
changes across the 12 months. With the change from baseline to the one-month elasticity 
variables, the data were normally distributed according to the Shapiro-Wilk test, and there 
were multiple outliers within both datasets, which were deemed to be correct values and left 
in the analysis. Pearson’s correlation coefficient produced an r-value of 0.611 (p=0.046). This 
was a statistically significant, moderate positive correlation between the two variables. The 
correlation is presented in Figure 4-13. 
 
 




Figure 4-13: Correlation between change in total fibroglandular volume (baseline to month 12) and change in breast 
elasticity (baseline to month 1) 
 
The last analysis was the elasticity changes from baseline to month two, and the TFV changes 
from baseline to month 12, the data were normally distributed according to the Shapiro-Wilks 
test. There was a single outlier in the TFV dataset, which was assessed and deemed a true 
value and left in the analysis. Pearson’s correlation coefficient produced an r-value of 0.818 
(p=0.002). This shows that there was a statistically significant high positive correlation 
between the elasticity change two months and the TFV changes at 12-months. The 
correlation is presented in Figure 4-14. 
 
 
Figure 4-14: Correlation between change in total fibroglandular volume (baseline to month 12) and change in breast 
elasticity (baseline to month 2) 
r-value = 0.611 
p=0.046 





This was a sub-study within a single dose, single-centre, open-label, non-randomised 
pharmacokinetic trial of HAVAHT+Ai™ conducted on 11 premenopausal women. This study 
aimed to determine the pharmacodynamic effect on breast tissue elasticity, which is an 
experimental biomarker to determine breast tissue changes.  
 
The breast tissue elasticity reduced progressively over time, with a relative reduction of 37% 
from baseline to the 3-month measurement. It has previously been reported that high MBD 
tissue shares similar characteristics to malignant breast tissue, specifically the fibrodense 
areas having a downregulation of fibroblasts, leading to a greater extracellular matrix 
component and low adipocytes (DeFilippis, Chang et al. 2012) and a decreased regulation of 
MMPs and their inhibitors TIMPs (Bonnans, Chou et al. 2014). This abnormal extracellular 
matrix deposition can lead to tissue stiffening, causing increased tissue elasticity as seen in 
breast cancer (Bonnans, Chou et al. 2014). We hypothesised that the characteristics of high 
MBD, such as high extracellular matrix content would lead to greater tissue elasticity; 
therefore, changes in elasticity may precede a change in MBD. These study results 
demonstrated that the HAVAHT+Ai™ combination had a rapid physiological effect on high 
breast tissue elasticity in this cohort of women with high MBD.  
 
With the additional analyses that could be conducted with the 12-month follow-up 
mammogram, within this sample, the combination of HAVAHT+Ai™ descriptively produced an 
overall mean decrease in %VBD across the 12-months. In addition, the analyses showed that 
the TFV decreased over the 12 months, and this reduction was approaching the conventional 
benchmark for statistical significance with consistently large effect sizes across the 
participants. This decrease in TFV is of particular interest as the fibroglandular tissue is what 
constitutes the dense tissue, so a reduction in this tissue specifically may be able to reduce 
the breast cancer risk. Additionally, if an intervention can reduce the breast volume and the 
TFV, the %VBD value may not show a reduction, which could lead to Type II errors when 
accepting or negating the null hypothesis. Therefore, specifically seeing a change in this 
variable may beneficial. 
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One of the key objectives of this thesis is to determine if breast tissue elasticity can be used as 
a biomarker for MBD. Within this study, we were able to conduct correlation analyses on the 
changes in the breast elasticity with the changes in %VBD and the changes TFV. From these 
analyses, it showed that there was a statistically significant moderate correlation with the 
change in elasticity over three months to the change in TFV over the 12 months. The results 
also showed a moderate and strong correlation with the elasticity changes at month one and 
month two, respectively, with the TFV changes at 12 months. These result shows great 
promise that the elasticity changes may be able to represent and predict the density changes 
in a timelier manner, which is one of the strongest reasons to research breast elasticity as a 
biomarker for breast tissue changes. However, this study was unable to inform us as to what 
would happen to the elasticity values across a full 12 months. Furthermore, as this study was 
not sufficiently powered, we are unable to statistically demonstrate the significance of the 
results. Future research needs to be conducted with a formally powered sample size to 
demonstrate whether this relationship exists. 
 
One of the limitations of this study, as previously mentioned, is the sample size, as this was a 
pilot study, no formal sample size calculation was completed. This unmeasured statistical 
power means that although the results can show a sign of effect, the results are unable to 
show the level of significance and need to be interpreted with caution. A further limitation of 
this study is the lack of previous research for the use of SWE for this indication. When using 
SWE, there are a variety of post-hoc analysis techniques that can be used to calculate breast 
elasticity. However, SWE hasn’t been used to measure and evaluate changes for this 
indication, so no validated techniques have been published in the literature. Some of the 
results that were produced during this trial appeared to have a substantial amount of 
variation in the within-subject repeat measures. As this machine has not been used previously 
and the design of this trial was Phase 1, with no control group, we are unsure if this variability 
is natural fluctuations, measurement error, or the true results of the intervention on the 
breast tissue elasticity. In order to distinguish what may be causing the fluctuations, a 
reliability study, in women not receiving any hormonal intervention that could affect the 
breast, controlling for fluctuations in the participant’s menstrual cycle needs to be completed. 
This additional information will allow us to calculate the intra-rater reliability and determine if 
there are natural fluctuations within the breast tissue elasticity. 
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As mentioned, another limitation with the SWE machine is the lack of validated protocols to 
produce the whole breast elasticity results. When using the SWE machine, once the image 
has been saved, Q-box™ are placed on the image, these produce the mean, max, min, SD 
elasticity of the area within the Q-Box™. These are customisable regarding the diameter and 
the location they are placed, and there is also the option of tracing the image to develop a 
customised shaped Q-Box™. There is no set protocol to utilise the Q-Box™ to find the whole 
breast average elasticity. By changing the number, diameter and location of the Q-Box™, the 
elasticity values can change. Future studies need to be conducted to analyse the best method 
to find the average breast elasticity. This further information could aid future studies, to find a 
reliable and consistent method to determine the elasticity, which will be especially beneficial 
when designing longitudinal trials with repeat elasticity measures to detect true change. 
 
4.6 Conclusion 
Overall, this pilot study generated evidence to show an association between a reduction in 
breast elasticity and a singular dose of HAVAHT+Ai™. There is also early evidence that these 
changes may correlate with the changes occurring in TGV in response to the same 
intervention.  
 
4.7 Future Studies 
Future studies need to be conducted to firstly determine consistency in the response of 
elasticity with another intervention that can affect MBD variables. In addition, due to the 
fluctuations seen in this study, a reliability study looking at the behaviour of breast elasticity, 
not on any interventions that can influence the breast tissue, needs to be conducted to 
determine if these fluctuations are, as mentioned, measurement error or typical findings. 
Studies of this nature can be found in Chapter 6 and Chapter 8 of this thesis. 
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Chapter 5 Anastrozole and GTx-024: The Effect of an Aromatase 
Inhibitor and Selective Androgen Receptor Modulator on 
Mammographic Breast Density and Breast Elasticity in 
Premenopausal Women 
5.1 Background 
In Chapter 4, in response to the therapeutic intervention of T and anastrozole (HAVAHT+Ai™), 
it was demonstrated that mean breast elasticity and mean TFV decreased within the recruited 
cohort of women. Further to this, the decreases in the mean breast elasticity were seen as early 
as the one-month repeat measurement. This early data is promising for the primary objective 
of this thesis and has generated initial findings and hypotheses, that can be further developed. 
As with all new, novel ideas, further research is required to validate the present findings, 
decrease the impact of research biases on the results and generate new evidence to contribute 
to the overall body of evidence. To determine if breast elasticity can be influenced by 
therapeutic interventions targeted at reducing MBD and determine if these changes correlated 
with the changes in MBD and the VolparaDensity™ variables, it needs to be established whether 
breast elasticity can be modified with a different intervention than HAVAHT+Ai™. By 
establishing whether a different intervention produces similar results with breast elasticity and 
MBD changes, we can show consistency with the response, which will contribute to 
demonstrating that breast elasticity may be a valid biomarker for MBD. 
 
In addition to validating the findings, this chapter aimed to work through some of the 
limitations discussed in Section 4.5, one of which was the timing of the outcome 
measurements; the main issue being the omission of a 12-month SWE ultrasound to measure 
breast elasticity. As the schedule of assessments in Chapter 4 varied between the SWE breast 
elasticity measurements and the mammography variables, a study that had both variables 
measured at the same time points needed to be conducted to accurately calculate the 
relationship between the variables, and also to analyse the behaviour of breast elasticity across 
a 12-month time period. 
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This chapter is the second experimental trial conducted for this research program. A different 
hormonal combination was used to reduce oestrogenic drive and shift the E/A ratio towards an 
androgenic environment. This hormonal combination utilised an Ai (anastrozole) to block the 
conversion of androstenedione to E1 and testosterone to E2. The second component of the 
combination was a SARM (GTx-024 also called enobosarm). As discussed in Chapter 1, the 
rationale for using a SARM is that Ai’s are contraindicated in premenopausal women due to 
perturbations in the homeostatic mechanisms controlling ovarian function (Casper 2007). Thus, 
by administering GTx-024, we postulated that the impact of an Ai on the hypothalamic-pituitary 
axis would be circumvented and not result in ovarian hyper-stimulation, allowing the 
combination to reduce MBD without undue side effects. 
5.2 Objectives 
The primary objective of this trial was to determine whether the combination of enobosarm 
and anastrozole reduces the VolparaDensity™ MBD measurements of %VBD and TFV and 
breast elasticity in kPa as measured by SWE. 
The secondary objective of this trial was to determine whether the changes (if changes are 
observed) in the VolparaDensity™ mammography variables (%VBD and TFV) correlate with 
the changes in the breast elasticity in kPa as measured by SWE. 
 
5.3 Research Questions 
5.3.1 Primary Research Questions 
1. Does the combination of GTx-024 and anastrozole reduce %VBD and TFV in 
premenopausal women with high MBD? 
2. Does the combination of GTx-024 and anastrozole reduce breast elasticity in kPa in 
premenopausal women with high MBD? 
 
5.3.2 Secondary Research Questions 





5.4.1 Research Design and Ethical Approval 
This trial was designed to obtain data regarding the effect of anastrozole and GTx-024 in a 
patient population in a clinical situation, during a 12-month dosing regimen. Given the lack of 
previous studies researching this treatment regimen, a single-centre, open-label pilot study 
with a small group of premenopausal women was deemed the most suitable design to 
determine any signal of effect. Bellberry Limited HREC approved the study (approval number 
2016-02-099), and all patients provided informed consent. The study has also been registered 
on Clinicaltrials.gov (clinical trial identifier: NCT032646651). 
 
5.4.2 Patient Population 
The trial population consisted of premenopausal women. Participants were referred to the 
clinic for either the evaluation of high MBD or breast pain or both factors. Participants were 
screened for eligibility for study participation during the 21 days prior to the scheduled dosing 
date. At the screening visit, medical histories (including menstrual history) and demographic 
data, including sex, age, race, body weight (kg), and height (cm) were recorded. Other 
assessments included physical examination, breast examination, mammography (if not 
performed within the previous three months, utilising VolparaDensity™ analysis), complete 
vital signs, and laboratory tests as specified. Participants were eligible if they had 
premenopausal levels of FSH/LH/E2, VolparaDensity™ volumetric breast density of ≥ 15.5% 
(combined average both breasts) and breast pain in the previous month of equal to or greater 
than 40mm on a 100mm VAS for pain.  
 
5.4.3 Treatment Regimens 
Patients were scheduled to be treated daily for a 12-month period with the investigational 
product of both GTx-024 (GTx Pharmaceuticals, Memphis, TN) 9mg a day as three x 3mg soft 
gel capsules and anastrozole 1mg a day as singular a solid tablet. These treatments were 
dispensed monthly, and treatment compliance was recorded for each participant. The 
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investigational product was labelled according to the Australian Code of Good Manufacturing 
Practice for medicinal products. As the study was open label, no blinding was required.  
 
5.4.4 Outcome Measures 
As per the methodology in Chapter 4, MBD was measured using VolapraDensity™, which 
analyses a digital mammogram to provide the measurements of TFV in cm3, TBV in cm3 and 
from these measurements %VBD is calculated. Figure 5-1 is the visual output that is produced 
with VolparaDensity™. Mammograms were performed at baseline and month 12. Shear wave 
elastography was conducted using SuperSonic™ Imagine Aixplorer®® ShearWave™ ultrasound 
machine (Aixplorer®, France). The methodology for the SWE was described in Section 4.3.3. 
Shear wave elastography was done at baseline, month one, month three and month 12. 
Breast pain was measured using a 100mm VAS for breast pain (Appendix 2). Menopausal 
symptoms were measured using the Menopause Rating Scale (MRS) (Appendix 3) at baseline, 
month one, month three and month 12. 
 
 
Figure 5-1: VolparaDensity™ Output 
 
Blood tests were conducted at baseline, month one, month three, month six, month nine and 
month 12 for haematology, biochemistry and a hormonal profile including LH, FSH, E2, 
progesterone, total testosterone, FAI, SHBG. Blood tests were done by Clinpath Laboratories 
at Burnside Hospital and analysed at the corresponding laboratory. Serum plasma anastrozole 
levels were measured at months nine and 12. This was done by CPR Pharma Services Pty Ltd 
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(now known as Agilex Biolabs Pty Ltd), South Australia. All AEs were documented. The 
Schedule of assessments and procedures are presented in Table 5-1. 
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Table 5-1: Schedule of Assessments and Procedures 
























Screening X X  X X    X  
Baseline (pre-
dose) 
  X   X X X X X 
1 Months    X X X X   X 
3 Months   X X X X X X  X 
6 Months    X X     X 
9 Months    X X     X 
12 Months 
(end of study) 
 X X X X X X X  X 
15 Months 
(Follow-up) 
  X X X  X X  X 
End of trial/Early termination 
 
a Assessments were to be made in the following order: Vital signs, adverse events and blood sampling. 
b Physical examination includes breasts, height, weight and BMI calculation. 
c Serum pregnancy test. 
d Unless mammography performed in previous three months using VolparaDensity™ analysis on a New Generation Hologic mammogram machine (Dr Jones & Partners at Burnside War Memorial Hospital or St Andrews Hospital). 
e Safety laboratory tests: haematology and biochemistry. 
f Hormonal profile included LH, FSH, E2, progesterone, FAI, dehydroepiandrosterone sulphate (DHEAS) and SHBG. Repeat measurement of progesterone was to be carried out, 3 days post result, in participants not in the luteal phase of their menstrual cycle 
at the time of first assessment. 
g Assessment of breast tissue elasticity. The pre-dose assessment denoted the baseline. 
h Breast pain/stiffness as measured by a 100mm visual analogue pain scale. 
i As measured by menopause rating scale  
j Vital signs included seated systolic and diastolic blood pressure, pulse rate and body temperature. 
k Adverse Events and Concomitant Medication were collected, following consent, at every visit and unsolicited for the duration of the trial. 
 105 
5.4.5 Data synthesis and Analytical Procedures 
All data were tabulated into Microsoft Excel 2016 (Microsoft, USA). SPSS version 25 (IBM, 
USA) was used to compute the descriptive statistics and inferential statistics. The significance 
level was set a priori with a p-value equal or less than 0.05, with a 95% CI presented for the 
primary and secondary analyses. All subjects were included in the analysis using the intention-
to-treat principle. Population sample characteristics were reported using descriptive statistics. 
 
The distribution of the data was assessed via the Shapiro-Wilk test with a p-value greater than 
0.05 determining the data were normally distributed. Outliers were determined by a visual 
assessment of a box plot; any determined outliers were further analysed to be grouped as 
true values or measurement errors; if the values were deemed true values, they were left 
within the analysis.  
 
The pre- and post-intervention data for the mammography variables (%VBD, TFV, TBV) were 
analysed using a paired samples T-test for parametric data; the Wilcoxon-Signed Rank test 
was used for non-parametric data. The breast elasticity at each of the four time points was 
analysed using a one-way repeat measure analysis of variance (ANOVA) with post-hoc 
Bonferroni adjustments for parametric data. Friedman test was the alternative statistical 
model for the one-way repeat measure ANOVA, for non-parametric data. Correlation analyses 
were conducted using Pearson’s correlation coefficient for the parametric data. Spearman’s 
Rank Order Correlation Coefficient was used for non-parametric data. 
 
5.5 Results 
5.5.1 Participant Characteristics 
Eight participants were recruited during the period of January 2017 to May 2017. Table 5-2 
presents the participant demographic characteristics. The average treatment compliance was 
97.7% (SD 3.7%), with 12.5%of participants having 100% compliance. One participant 








Age (years) 40 (3.2) 
Weight (kg) 64.6 (11.1) 
Height (m) 168.4 (2.5) 
BMI (kg/m2) 22.8 (3.5) 
%VBD 21.70% (3.7) 
Pain (VAS) 71.13 (16.4) 
MRS 12.86 (6.2) 
% of Participants 
Gender (Female) 100% 
Race (White) 100% 
Race (White/Asian) 0% 
Ethnicity  




5.5.2 Mammography Variables 
5.5.2.1 Percentage Volumetric Breast Density 
Table 5-3 presents the mammography variable data. The %VBD data were normally 
distributed, and no outliers were present in the data. The participants had a greater 
baseline %VBD of 21.7% (SD 3.7%) compared to the end of study (EOS) values of 18.5% (SD 
4.7%), this was a decrease of 3.2% (95% CI -6.67 to 0.26; p = 0.065). This result had a Cohen’s 
D effect size of 0.78.  
  
%VBD = Percentage volumetric breast density as 
measured with VolparaDensity™ 
VAS = Visual analogue scale 
MRS = Menopause rating scale 
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Table 5-3: Mammography Variable Values 





95% CI p-value 
%VBD 
Baseline 21.7% (3.7)    
12 Month 18.5% (4.8) -3.2% (4.1%) -6.67% to 0.26 0.065 
Total Fibroglandular Volume 
Baseline 226.3cm3 
(112.1) 
   
12 Month 131.6cm3 
(82.0) 
-94.7cm3 (33.7%) 67.01 to 122.45  <0.005 
Total Breast Volume 
Baseline 1115.4cm3 
(235.9) 
   









5.5.2.2 Total Fibroglandular Volume 
Table 5-3 presents the TFV variable data. The TFV data was positively skewed, with a Shapiro-
Wilk test result showing a p-value of 0.034; thus, the data was not normally distributed. There 
were no outliers present within the data. The Wilcoxon-Sign Rank test was used to analyse 
the data. The median TFV was greater at baseline with a value of 185.1cm3 compared to the 
12-month time point with a median value of 111.4cm3. There were eight negative differences, 
and zero positive differences and ties. This was a median difference of -79.4cm3 with a p-
value of 0.008.  
 
5.5.2.3 Total Breast Volume 
Table 5-3 presents the TBV data. The TBV data were normally distributed as per the Shapiro-
Wilk test with a p-value of 0.735. There were no outliers present within the data. Total breast 
volume was greater at baseline with a value of 1115.4cm3 (SD 667.6cm3) compared to the 
12-month (end-of-study) values of 794.8cm3 (SD 660.3cm3). This was a change of -320.6cm3 
(95% CI -430.8cm3 to -210.4cm3; p<0.005). This result had a Cohens D value of 0.65. 
 
%VBD = Percentage volumetric breast density as measured with VolparaDensity™ 
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5.5.3  Average Whole Breast Elasticity 
Table 5-4 presents the average and median whole breast elasticity values at each time point. 
The baseline, month three and month 12 data were not normally distributed; the month one 
data were normally distributed. 
 
Table 5-4: Whole breast elasticity average, median and test for normality values 
Time Point Average Elasticity in 
kPa (SD) 
Median 
Elasticity in kPa 
Shapiro-Wilk 
Test p-value 
Baseline 17.9 (9.4) 17.2 0.015 
Month 1 14.3 (4.8) 13.5 0.396 
Month 3 13.9 (7.8) 12.8 0.000 
Month 12 12.6 (5.3) 11.9 0.048 
 
Within the four datasets, there were five outliers that were greater than one-point-five box 
lengths from the edge of the boxplot; these were in the baseline, month three and month 12 
dataset. These were deemed to be correct values and were not excluded from the analysis. 
There was an extreme outlier in the three-month dataset; this is classified as being greater 
than three box lengths from the edge of the box. Again, this was deemed to be a correct 
figure and was left in the analysis. Due to the data being non-parametric, the Friedman test 
was used to analyse the data.  
 
The results from the Friedman test showed that breast elasticity was statistically significantly 
different at the different time points in response to the GTx-024 and anastrozole hormonal 
combination with a p-value of 0.003. Pairwise comparisons were performed with Bonferroni 
corrections for multiple comparisons. There were statistically significant differences between 
the baseline and the 12-month elasticity data with a p-value of 0.001. The complete results 
from the pairwise comparisons are presented in Table 5-5. 
 
Table 5-5: Results of the whole breast elasticity Friedman pairwise comparisons 
Pairwise Comparison p-value 
Baseline – 1 month 0.490 
Baseline – 3 months 0.147 
Baseline – 12 months 0.001 
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5.5.4 Correlations Between Mammography Variables and Breast Elasticity 
Correlation analyses were run between the mammography variables and the whole breast 
elasticity data. All of the correlation coefficient results are presented in Table 5-6. The most 
notable correlation was between the change in breast elasticity from baseline to month 12 
and the change in TFV from baseline to month 12; this resulted in a moderate correlation 
with a r-value of 0.586, this correlation had a p-value of 0.127 (Figure 5-2). In this analysis, the 
data of the change in TFV was not normally distributed and was transformed using 
logarithmic transformation. The correlation analysis between the change in breast elasticity 
from baseline to one month and the change in TFV from baseline to month 12 resulted in an 
r-value of 0.500, with a p-value of 0.313. Lastly, the change in breast elasticity from baseline 
to month one and the change in TBV from baseline to month 12 with a r-value of 0.585, with 
a p-value of 0.223. 
 
 
Figure 5-2: Correlation between total fibroglandular volume change (baseline to month 12) and elasticity change (baseline 




Table 5-6: Correlation coefficient results between breast elasticity and mammography variables 
Correlation Pearson’s R p-value 
Baseline Correlations 
Breast elasticity and TBV 0.246 0.557 
Breast elasticity and TFV 0.470 0.221 
Breast elasticity and %VBD 0.264 0.528 
End of Study Correlations 
Breast elasticity and TBV 0.854 0.007 
Breast elasticity and TFV 0.842 0.009 
Breast elasticity and %VBD 0.273 0.523 
Baseline to End of Study Change Correlations   
Breast elasticity and TFV 0.586 0.127 
Breast elasticity and TBV 0.280 0.502 
Breast elasticity and %VBD -0.12 0.997 
Elasticity Change at 1 month and all other Baseline to 
End of Study Change Correlations 
  
Breast elasticity and TFV 0.500 0.313 
Breast elasticity and TBV 0.585 0.223 
Breast elasticity and %VBD -0.451 0.262 
 
 
5.5.5 Blood Analysis 
All blood serum hormone results are presented in Appendix 4; LH, FSH, E2, progesterone, 
testosterone and DHEAS remained stable through the study, with no out of range values. Free 
androgen index was increased at all time points except for baseline; the mean values at 
month six, nine, and 12 being 7.44%, 10%, 6.53%, respectively. Sex hormone binding globulin 
was significantly decreased at all time points in 87.50-100% of the participants, the mean 
values at month one, three, six, nine and 12 being 12.88nmol/L, 11.63nmol/L, 10nmol/L, 
11.00nmol/L, 11.63nmol/L, respectively. Serum plasma anastrozole levels were 30.09ng/ml 
(SD 9.42ng/ml) at nine months and 29.74ng/ml (SD 7.59ng/ml) at 12 months.   
 
%VBD – Percentage volumetric density as analysed with 
VolparaDensity™  
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5.5.6 Adverse Events 
There was a total of 88 AEs across all eight participants. There were 11 AEs that were deemed 
related or possibly related to GTx-024 and anastrozole, and these are all listed in Table 5-7. 
These AEs ranged from mild to moderate severity, the most commonly occurring AEs being 
increased alanine aminotransferase (ALT) (47u/L, 125 u/L and 98 u/L). There were no serious 
adverse events, deaths or withdrawals from the study due to any AEs. 
 
Table 5-7: List of adverse events (AEs) related 
Commonly Occurring 





Night Sweats 2 
Acne 2 
Voice changes 2 
Hair Loss 1 
Moderate Severity 
Increased ALT 3 
Voice changes 1 
 
5.6 Discussion 
This is the first study utilising GTx-024 and anastrozole therapy in premenopausal women for 
the reduction of MBD. This initial evidence for the proof of concept regarding the efficacy of 
this combination was demonstrated in both the primary endpoint of %VBD and TFV and the 
secondary endpoint of breast elasticity. In regards to the primary research question, the 
results showed that %VBD had an average reduction of -3.2%, this is a relative reduction of -
14.75% which is above the 10% MBD reduction required for breast cancer risk reduction 
benefits as stated by Cuzick, Warwick et al. (2011). This reduction was also trending towards 
the conventional level of statistical significance with a p-value of 0.065. Following the 
decreases in %VBD, the TFV had a statistically significant reduction of -79.35cm3, which was a 
relative reduction of 41.86%. This TFV reduction is more than double the 20% reduction in the 
dense area seen in women treated with tamoxifen, which lead to a 50% reduction in breast 
cancer mortality (Li, Humphreys et al. 2013). Furthermore, TBV had a statistically significant 
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reduction of -320.63cm3, this being an absolute reduction of 28.75%. These are significantly 
large decreases that have been seen in a small number of women and indicate that this 
treatment may be favourable for the indication of reducing MBD variables. The significant 
decrease in TFV is of great relevance as this reduction represents a decrease in the stromal 
and fibroglandular part of the breast tissue; this being the tissue of interest regarding MBD 
and the reductions that lead to beneficial effects in breast cancer risk. These results indicate 
that the combination of GTx-024 and anastrozole is able to reduce %MBD, TBV and TFV in a 
small population of women. Having validated the effect of this combination on MBD variables, 
the next stage is to analyse how the breast elasticity responds to the same hormonal 
intervention and how these changes correlate with the changes in the mammography 
variables. 
 
The second objective of this study was determining whether the hormonal combination of 
GTx-024 and anastrozole, in addition to the MBD variables, was able to reduce breast 
elasticity. For this research objective, there were also favourable results, as the findings show 
that there was a statistically significant reduction in breast elasticity at the 12-month 
measurement, with a reduction of -5.37kpa, this being a relative reduction of 30.4%. There 
were also decreases in breast elasticity reported at each time point with a reduction of -
3.69kPa (relative reduction of 20.6%) at one month and -4kPa (relative reduction of 22.3%) at 
the three-month time point. This investigational product is the second hormonal combination 
that has decreased both MBD variables and breast elasticity, which indicates that there is 
consistency in the response, which can further provide evidence that breast elasticity may be 
a valid biomarker for MBD. These results also further demonstrate that breast elasticity 
responds at a very early stage to the intervention. Within the first month, 67% of the 
reduction that occurred over the 12 months had already been observed. This early elasticity 
reduction may be used to show signs of early response. With this early response being 
favourable for the indication of determining patient response to interventions that reduce 
MBD. Aiding the decision that a woman may be a responder or a non-responder to the 
therapy and whether they should continue the therapy, as many of these interventions have 
undesirable side effect profiles.  
 
The third part of this study was analysing whether the changes in %VBD and TFV correlate 
with the changes in breast elasticity. This analysis needed to be conducted to demonstrate 
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that the change in elasticity relates to the changes in the mammography variables. If there is 
the correlation, and as elasticity is responding to the intervention at such an early time point, 
breast elasticity may be able to predict the changes in %VBD and TFV. The results from this 
study show that there was an insignificant negative, weak correlation between the changes in 
breast elasticity with the change in %VBD. It was also analysed whether the changes in breast 
elasticity at one month correlated with the changes in %VBD across the 12-month 
intervention period. This analysis was done to determine if breast elasticity has the potential 
to be used as an early indicator for MBD changes. These results demonstrate that within this 
cohort, there is no correlation between these two variables. 
 
However, when analysing the correlation between breast elasticity and TFV, there were more 
favourable results. The results showed that there was a moderate correlation at one month 
and at 12 months. Both of these findings were statistically insignificant, but as the study was 
underpowered, there is some data to promote further research that change in breast 
elasticity may correlation with changes in TFV, which is still beneficial for breast cancer risk 
and mortality reduction (Li, Humphreys et al. 2013).  
 
These correlations with both %VBD and TFV, in particular, TFV showed that there is somewhat 
of a relationship. However, the aim of this research program is to validate elasticity to be used 
as an early indicator of response to interventions to reduce MBD as MBD takes an extended 
time to show significant changes. Longer studies may lead to a stronger correlation between 
these three variables, as there is more time for changes in %VBD and TFV to occur. Another 
explanation for the weaker than expected correlation between elasticity and %VBD is 
that %VBD is calculated with the TFV and TBV, which in this study both decreased. This 
indicates that the %VBD may not have changed at the same rate as the elasticity and the TFV 
variables. 
 
As mentioned, some of these findings were statistically insignificant, however, this was a pilot, 
proof of concept pharmacokinetic study, so when observing the trends for the decreases and 
the correlations that were described, the results are favourable to generate and guide future 
studies. The findings within this study indicate that as the fibrodense region of the breast 
decreases, the breast elasticity may also decrease. This is favourable as with further research, 
elasticity may be used as a non-invasive and comfortable biomarker to determine the early 
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response of breast tissue to hormonal interventions. Thus, allowing healthcare providers to 
modify the treatment approach based on whether the patient is a responder or a non-
responder. This knowledge can influence patient management, their health-related outcomes 
and the cost of the treatment (Manton, Chaturvedi et al. 2006). 
 
This study does have some limitations which need to be taken into consideration when 
interpreting the findings. Firstly, as it was an early proof of concept pharmacokinetic study, 
only eight women were recruited. For this reason, this study was not powered to prove 
statistical significance; this meaning that although the results can show a sign of effect in 
regard to the breast tissue elasticity and the mammography variables, we cannot provide a 
definitive conclusion regarding the outcomes. A further limitation was the study design; it was 
an open-label, phase II drug trial, which did not have a control group. By not having a control 
group (and not controlling all variables), we are unable to determine if there was a causal 
relationship between the hormonal intervention and the effect on the breast tissue. For the 
same reason, we are also unable to report what would have occurred in the breast tissue of 
women not on the hormonal intervention. More rigorous research designs, such as an RCT, 
with a placebo-controlled group are required to determine if GTx-024 and anastrozole is the 
causal factor for the reduction in MBD and breast elasticity, and the subsequent reduction in 
breast cancer risk. 
 
A further limitation of this study was the within-subject variation of the breast elasticity data. 
There appeared to be a substantial level of observed fluctuations in the SWE repeat 
measurements (which was also reported in Chapter 4). As there was no control group and no 
normative data from previous research using SWE for this indication, we are unable to 
determine if the elasticity values were reflecting the response of the breast tissue to the 
intervention, measurement error or natural fluctuations. Further research should done on 
healthy subjects, controlling for hormonal fluctuations to determine the normative values, 
and the normal fluctuations in breast tissue elasticity that may occur in a premenopausal 
patient population. This data is integral for the interpretation of these results and any future 





5.7  Conclusion 
This study aimed to determine if enobosarm and anastrozole, a novel hormonal combination 
of an Ai and a SARM, used in premenopausal women with high MBD, could reduce %VBD, TFV 
and breast elasticity. This study generated evidence that this combination had signs of being 
efficacious at reducing %VBD, TFV and breast elasticity. Although not reaching the 
conventional threshold for statistical significance, there was a strong correlation between the 
changes in breast elasticity and TFV. These results are encouraging for breast elasticity being 
a viable biomarker for MBD. To further validate these findings, future research needs to be 
conducted with a more rigorously designed, adequately powered, placebo-controlled, 
double-blind RCT to determine if there was a causal relationship between GTx-024 and 
anastrozole and the reductions in %VBD, TFV and breast elasticity. Additionally, as suggested, 
further research also needs to be done to determine the natural fluctuations that occur with 
the elasticity of the breast across the month due to hormonal fluctuations when a woman is 
not on any hormonal interventions. 
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Chapter 6 Does the Region of Interest Size Affect the Breast 
Elasticity and Coefficient of Variation of a Data Set Analysing the 
Average Breast Elasticity of Women on Hormonal 
Chemopreventative Therapy? 
6.1 Introduction 
Shear wave elastography operates by having the ultrasound beams generate acoustic 
radiation force impulses (ARFI), which provide the mechanical excitation through pushing 
beams that deform the underlying tissue of interest. Several of these pushing beams are 
transmitted at different depths, which result in the propagation of transient shear waves. The 
speed of these shear waves is then measured using a scanner with a very fast frame rate, 
allowing the shear waves to be followed in real-time. This is repeated for different lines; 
allowing a map of a ROI to be created from analysing the differences in arrival times and 
calculating the shear wave speeds. A colour-coded image is then displayed on the SWE 
monitor, a Q-Box™ which is a measuring tool is placed on this image, which provides an area 
for the elasticity variables to be calculated.  The quantitative data is presented as a measure 
of shear wave speed in m/s-1 or converted to the Young’s Modulus and displayed as kPa 
(Bercoff, Pernot et al. 2004, Bercoff, Tanter et al. 2004, Sebag, Vaillant-Lombard et al. 2010, 
Shiina, Nightingale et al. 2015).  
 
To date, within the field of breast imaging, the predominant use of SWE is differentiating 
between benign and malignant lesions. For this indication, the common technique to quantify 
the tissue elasticity is to use a circular Q-Box™ that usually ranges in size from 2-3mm in 
diameter, which is then placed over the stiffest part of the lesion (it may also include the area 
immediately adjacent to this region). Another Q-Box™ is then placed on an adjacent area of 
fatty tissue to provide a reference value (Chang, Moon et al. 2011, Berg, Zhang et al. 2012, 
Youk, Gweon et al. 2013, Au, Ghai et al. 2014). This is a practical technique as it has been 
found that, with exceptions, malignant masses are of a greater elasticity than benign, so it is 
imperative that the quantitative values of the stiffest region of the lesion are known. A further 
use of SWE is determining the effectiveness of neoadjuvant chemotherapy on malignant 
breast lesions, for which the same technique as differentiating benign or malignant breast 
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lesions is used. However, this indication uses repeat measures to quantify the changes 
occurring in the elasticity values (Evans, Armstrong et al. 2013, Jing, Cheng et al. 2016, Ma, 
Zhang et al. 2017).  
 
Few studies have used SWE to calculate the average breast elasticity of the entire breast and 
not just a particular lesion. In current literature, the techniques chosen to measure breast 
elasticity with the absence of a lesion, have been to use either the outer upper region of the 
breast (Li, Wang et al. 2015) or divide the breast into four quadrants (Rzymski, Skórzewska et 
al. 2011, Rzymski, Wysocki et al. 2011, Rzymski, Wilczak et al. 2012) and place one 3mm Q-
Box™ on an area of the image that represents the glandular tissue and one that represents 
the fatty tissue, which provides the minimum, mean, maximum and SD of both the fatty and 
the glandular tissue and additionally the glandular to fatty ratio. There are weaknesses with 
using these techniques. Firstly, the different regions of the breast have varying amounts of 
glandular and fatty tissue and it has been seen that the mean elasticity of the glandular tissue 
can vary in the different quadrants (some areas having greater or lower elasticity). Secondly, 
the elasticity values are variable throughout each SWE image; relying on one Q-Box™, again, 
may not provide an accurate representation of the true mean elasticity for each quadrant of 
the breast and subsequently, the whole breast. Using this technique can also increase the 
operator’s influence on the elasticity values, as the operator can bias the data by placing the 
Q-Box™ on an area of greater or lesser elasticity, whichever favours their intentions. This 
operator dependence is particularly problematic for longitudinal studies or studies analysing 
the efficacy of therapeutic interventions, as unless the Q-Box™ location is kept constant, 
unreliable findings can be reported. 
 
6.2 Objective 
Currently, there is no published literature reporting the differences in the mean elasticity 
values between differing breast quadrants and the impact of using different sized Q-Box™ or 
the number of Q-Box™ on the overall elasticity values. As there is increasing interest in 
researching whole breast elasticity for a variety of indications, there needs to be a 
standardised protocol in regard to the breast quadrants used and Q-Box™ size, frequency and 
location on the SWE image. This will improve the reliability and accuracy of calculating the 
mean whole breast elasticity. The objective of this research is to determine if using different 
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post-hoc analysis protocols can significantly change the overall elasticity values and to find a 
protocol which provides the most precise data attenuation for future research. 
 
6.3 Method 
6.3.1 Patient Demographics 
The data was acquired from a collection of SWE images of 11 women who were participants 
of a clinical trial at Wellend Health Pty Ltd (Chapter 4 – HAVAHT+Ai™ study), South Australia 
(Bellberry Limited Human Research Ethics Committee approval number 2017-06-434). 
Participants of this trial all provided permission for their images and data to be used for 
subsequent research. Women were recruited into the initial trial if they had a 
VolparaDensity™ %VBD of ≥ 15.5% (combined average both breasts), aged between 33-55 
years inclusive, body weight between 50 and 90kg inclusive and in good general health. 
Please refer to Chapter 4, Section 4.3.1 for full eligibility criteria. 
 
6.3.2 Shear Wave Elastography Imaging Protocol 
Breast SWE was conducted using the SuperSonic™ Imagine Aixplorer® ShearWave™ 
elastorgaphy machine (Aixlorer, France). Four images were taken per breast, one in each 
quadrant (Fig. 6-1), the transducer head was held still for 5 to 10 seconds in order for the 
shear waves to propagate through the tissues. A generous amount of contact gel was used to 
prevent artefactual stiffness from being recorded. Please refer to Chapter 4, Section 4.3.3 for 
further details regarding the method for the capturing of the SWE images.  
 
 
Figure 6-1: Image sequence of the breast quadrants used in shear wave elastography 
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6.3.3 Elasticity Data Generation 
Seven different protocols were used to generate the elasticity data from the SWE images. The 
protocols used were a circular Q-Box™ with varying diameter and frequencies, the Q-Box™ 
trace function and the Q-Box™ ratio function. The original protocol that was used in Chapter 4 
and 5 of this thesis was the 6 x 3mm Q-Box™ placed evenly across the image (Figure 6-2), this 
then determined the minimum, maximum, mean and standard deviation of the tissue 
elasticity measured in kPa and the depth of the placing of each Q-Box™. The 6 x 3mm Q-Box™ 
protocol, as stated in Section 4.3.3, was advised as the method to be used by the Medical 
Director of Wellend Health Pty Ltd. 
 
 
Figure 6-2: Shear Wave Elastography Image with 6 x 3mm Q-Box™ places evenly over the image 
 
From the 6 x 3mm Q-Box™, the mean elasticity was calculated per quadrant, per breast and 
the overall breast elasticity. The same calculations were conducted using six, six-millimetre (6 
x 6mm) Q-Box™ (Figure 6-3), one ten millimetre Q-Box™ (Figure 6-4), using the Q-Box™ trace 
function to trace the entire image (Figure 6-5), and using the Q-Box™ trace to trace the 
desired ROI, not including the elasticity artefacts and ‘black holes’, which are locations within 
the image where the elasticity does not correspond to the B-mode images and produces 
extremely high elasticity figures or where shear waves have not been calculated, leaving the 
elasticity as zero, respectively (Figure 6-6). These different protocols were chosen for a variety 
of reasons; the diameter of the other Q-Box™ were arbitrary in value but were used to 
determine if altering the size and frequency could have a greater clinical utility or a greater 
level of reliability. The Q-Box™ trace function was chosen, as on face value, appeared as 
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though it would be time-efficient and as it incorporates the largest area of the breast easily 
omitting any artefacts and black holes, it was hypothesised that it could generate the most 
valid data. The Q-Box™ trace function was also a technique used by Evans (2015) for research 




Figure 6-3: Shear Wave Elastography image with 6 x 6mm Q-Box™ es places evenly across the image 
 
 




Figure 6-5: Shear Wave Elastography image with a Q-Box™ traced around the border of the region of interest 
 
 
Figure 6-6: Shear Wave Elastography image with the Q-Box™ traced within the region of interest, avoiding artefacts or black 
holes 
 
The last two methods of calculating the elasticity were using the Q-Box™ ratio function, firstly 
placing one 3mm Q-Box™ on an area that represents glandular tissue and another 3mm Q-
Box™ on an area that represents predominately fatty tissue (Figure 6-7). Within the image, 
fatty tissue appeared black on the B-mode image and dark blue on the shear wave image. 
Glandular tissue appeared white on the B-mode image and light blue on the shear wave 
image. This technique provided the minimum, maximum, mean elasticity of both the 
glandular and the fatty tissue in addition to the glandular-to-fatty elasticity ratio. The Q-Box™ 
ratio function was then repeated, this protocol was slightly altered with a customised sized Q-
Box™ (Figure 6-8); the size of the Q-Box™ depended on the area of the glandular and the fatty 
tissue. This protocol was done to ensure the Q-Box™ only contained the tissue of interest. For 
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this study, the elasticity from the singular glandular tissue Q-Box™ was used as the breast 
elasticity data; the actual ratio was not included in this analysis. 
 
 
Figure 6-7: Shear Wave Elastography image using Q-Box™ ratio function, placing a 3mm Q-Box™ on an area of glandular 
tissue and an area of fatty tissue 
 
 
Figure 6-8: Shear Wave Elastography Image using Q-Box™ ratio function, placing a 3mm Q-Box™ on an area of glandular 
tissue and a 1mm Q-Box™ on an area of fatty tissue. This image also shows areas where the shear wave hasn't propagated 
 
 
6.3.4 Statistical Analysis 
The data were entered into Microsoft Excel (2016), and statistical analysis was conducted 
using SPSS 25 (IBM, New York, USA). The 6 x 3mm Q-Box™™ protocol was used as the 
reference standard for the analyses, while the other protocols are the index tests. The data 
were analysed using repeated measures ANOVAs with Bonferroni post-hoc analysis to 
determine if there was a statistically significant difference between the reference standard 
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and the index test, this analysis was done for all of the different quadrants of the breast, left 
and right breast and both breasts combined. In addition, the coefficient of variation (CV) was 
calculated for each protocol, and this provided the levels of dispersions of each of the 
variables. A Bland-Altman plot was used to find the level of agreement between the 
references standard and the other variables. Where applicable, statistical significance was 
determined with a p-value ≤ 0.05, and a confidence interval that did not cross zero.  
 
6.4 Results 
6.4.1 Participant Demographics 
The data for this chapter were collected from the 11 participants that were recruited for the 
study in Chapter 4. All the participant demographic data have previously been reported in 
Section 4.4.1. All participants had their data included in all the analyses. 
 
6.4.2 Determining the Reference Standard 
As reported in Section 6.2, the objective of this study was to determine the best method of 
extracting the breast elasticity data from the shear wave elastography image. The 6 x 3mm Q-
Box™ was decided as the reference standard as it was the method previously advised as the 
method to use to collect elasticity data from the Medical Director at Wellend Health Pty Ltd, 
who worked closely with the Supersonic Aixplorer® Adelaide, South Australia representative.  
 
The initial analysis was looking at the whole breast combined dataset; this was the mean of 




Table 6-1: Descriptive statistics for average breast elasticity for each protocol 
Variable Mean (SD) in kPa 
6 x 3mm Q-Box™ 10.90 (4.35) 
6 x 6mm Q-Box™ 11.30 (4.30) 
1 x 10mm Q-Box™ 9.71 (3.780) 
ROI Full trace 12.21 (4.81) 
ROI Free-Trace 10.68 (3.60) 
Ratio Glandular Q-Box™ 13.51 (4.71) 




The whole breast elasticity dataset was normally distributed, and there were no outliers 
present within the data. According to Mauchly’s test for sphericity, the sphericity of the data 
was violated. The Epsilon (ε) was 0.605, as calculated according to Greenhouse and Geiser 
(1959) and was used to correct the one-way repeated measure ANOVA. The breast elasticity 
values from a number of the difference protocols were statistically significantly different from 
the 6 x 3mm Q-Box™™ protocol, F (3.318, 142.661) = 40.833, p<0.0005. In regard to the 
pairwise comparison, all the results can be found in Table 6-2.  
 




Index Protocol Mean Difference 
(kPa) 
95% Confidence Interval p-value 
6 x 3mm Q-Box™ 6 x 6mm Q-Box™ -0.40 -0.82 to 0.02 0.081 
 1 x 10mm Q-Box™ 1.19 0.68 to 1.70 <0.0005 
 ROI Full Trace -1.31 -2.12 to -0.50 <0.0005 
 ROI Free-Trace 0.22 -0.30 to 0.74 1.000 
 Ratio -2.61 -3.40 to -1.82 <0.0005 
 Alternative Ratio -0.40 -1.45 to 0.66 1.000 
 
When comparing the 6 x 3mm Q-Box™ data to the 6 x 6mm Q-Box™ data, there was a 
statistically insignificant mean difference of -0.40kPa (95% CI -0.82 to 0.02; p = 0.081). This 
demonstrates that although the 6 x 6mm data provides a slightly lower mean elasticity value, 
there were no real differences between the protocols. The comparison between the 6 x 3mm 
Q-Box™ data to the 10mm data revealed a statistically significant mean difference of 1.19kPa 
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(95% CI 0.68 to 1.70; p<0.0005). This result demonstrated that the 10mm Q-Box™ 
consistently gave higher readings than the 6 x 3mm protocol. There was a statistically 
significant mean difference between the 6 x 3mm Q-Box™ data and the full-box trace data 
with a mean difference of -1.31kPa (95% CI -2.12 to -0.50; p<0.0005). This result 
demonstrates that the full-box trace produced consistently lower whole breast elasticity 
values when compared to the 6 x 3mm Q-Box™ data. There was a statistically insignificant 
difference between the 6 x 3mm Q-Box™ and the Free-Trace Q-Box™ data of 0.22kPa (95% CI 
-0.29 to 0.74; p=1.000), as with the 6 x 6mm Q-Box™ data, there was no real difference 
between the Free-Trace Q-Box™ data and the 6 x 3mm Q-Box™ data. There was a statistically 
significant difference of -2.61kPa (95% Ci -3.40 to -1.82; p<0.0005) between the original ratio 
data and the 6 x 3mm Q-Box™ data. Interestingly, there was a statistically insignificant 
difference of -0.40kPa (95% CI -1.45 to 0.66; p=1.000) between the alternative ratio data and 
the 6 x 3mm Q-Box™ data. 
 
As there seemed to be a significant difference between the original ratio data and the 
alternate ratio data, the results from the repeat measures ANOVA were recorded for these 
two variables. When comparing the original Q-Box™ ratio data to the alternative Q-Box™ ratio 
data, there was a statistically significant mean difference of 2.22kPa (95%CI 1.08 to 3.35; 
p<0.0005). This result alluded to the hypothesised inconsistency that can occur when using 
the Q-Box™ ratio as a technique to generate the breast elasticity data. This is due to this 
technique using a singular Q-Box™, and the fluctuating elasticity within a particular ROI; so, 
the positioning of the Q-Box™ can significantly influence the elasticity data. This may be why 
there is a statistically significant difference between the data using the original ratio and the 
alternate ratio protocol. 
 
The next stage of the analysis was to determine the coefficient of variation for the data 
generated using each of the protocols. The coefficient of variation is a measure of the 
dispersion of the data and is defined as the ratio of the SD to the mean. The protocol which 
generates the lowest CV shows a greater level of precision than the remaining protocols. The 
CV results are presented in Table 6-3. The protocol with the lowest coefficient of variation 
was the whole breast Free-Trace Q-Box™. 
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Table 6-3: Coefficient of variations of elasticity protocols 
Elasticity Protocol Mean Coefficient of 
Variation % (SD) 
6 x 3mm Q-Box™ 51.80% (8.81) 
6 x 6mm Q-Box™ 52.22% (19.80) 
1 x 10mm Q-Box™ 39.76% (11.94) 
Q-Box™ Full Trace 31.02% (9.77) 
Free-Trace 30.96% (9.22) 
Original Ratio Data 39.27% (10.33) 
Alternative Ratio Data 34.28% (9.17) 
 
 
6.4.3 Bland Altman Plots 
The next stage of this analysis is using a Bland Altman plot. A Bland Altman plot was proposed 
in 1983 (Altman and Bland 1983) and is used to describe the agreement and precision of two 
quantitative measurements by creating limits of agreement. These limits of agreement are 
calculated using the mean and the standard deviation of the differences between the two 
measurements. The Bland Altman plot is interpreted informally; however, Altman and Bland 
(1983) recommended that 95% of the data points should lie between the limits of agreement. 
When interpreting the plot, the solid line represents the bias, which is computed as the 
breast elasticity value generated by one of the protocols minus the value of the other 
method. Ideally, this bias should be close to zero; however, if not, it indicates that the two 
methods are systematically producing different results. In addition, when interpreting the 
plot, the limits of agreement and the bias need to be considered in a clinical manner, if the 
bias is large and the limits of agreement are wide, this may indicate the results are 
ambiguous, and the SWE protocol is not a valid method to generate the breast tissue 
elasticity. The 6 x 3mm Q-Box™ protocol remains the reference standard for the Bland Altman 
plots. Figure 6-9 shows the Bland Altman plot of the 6 x 6 mm Q-Box™ protocol and the 3 x 




Figure 6-9: Bland Altman plot with 6 x 6mm Q-Box™ and 6 x 3mm Q-Box™ protocol data 
 
For this plot, the bias is 0.4kPa which is a relatively small bias and would not impact the 
clinical interpretation of the data. The upper limit of agreement was 2.09kPa, and the lower 
limit of agreement was -1.29kPa, there is a large spread of the data points above and below 
the bias, and there are three data points that fall outside the 95% limits of agreement. There 
also is appears to be a larger spread of the data as the elasticity increases, which may 
represent a proportional bias. Figure 6-10 shows the Bland Altman plot of the 10mm Q-Box™ 
data and the 6 x 3mm Q-Box™ protocol data. 
 
 

































Mean Elasticity (kPa) of original Ratio Q-Box™ and 6 x 3mm Q-Box™
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This plot has a larger bias of -1.19kPa, which demonstrates that the measures are producing 
systematically different elasticity measurements. The limits of agreement are also clinically 
relevant as the lower limit is -3.23kPa, which shows the measurement error with the 10mm 
Q-Box™ would produce ambiguous results as the limits are large enough to make the 
interpretation of the results by clinicians or researchers difficult; as they would not be able to 
determine if changes in elasticity are relating to a true change in the tissue or due to 
measurement error. Figure 6-11 shows the Bland-Altman plot of the full-box trace Q-Box™ 
data and the 6 x 3mm Q-Box™ protocol data. 
 
 
Figure 6-11: Bland Altman plot with Full-Box Trace Q-Box™ and 6 x 3mm Q-Box™ protocol data 
 
The Bland-Altman plot for the full-box trace Q-Box™ shows that the bias is quite high with a 
value of 1.31kPa and the upper limit of agreement is 4.58kPa. Again, this shows that using this 
method to generate elasticity data would not be appropriate for clinical trials as the limits of 
agreement are so wide any changes observed would be ambiguous as we would not be 
certain the changes recorded are due to changes in the tissue or just measurement error. 
There is also substantial spread within the data, which shows a lack of precision within the 
data collected. There is also a proportional bias as there appears to be a larger spread of the 
data as the elasticity increases. Figure 6-12 shows the Bland Altman plot of the Free-Trace Q-




















Mean Elasticity (kPa) of original Ratio Q-Box™ and 6 x 3mm Q-Box™
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Figure 6-12: Bland Altman plot with Free-Trace Q-Box™ and 6 x 3mm Q-Box™ protocol data  
 
The Bland-Altman plot of the Free-Trace Q-Box™ data and the 6 x 3mm Q-Box™ data show a 
small bias with a value of -0.22kPa, which demonstrates that the two methods of generating 
elasticity data are essentially equivalent. The limits of agreement are also lower than some of 
the other variables. This plot shows that as the elasticity increases the differences also 
increases, which could indicate a proportional bias is present within the data. Upon doing a 
linear regression, there was a r-value of 0.585 with a p-value of <0.0005, showing that 
statistically no proportional bias was present. Figure 6-13 shows the Bland Altman plot of the 
original ratio Q-Box™ data (glandular tissue) and the 6 x 3mm Q-Box™ protocol data. 
 
 




































Mean Elasticity (kPa) of original Ratio Q-Box™ and 6 x 3mm Q-Box™
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The Bland-Altman plot of the original ratio Q-Box™ data (glandular tissue) and the 6 x 3mm Q-
Box™ protocol data shows that the data lacks precisions with the data points scattered 
around the bias and through the limits of agreement. The bias itself is large with a value of 
2.61kPa, and the limits of agreement are very wide showing that any results produced using 
this method are ambiguous and may or may not reflect changes within the tissue of 
measurement error. Figure 6-14 shows the Bland Altman plot of the alternative ratio 
glandular Q-Box™ data and the 6 x 3mm Q-Box™ protocol data. 
 
 
Figure 6-14: Bland Altman plot with Alternative ratio glandular Q-Box™ and 6 x 3mm Q-Box™ protocol data 
 
The Bland-Altman plot of the alternative ratio Q-Box™ data (glandular tissue) and the 6 x 
3mm Q-Box™ protocol data shows that the limits of agreement are wide and as reported with 
other methods, this demonstrates that results gathered using this method of breast elasticity 
generation are ambiguous as we are unable to determine if the change has come from 
changes in the tissue elasticity or just due to measurement error.  
 
Out of all the Bland Altman plots presented and the visual, objective interpretation that 
followed, it was decided that the greatest level of agreement is between the Free-Trace Q-
Box™ protocol and the reference standard of the 6 x 3mm Q-Box™ protocol. The 6 x 6mm Q-

















Mean Elasticity (kPa) of original Ratio Q-Box™ and 6 x 3mm Q-Box™
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6.4.4 Comparison of Quadrants 
The next analysis conducted was to determine if there was a difference in the value of each 
quadrant, as some studies use a singular quadrant to determine the breast elasticity. This 
analysis was conducted for the 6x3mm Q-Box™, 6x6mm Q-Box™ and the Free-Trace Q-Box™. 
6.4.4.1  6 x 3mm Q-Box™ 
The initial analysis was to determine if the data were normally distributed. According to the 
Shapiro-Wilks analysis, the data were not normally distributed. Results from the Shapiro-Wilks 
test are presented in Table 6-4. 
 
Table 6-4: 6 x 3mm Q-Box™ Shapiro-Wilks test for normality values 
Quadrant Shapiro-Wilk 
p-value 
Lower Outer 0.045 
Upper Outer 0.061 
Upper Inner 0.000 
Lower Inner 0.090 
 
As the data was not normally distributed a non-parametric statistical model was chosen. The 
Friedman Test was used to determine if there were differences between the breast 
quadrants. The descriptive statistics are presented in table 6-5. 
 
Table 6-5: 6 x 3mm Q-Box™ descriptive statistics for comparison of values between breast quadrants 
 Breast Quadrant Median Elasticity (kPa)  
Lower Outer 10.03 
Upper Outer 11.40 
Upper Inner 9.78 
Lower Inner 10.06 
 
According to the Freidman Test, the breast elasticity was statistically significantly different 
within the different breast quadrants X2(3) = 8.12, p=0.043. To conduct the pairwise 
comparisons, the Wilcoxon Signed-Rank Test was used, so the number of measurements 
were not taken into account. In order to use the Wilcoxon Signed-Rank Test to determine if 
there is a statistically significant median difference between two related groups, the shape of 
the distribution of the median differences should be symmetrical. All of the differences in the 
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following results were symmetrical. The results for the individual Wilcoxon Signed-Rank test 
are presented in Table 6-6. 
 
Table 6-6: Wilcoxon Signed-Rank Test Pairwise Comparison results for 6 x 3mm Q-Box™ 












Lower Outer Upper Outer -1.69 28 16 0.037 
 Upper Inner -0.14 23 21 0.981 
 Lower Inner -0.60 22 22 0.506 
Upper Outer Upper Inner 2.41 13 31 0.043 
 Lower Inner 1.53 16 28 0.126 
Lower Inner Upper Inner 0.32 21 23 0.912 
 
These results suggest, when compared to the Lower Outer breast quadrant and the Upper 
Inner breast quadrants, the Upper Outer breast quadrant had a statistically significantly 
greater breast elasticity. The other quadrants had no significant differences. 
 
The Final Analysis was using the CV to determine if there was a difference in the level of 
variability of elasticity data collected from each of the four quadrants. The results of the CV 
are presented in Table 6-7 below. 
 
Table 6-7: Coefficient of Variation of the breast quadrants using the 6 x 3mm Q-Box™  
Breast Quadrant Coefficient of Variation 
(%) 
Lower Outer 44.76 
Upper Outer 41.35 
Upper Inner 53.93 
Lower Inner 50.76 
 
From these results, it can be seen that there were some differences in the variability of the 
data; the CV was lowest for the Upper Outer and highest for the upper inner.  
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6.4.4.2 6 x 6mm Q-Box™  
According to the Shapiro-Wilks analysis, the data showed to be not normally distributed. The 
Shapiro-Wilks results are shown in Table 6-8. 
                                          
Table 6-8: 6 x 6mm Q-Box™ Shapiro-Wilk test for normality values 
Quadrant Shapiro-Wilk p-value 
Lower Outer 0.080 
Upper Outer 0.053 
Upper Inner 0.001 
Lower Inner 0.111 
 
As the data was not normally distributed, again, a non-parametric test (Friedman Test) was 
used to analyse the data. The descriptive statistics are presented in Table 6-9. 
 
Table 6-9: 6 x 3mm Q-Box™ descriptive statistics for comparison of values between breast quadrants 
Quadrant Median Elasticity (kPa)  
Lower Outer 10.02 
Upper Outer 11.85 
Upper Inner 10.28 
Lower Inner 10.38 
 
The breast elasticity was statistically significantly different in the different breast quadrants 
X2(3) = 11.645 and p-value of 0.009. The Wilcoxon Signed-Rank test was used for the pairwise 
comparison between the quadrants. The results from the Wilcoxon Signed-Rank test are 
presented in Table 6-10. 
 
Table 6-10: Wilcoxon Signed-Rank Test Pairwise Comparison results for 6 x 6mm Q-Box™  












Lower Outer Upper Outer -1.75 30 14 0.056 
 Upper Inner -0.72 24 20 0.718 
 Lower Inner -0.57 24 20 0.653 
Upper Outer Upper Inner 2.44 13 31 0.080 
 Lower Inner 1.98 14 30 0.071 
Lower Inner Upper Inner -0.18 23 21 0.480 
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When using the 6 x 6mm Q-Box™, there were no statistically significant differences between 
any of the breast quadrants.  
 
The Final Analysis was using the CV to determine if there was a difference in the level of 
variability of elasticity data collected from each of the four quadrants. The results of the CV 
are presented in Table 6-11 below. 
 
Table 6-11: Coefficient of Variation of the breast quadrants using the 6 x 6mm Q-Box™  
Breast Quadrant Coefficient of Variation 
(%) 
Lower Outer 45.71 
Upper Outer 37.92 
Upper Inner 49.14 
Lower Inner 48.13 
 
From these results, it can be seen that there were some differences in the variability of the 
data, as with the 6 x 3mm Q-Box™ elasticity data, the CV was lowest for the Upper Outer and 
highest for the Upper Inner.  
 
6.4.4.3 Free-Trace Q-Box™ 
When using the Free-Trace Q-Box™, according to the Shapiro-Wilks analysis, the data were 
not normally distributed. The results from the Shapiro-Wilks analysis are presented in Table 6-
12. 
 
Table 6-12: Free-Trace Q-Box™ Shapiro-Wilk test for normality values 
Quadrant Shapiro-Wilk p-value 
Lower Outer 0.059 
Upper Outer 0.187 
Upper Inner 0.012 
Lower Inner 0.374 
 




Table 6-13: Free-Trace Q-Box™ descriptive statistics for comparison of values between breast quadrants 
Quadrant Median Elasticity in kPa  
Lower Outer 9.88 
Upper Outer 11.58 
Upper Inner 10.28 
Lower Inner 10.28 
 
The Friedman test results were X2(3) = 3.144 with a p-value of 0.370. This demonstrates that 
there were no significant differences between the breast quadrants when using the Free-
Trace Q-Box™ protocol, and for this reason, the pairwise comparison does not need to be 
completed. This concludes that the group means were equal within this specific population 
when using this specific protocol. 
 
The Final Analysis was using the CV to determine if there was a difference in the level of 
variability of elasticity data collected from each of the four quadrants. The results of the CV 
are presented in Table 6-14 below. 
 
Table 6-14: Coefficient of Variation of the breast quadrants using the 6 x 6mm Q-Box™  
Breast Quadrant Coefficient of Variation 
(%) 
Lower Outer 41.24 
Upper Outer 32.12 
Upper Inner 44.24 
Lower Inner 42.94 
 
From these results, it can be seen that there were some differences in the variability of the 
data, as with both the 6 x 3mm and 6 x 6mm Q-Box™ elasticity data, the CV was lowest for 
the Upper Outer and highest for the Upper Inner.  
 
6.4.4.4 Comparison of Quadrants Summary 
For all three protocols, the upper outer breast quadrant had the greatest elasticity. This was 
statistically significant when compared to the lower outer and the upper inner quadrants 
when using the three x 3mm Q-Box™ protocol. This quadrant also consistently had the lowest 
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CV, showing the least amount of variability of the collected data of the four quadrants. All 
other quadrants and protocols showed that the elasticity in the breast quadrants were equal.  
 
6.4.5 Comparison of Left and Right Breast 
The next analysis that needed to be completed was to determine if there was a difference 
between the left and right breast with the 6 x 3mm, 6 x 6mm and Free-Trace Q-Box™ data. 
 
6.4.5.1 6 x 3mm Q-Box™ 
The initial analysis was to determine if the data was normally distributed. The data was tested 
for violation of normality using the Shapiro-Wilk test; the results suggest the data was not 
normally distributed for the left breast (p= 0.014) and was normally distributed for the right 
breast (p= 0.339). 
                                                  
Due to the non-parametric nature of the left breast data, the data were analysed using the 
Wilcoxon Signed-Rank test. All results are median values unless otherwise described. The 
descriptive statistics for the analysis are presented in Table 6-15. 
 
Table 6-15: Descriptive statistics for 6 x 3mm Q-Box™ comparison of left and right breast 
 Left Breast Right Breast Difference 
10.34 kPa 10.16 kPa -0.22 
 
The data of eleven participants with four repeat measure were used to determine if there was 
a difference in the elasticity values between the left and the right breasts as measured using 
the 6 x 3mm Q-Box™ protocol. The Wilcoxon Signed-rank test demonstrated there were no 
statistically significant median differences between the left and right breast, z=0.37, P=0.709. 
 
Upon looking at the CV between the right and left breast, there were some differences when 
using the 6 x 3mm Q-Box™ protocol. The left breast had a CV of 45.90% and the right was 
39.42%.  
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6.4.5.2 6 x 6mm Q-Box™  
The initial analysis was to determine if the data were normally distributed. The data was 
tested for violation of normality using the Shapiro-Wilk test; the results suggest the data was 
normally distributed (left breast p-value = 0.0.051; right breast p-value = 0.195) 
 
The paired samples T-test was used to analyse the data; the descriptive statistics are 
presented in table 6-17. 
 
Table 6-16: Descriptive statistics for 6 x 6mm Q-Box™ comparison of left and right breast 
Breast Mean Elasticity in kPa 
(SD) 
Left 11.29 (4.96) 
Right 11.31 (4.22) 
 
The mean difference was 0.015 (± 3.32) (95% CI -1.02 to 0.99; p=0.976). There were no 
statistically significant differences between the left and right breast when using the 6 x 6mm 
Q-Box™. Upon looking at the CV between the right and left breast, there were some 
differences when using the 6 x 6mm Q-Box™ protocol. The left breast had a CV of 43.99%, 
and the right was 37.28%. 
6.4.5.3 Free-Trace Q-Box™ 
The initial analysis was to determine if the data was normally distributed. The data was tested 
for violation of normality using the Shapiro-Wilk test; the results suggested that the data was 
normally distributed (left breast p-value = 0.315; right breast p-value = 0.311). The paired 
samples T-test was used to analyse the data; the descriptive statistics are presented in Table 
6-22. 
Table 6-17: Descriptive statistics for Free-Trace Q-Box™ comparison of left and right breast 
Breast Mean Elasticity in kPa (SD) 
Left 11.29 (4.97) 
Right 11.31 (4.22) 
 
The mean difference was -0.18 (±2.64) (95% CI -0.98 to 0.63; p=0.662). There are no 
statistically significant differences between the left and right breast when using the Free-
Trace Q-Box™. Upon looking at the CV between the right and left breast, there were some 
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differences when using the Free-Trace Q-Box™. The left breast had a CV of 37.25% and the 
right breast was 34.58%.  
 
6.4.5.4 Comparison of Left and Right Breast Summary 
These analyses showed that with each of the three protocols, there were no differences 
between the left and right breasts. The CV showed some differences, with the right breast 
always having a lower CV but these differences may be arbitrary due to the singular data set 
and may have occurred due to chance. 
 
6.5 Discussion 
This study analysed the effect of using differing post-hoc SWE image analysis protocols on 
breast elasticity values. This analysis was undertaken to find the most precise method of 
measuring whole breast elasticity, as to date, there is no protocol to find the average whole 
breast elasticity; this being due to the novel and experimental nature of SWE being used for 
this indication. The data included in this study were re-analysed from the pharmacokinetic 
sub-study, which was presented in Chapter 4. This trial had recruited 11 participants who had 
four repeat SWE measurements, across a three-month time period. The Q-Box™ protocols 
that were used were as follows; 
• 6 x 3mm Q-Box™ placed across the image 
• 6 x 3mm Q-Box™ placed across the image 
• A singular 10mm Q-Box™ placed in the middle of the image 
• Full-Box trace Q-Box™, which was done using the Q-Box™ trace function to trace the 
border of the image 
• Free-Trace Q-Box™, which was done using the Q-Box™ trace function and tracing the 
image to avoid all ultrasound artefacts and black holes present within the SWE image 
 
In addition to these protocols, the Q-Box™ ratio function was used, this is when a singular Q-
Box™ is placed on an area of glandular tissue, and another singular Q-Box™ is placed on an 
area of fatty tissue. This was done twice with some variation in the sizes of the Q-Box™ 
capturing the data for each of the tissue types. These additional protocols were used because 
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this is a commonly used protocol in previous research, and it needed to be determined if it is 
a reliable and valid method to find the whole breast elasticity.  
 
As using whole SWE to measure whole breast elasticity is a novel biomarker for changes in 
the breast tissue, there is no gold standard of data collection methods in the literature to 
compare these SWE results to. This meant that there were some limitations in findings the 
protocol with the most valid results. The statistical model that was initially conducted was a 
one-way repeated measures ANOVA with post-hoc Bonferroni adjustments. The 6 x 3mm Q-
Box™ was the reference standard for this analysis, as it was the original protocol used to 
collect the breast elasticity data. This statistical model was used to determine if any of the 
protocols produced elasticity values that were statistically similar or different to the 6 x 3mm 
Q-Box™ data. As there is no gold standard to provide the ‘true’ elasticity values, we can be 
more confident in the validity of the findings if multiple protocols produced similar results. 
When looking at the repeated measures ANOVA, if no other protocol produced similar data to 
the 6 x 3mm Q-Box™, it would have been reconsidered as the reference standard for this 
analysis. From the repeated measures ANOVA, the 6 x 6mm, Free-Trace, and alternative ratio 
Q-Box™ data showed no statistically significant differences in the acquired data. Bland-Altman 
plots were created to visually show the agreement and precision of the different Q-Box™ 
protocols when compared to the 6 x 3mm Q-Box™ data. Finally, the CV was calculated for all 
the datasets; this analysis presents a value that represents the dispersion of the data around 
the mean and can help determine the protocol with the most precise results. 
 
From the statistical calculations and observations, it was found that the method with the 
greatest agreement and lowest amount of variation (lowest CV) was the Free-Trace Q-Box™ , 
which has previously been used in research by Evans (2015) for which the whole breast 
elasticity was also calculated using SWE. The other protocols which had similar data to the 6 x 
3mm Q-Box™ data were the 6 x 6mm Q-Box™ and the alternative ratio data. The three main 
protocols that were considered to be used as the reference standard for future research were 
the 6 x 3mm Q-Box, 6 x 6mm Q-Box™ and Free-Trace Q-Box™ protocols. The Q-Box™ ratio 
data was omitted from this consideration, as although commonly used in scientific research 
as a method to calculate the elasticity of the glandular tissue in the breast, it did not appear 
to be a reliable method of breast elasticity quantification. This opinion is due to the fact that 
when using a singular Q-Box, the elasticity can be greatly influenced by where the Q-Box™ is 
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placed. As the elasticity differs throughout the image, one Q-Box™ is not a good 
representation of the whole breast quadrant. This misrepresentation was demonstrated 
within this study, as there were statistically significant differences in the average elasticity 
between the two ratio datasets. Using the Q-Box™ ratio function can also introduce large 
measurement bias to the study, as the operator can choose where the Q-Box™ is placed. This 
operator dependence and small ROI of an area of variable data potentially allows the 
elasticity to be manipulated by the researcher. This potential for manipulation can lead to 
unreliable data, especially in longitudinal studies, with repeat measurements, with the 
objective of determining the efficacy of an intervention or determining changes within the 
breast tissue.  
 
As previously mentioned, the Free-Trace Q-Box™ was chosen as the protocol to use as the 
reference standard for future research. During this study, the Free-Trace Q-Box™ had the 
lowest CV; this showed that elasticity generated using this protocol had the greatest precision 
out of all the different protocols. The precision of a measurement shows the variability of the 
results and is a description of the random errors in the data. The Free-Trace Q-Box™ may 
have had the least variability due to the operator being able to omit objects within the image 
that are not true representations of the elasticity values. These objects include artefacts, 
which are areas on the colour elasticity image that might not be a representation of the 
mechanical properties of the breast tissue but rather an issue with the SWE. The areas in the 
image that have artefacts have extremely high elasticity values, which do not correspond to 




Figure 6-15: Shear wave Elastography image with Ultrasound artefact highlighted 
 
The other objects that can induce random errors in the results are a phenomenon called 
‘black holes’; these are areas within the image for which the shear waves have not 
propagated. These black holes appear dark on the colour coded SWE output (Figure 6-16). As 
the shear waves have not propagated through the tissue, no elasticity values are recorded; 
consequently, the elasticity is displayed as 0.00kPa. With the Free-Trace Q-Box™, the 
operator can visualise, and trace around the artefacts and ‘black holes’, which decreases the 
random errors and variability in the data. This ability to trace around artefacts and ‘black 
holes’ increases the precision of the data when compared to the 6 x 3mm Q-Box™ data, as 
these can be placed around these areas but without as much precision, so may still include 
sections of ‘black holes’ or artefacts and lead to inaccurate elasticity data. As the Free-Trace 
Q-Box™ is still operator dependent, there is still the opportunity for operator bias to influence 
the elasticity values. However, as a larger ROI is included in the analysis, the actual placement 








Figure 6-16: Shear Wave Elastography image with a 'black hole'; an area the shear waves have not propagated 
 
Another reason for why the Free-Trace Q-Box™ was chosen as the future reference standard 
was its clinical utility. One of the key aspects of outcome measures that need to be analysed 
and considered, when being used for clinical and research purposes is the clinical utility. The 
clinical utility is how easy the outcome measure is to use, and the time taken to use the 
measure, this including the time taken to administer, enter the data and calculate the results. 
When using the SWE machine, manual analysis always needs to be conducted, as the process 
is not automated. The Free-Trace Q-Box™ is one of the quickest protocols studied with this 
analysis. For the protocols that require multiple Q-Box™, you are required to press the Q-
Box™ button on the screen for each new Q-Box™ (Figure 6-17), size it using the roll-ball on 




Figure 6-17: Shear Wave Elastography machine with the Q-Box™ function highlighted. This needs to be pressed six times 
when using the 3 x 6mm and 6 x 6mm protocols 
 
 
Figure 6-18: Shear Wave Elastography dial that can be slid from left to right to re-size the Q-Box™ 
 
Additionally, with the six Q-Box™, you then need to calculate the average elasticity from the 
six mean values for each Q-Box™ on the image. In contrast, when using the Free-Trace Q-
Box™, the Q-Box™ command on the machine only needs to be pressed once, and then the 
operator proceeds to trace the ROI, avoiding the artefacts and black holes, using the attached 
stylus on the SWE machine (Figure 6-19). Only one set of data is also produced for each 
quadrant (Figure 6-20). This method generally only takes a few seconds per image. The 
clinical utility of the Free-Trace Q-Box™ is beneficial for larger clinical trials as the data can be 
generated in a timelier manner, there is less data that needs to be entered, and there is less 




Figure 6-19: Using the attached stylus on the shear wave elastography machine to trace the region of interest using the 




Figure 6-20: Comparison of the different shear wave elastography reports when using the 3 x 6mm Q-Box™ protocol and the 
Free-Trace Q-Box™ protocol 
 
 
This study also analysed whether there were differences in the elasticity of the different 
breast quadrant, this was important as some studies analyse the data from just one quadrant 
and it is important that we know if there are inherent differences across the breast. The 
findings from this study suggest that when using all three of the protocols, the upper outer 
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breast quadrant consistently had a higher elasticity value. This data agreeing with pre-existing 
data, showing that the upper outer quadrant having the greatest dense area when compared 
to the other three quadrants (Chan, Chen et al. 2017), which may explain why the elasticity 
was increased in this area. When using the Free-Trace Q-Box™ method, there were no 
statistically significant differences in the breast elasticity. This showing that if a researcher 
wanted to make the SWE measure quicker, they could use a single breast quadrant if using 
the Free-Trace Q-Box™. The upper outer quadrant also consistently had the lowest CV, so if 
using just a single quadrant to measure the changes in the breast with repeat measures, it 
would be recommended to use the upper outer quadrant. These calculations, however, were 
based on a small sample size and with a repeat study may reveal that there are significant 
differences in the breast quadrants. Further research is required to make a definitive 
statement.  
6.6 Conclusion 
Using the SWE machine to measure the whole breast elasticity is a new indication for this 
device, and as such, there is limited research to guide the user towards the most valid and 
reliable method for collecting this data. This current study utilised a number of different 
protocols and found that the Free-Trace Q-Box™ protocol was the most precise method, with 
the lowest CV, and had one of the lowest levels of potential for the researcher or assessor to 
manipulate the data. These results and analyses into the different methods of elasticity data 
generation will aid future use of SWE in the research and clinical environment and can aid the 
increased consistency among different studies. As this was not the method used in the first 
two interventional studies in this research program, a re-analysis of the data of those studies 
is required to determine if the findings are significantly altered. 
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Chapter 7 Re-analysis of data from Chapter 4 and 6: utilising the 
Free-Trace Q-box™ function as described in Chapter 5. 
 
7.1 Introduction 
As described in both Chapter 4 and Chapter 5, the breast elasticity data showed a significant 
amount of within-subject variations; this variation did not appear to follow any particular 
trend or pattern. To further analyse this, the previous chapter (Chapter 6) described an 
analysis where the method of elasticity data generation was evaluated to see if this was an 
influence on the within-subject variation in the data. Seven different protocols were used, and 
from the analyses, it was determined that the method of using the Free-Trace Q-Box™ 
function had similar values to the 6 x 3mm Q-Box™ and 6 x 6mm Q-Box™ values. The Free-
Trace Q-Box™ also had the lowest CV and therefore was the method which had the greatest 
precision. This level of precision was hypothesised to be due to the Free-Trace Q-Box™ having 
the largest area of the image included in in the ROI for which the elasticity is calculated for the 
quadrant. Also, when using the Free-Trace Q-Box™, the regions where the shear waves did not 
propagate, and the ultrasound artefacts that distort the elastic properties of the image, were 
omitted from the calculation. As the breast elasticity in Chapter 4 and Chapter 5 was collected 
using the 6 x 3mm Q-Box™ protocol, it was deemed to be of significant importance to repeat 
these analyses using the Free-Trace Q-Box™ to evaluate whether the initial results and 
conclusions are still valid. 
 
7.2 Objective 
The objective of this study was to re-analyse the data from Chapter 4 (HAVAHT+Ai™) and 
Chapter 5 (enobosarm and anastrozole) studies to determine if there were significant 
differences, which changed the findings and conclusions of the studies when using the Free-




The shear wave images that were taken for both the Chapter 4 (HAVAHT+Ai™) and Chapter 5 
(enobosarm and anastrozole) studies were reopened on the SuperSonic™ Aixplorer® Shear 
Wave Ultrasound Machine. Each image for all the participants had the elasticity re-acquired 
using the Free-Trace Q-Box™ function. As per the previous description, the Free-Trace Q-Box™ 
function aimed to incorporate the largest ROI possible yet avoiding the areas that the shear 
waves have not propagated and any artefacts that may have distorted the average elasticity of 
the image.  
 
Once the elasticity data for each image had been reacquired, reports were created for each 
participant visit and the data was entered into Microsoft Excel (2016). Following data entry, 
the same analyses that were initially conducted in each of the chapters, were redone with the 
data from the Free-Trace Q-Box™. The statistical analyses that were done for this chapter 
included; 
• The comparison of the within-subject data of the different elasticity acquirement 
protocols for the HAVAHT+Ai™ study and the enobosarm and anastrozole study. If the 
data were normally distributed, it was analysed using a paired samples T-test. If not, 
the Wilcoxon-Sign tank test was used. If the distribution of the median difference was 
not symmetrical, the sign test was used to determine if there was a significant 
difference between the median values for each group. 
• The repeat analysis of the change in elasticity over-time for the HAVAHT+Ai™ study 
and the enobosarm and anastrozole study. The initial analyses were conducted using 
the one-way repeat measures ANOVA if the data were normally distributed. If the data 
were not normally distributed, the Friedman test would be the statistical model 
chosen.  
• The correlation between the elasticity values and mammography variable values for 
the HAVAHT+Ai™ study and Study two. This analysis was conducted using Pearson’s 
correlation coefficient if the data were normally distributed. If the data was not 
normally distributed, a Spearman’s rank-order correlation was used.  
Statistical significance was set at p≤ 0.05 and with the confidence intervals for differences 




7.4.1 Comparison of Within-subject Data - Pharmacodynamics (Breast Tissue 
Elasticity) of Combination Subcutaneous Testosterone and Anastrozole 
(HAVAHT+Ai™) in Premenopausal Women with High Mammographic 
Breast Density  
 
The first analysis that was completed had the objective of determining if there was a 
statistically significant difference between the within-subject data points of the Free-Trace Q-
Box™ values and the 6 x 3mm Q-Box™ values. The breast elasticity from each participant, at 
each time point, for both of the variables were used in this analysis. The difference score was 
computed, the data were checked for outliers, and the Shapiro-Wilk test was used to assess 
the normality of the data. The p-value for the Shapiro-Wilk test was 0.000, which established 
that the data was not normally distributed; from visually inspecting the data on a histogram, it 
was observed that there was a strong positive skew in the dataset. From visually inspecting a 
box-plot of the data, it was observed that there were two outliers present in the dataset. 
These outliers were assessed and were deemed to be true values and were included in the 
analysis. Upon looking at the symmetry of the median differences, it was observed that the 
data was not symmetrical. Therefore, the Sign Test was the statistical model chosen to analyse 
the data. The data are all reported as median values unless otherwise stated; the descriptive 
statistics are presented in Table 7.1. 
 
Table 7-1: Descriptive statistics for the comparison of Q-Box™ protocols of within-subjects from the pharmacodynamic 
(breast tissue elasticity) of combination subcutaneous Testosterone (T) and anastrozole (Ai) in premenopausal women with 
high MBD 
6 x 3mm Q-Box™ Median 
Elasticity 
Free-Trace Q-Box™ Median 
Elasticity 
Difference 
10.39kPa 10.14kPa -0.11kPa 
 
There was a total of 44 data-points included in the analysis; 25 of these had positive 
differences, 19 had negative differences, and there were zero ties within the differences. The 
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results from the Sign Test show that there were no statistically significant median differences 
between the 6 x 3mm Q-Box™ data and the Free-Trace Q-Box™ data, z= 0.754, p= 0.451. 
 
7.4.1.1 Summary 
These results showed that when using the Free-Trace Q-Box™ protocol, there were no 
differences in the elasticity values that were obtained using the original 6 x 3mm Q-Box™ 
protocols.  
 
7.4.2 Repeat Analyses - Pharmacodynamics (Breast Tissue Elasticity) of 
Combination Subcutaneous Testosterone and Anastrozole 
(HAVAHT+Ai™) in Premenopausal Women with High Mammographic 
Breast Density  
 
7.4.2.1 Change in Breast Elasticity Over Time with Repeat Measurements 
The following analysis was evaluating the change in the breast elasticity data, at different time 
points, with the repeat measurements. This analysis was done to calculate if there were 
changes in the breast elasticity across the study using the Free-Trace Q-Box™ data, and 
whether this outcome differed from the original calculations using the 6 x 3mm Q-Box™ 
elasticity data. As with the analysis above, initially, the data was assessed using the Shapiro-
Wilk test. The Shapiro-Wilk test results are presented in Table 7-2. 
 
 
Table 7-2: Shapiro-Wilk values for the repeat measure analysis using the Free-Trace Q-Box™ elasticity 
Measurement Shapiro-Wilk p-value 
Baseline 0.052 
Month 1 0.001 
Month 2 0.000 
Month 3 0.001 
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The Shapiro-Wilk test result suggests that the data was not normally distributed. Using the 
boxplot to visually assess the data, five outliers were observed within the data; three outliers 
were in the one-month dataset, one was in the second-month dataset, and one was in the 
third-month dataset. These outliers were checked and were deemed to be true values and 
were to be included in the analysis. As the data was non-parametric, the Friedman test was 
used to analyse the data. 
7.4.2.1.1 Friedman Test of Free-Trace Q-Box™ Data 
The median values for the Friedman test are presented in Table 7-3. 
 
Table 7-3: Median values for each time point using the Free-Trace Q-Box™ for the repeat analysis of pharmacodynamics 
(breast tour elasticity) of combination subcutaneous Testosterone (T) and anastrozole (Ai) (HAVAHT+Ai™) in premenopausal 
women with high MBD 




Baseline 12.20  
Month 1 10.65 -1.55 
Month 2 8.50 -3.70 
Month 3 7.85 -4.35 
 
The results from the Friedman test demonstrated that the breast elasticity values were 
statistically significantly different at the different time points during the time period that the 
women were on the HAVAHT+Ai™ intervention, X2 = 27.734, p<0.0005. The pairwise 
comparisons from the Friedman test are presented in Table 7-4. 
 
Table 7-4: Results of the pairwise comparison of the Friedman test with comparisons from baseline to the different time 
points and adjusted significance values 
Timepoint Adjusted Significance 
Baseline to Month 1 1.000 
Baseline to Month 2 0.002 
Baseline to Month 3 <0.0005 
 
The results from the pairwise comparison component of the Friedman test demonstrate that 
the breast elasticity had statistically significant reductions from baseline to month two, and 
from baseline to month three. 
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7.4.2.1.2 Original Results from Chapter 4 
 
The original results of the one-way repeat measure ANOVA using the 6 x 3mm Q-Box™ data 
are presented in table 7-5. 
 
Table 7-5: Original results using the 6 x 3mm Q-Box™ for the one-way repeat measures ANOVA 
Timepoint Breast Elasticity 
(SD) in kPa 
Change from 
Baseline (kPa) 
95% CI p-value 
Baseline 13.67 (7.89)    
Month 1 11.68 (5.58) -1.99 -4.35 to 0.36 0.148 
Month 2 9.86 (5.63) -3.80 -6.72 to -0.87 0.004 
Month 3 8.63 (3.96) -5.04 -7.31 to -2.78 >0.005 
 
These two results demonstrate that when using the Free-Trace Q-Box™, the results are not 
substantially different from the original calculations using the 6 x 3mm Q-Box™ data. The 
original figures showed greater decreases over the three months of the study, however both 
reductions at month two and month three reached statistical significance, and both of the p-
values were similar between the two different data collection protocols. 
 
7.4.2.2 Correlations Between Breast Elasticity and Per Cent Volumetric Breast Density 
Using the Free-Trace Q-Box™ Elasticity Data 
The next section of analyses is the correlations between the breast elasticity data and 
the %VBD data. The first analysis was the correlation between the baseline %VBD and baseline 
breast elasticity.  
7.4.2.2.1 Baseline Breast Elasticity and Baseline Per Cent Volumetric Breast Density 
The Shapiro-Wilk test was again used to determine the normality within the data. The 
normality of the data was not violated from the results of this test (baseline elasticity p-value = 
0.128; baseline %VBD p-value 0.286). For this reason, Pearson’s correlation coefficient was the 
statistical model chosen to perform the analysis. Using Pearson’s correlation coefficient, the 
results produced an r-value of 0.252 (p=0.456); this is a negligible correlation between the two 




Figure 7-1: Correlation between baseline %VBD and baseline breast elasticity in kPa 
 
The original 6 x 3mm Q-Box™ data produced an r-value of 0.184 (p=0.589). This result was a 
negligible correlation between the two variables. Using the Free-Trace Q-Box™ elasticity data 




7.4.2.2.2 End of Study Breast Elasticity and End of Study Per Cent Volumetric Breast 
Density 
The next analysis that was conducted was to analyse the correlations between the EOS %VBD 
data and the EOS breast elasticity data. The Shapiro-Wilk test was again used to determine 
normality within the data. The results showed that the data was normally distributed (EOS 
elasticity p-value = 0.559; EOS %VBD p-value = 0.320). For this reason, the Pearson’s 
correlation coefficient was the statistical model chosen for the analysis. The results showed an 
r-value of 0.256 (p=0.448), which is a negligible correlation between the two variables. The 
scatterplot with the trendline for this correlation is presented in Figure 7-2.  
 




Figure 7-2: Correlation between EOS %VBD and breast elasticity at 3 months (final Breast elasticity measurement) 
 
The original correlation coefficient using the 6 x 3mm Q-Box™ data produced an r-value of 
0.233 (p=0.491), which is also a negligible correlation between the two variables. Using the 
Free-Trace Q-Box™ elasticity data did not change the overall outcome of the correlation 
analysis. 
 
7.4.2.2.3 Changes in Breast Elasticity and Changes in Per Cent Volumetric Breast 
Density 
When determining if there was a correlation between the changes in %VBD and the change in 
the breast elasticity values for the Free-Trace Q-Box™ data, the same analyses that were 
originally conducted in Chapter 4 were completed. The initial correlation was on the 
difference values between the baseline %VBD and the 12-month %VBD results, and the 
difference values between the baseline elasticity and the three-month elasticity findings. The 
Shapiro-Wilk test results suggested the data was normally distributed (change in elasticity 
(baseline to 3 months) p-value = 0.099; change in %VBD (baseline to 12 months) p-value = 
0.287). For this reason, the Pearson’s correlation coefficient was used to analyse the data. The 
results show an r-value of 0.234 (p = 0.488), which showed a negligible correlation between 
the two variables. The scatterplot with the trendline for this correlation is presented in Figure 
7-3. 
 




Figure 7-3: Correlation between change in %VBD (baseline to month 12) and breast elasticity in kPa (baseline to month 3) 
 
The original calculation using the 6 x 3mm Q-Box™ data had a similar finding with an r-value of 
0.315 (p=0.345), which was a low positive correlation between the variables across the study. 
Using the Free-Trace Q-Box™ elasticity data did slightly alter the outcome of the correlation 
analysis, as it went from low to a negligible correlation. Both findings are clinically 
insignificant, as it does not show a valuable relationship between the two variables. 
 
7.4.2.2.4 Summary 
These results show that there were some differences in the individual correlation coefficients, 
but these differences did not change the overall outcomes and conclusions of the analyses. 
The findings using the Free-Trace Q-Box™ data suggest that there were negligible correlations 
between %VBD and breast elasticity, and the changes in %VBD and changes in elasticity. 
 
7.4.2.3 Correlations Between Elasticity and Total Fibroglandular Volume  
The next group of analyses was the correlations between the TFV measurements, and the 
breast elasticity values and the changes in these variables. 
  




7.4.2.3.1 Correlation Analysis Between Baseline Total Fibroglandular Volume and 
Breast Elasticity 
The initial analysis was to determine if there was a correlation between the baseline TFV and 
the baseline breast elasticity. The Shapiro-Wilk test results suggest the baseline elasticity was 
normally distributed (p=0.128), and the baseline TFV data violated normality (p=0.014). As one 
of the variables was not normally distributed, the Spearman’s rank-order correlation 
coefficient was the statistical model chosen to analyse the data. Spearman’s coefficient 
produced an r-value of 0.100 (P=0.770). This was a negligible correlation between the baseline 
TFV and the baseline breast elasticity (Figure 7-4).  
 
 
Figure 7-4: Correlation between total fibroglandular volume at baseline and breast elasticity at baseline 
  
This result was a similar result to the original analysis using the 6 x 3mm Q-Box™ data which 
produced an r-value of -0.188 (p=0.729). Using the Free-Trace Q-Box™ elasticity data did not 
change the overall outcome of the correlation analysis, except one was a positive and one was 
a negligible correlation.  
 
  




7.4.2.3.2 End of Study Total Fibroglandular Volume and End of Study Breast Elasticity 
The next analysis was conducted to determine the correlation between the EOS TFV, which 
was measured at 12 months and the EOS breast elasticity, which was measured at 3 months. 
The Shapiro-Wilk test results suggest the EOS elasticity is normally distributed (p-value = 
0.559), and the EOS TFV data violated normality (p-value = 0.035). Again, the Spearman’s rank-
order correlation coefficient was used to analyse the data. The Spearman’s coefficient 
produced an rs value of -0.427 (p=0.190); this demonstrates a low correlation between the 
two variables (Figure 7-5). 
 
 
Figure 7-5: Correlation between EOS total fibroglandular volume (12 month) and EOS Breast Elasticity (3 months) 
 
The original analyses using the 6 x 3mm Q-Box™ data, the Spearman’s rank-order correlation 
produced a rs value of -0.436 (p=0.180), which again was a low, negative correlation between 
the variables. Using the Free-Trace Q-Box™ elasticity data did not alter or change the overall 
outcome of the correlation analysis.  
 
  
rs value =  -0.427 
p=0.190 
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7.4.2.3.3 Correlation Between Change in Total Fibroglandular Volume and Change in 
Breast Elasticity 
The next analysis is a correlation between the change in TFV from baseline to month 12 and 
the change in breast elasticity from baseline to month three. The Shapiro-Wilk test results 
suggest that both sets of the data were normally distributed (change in elasticity (baseline to 3 
months) p-value = 0.099; change in TFV (baseline to 12 months) p-value = 0.104). As the data 
was parametric, the Pearson’s correlation coefficient was the statistical model chosen, and 
this analysis produced and r-value of 0.616 (p=0.044), this was a statistically significant 
moderate correlation between the two variables (Figure 7-6). 
 
 
Figure 7-6: Correlation between change in total fibroglandular volume (baseline to month 12) and change in breast elasticity 
(baseline to month 3) 
 
In regard to the previous analysis conducted in Chapter 4, Pearson’s correlation coefficient 
demonstrated that the r-value was 0.689 (p=0.019). This result again was a statistically 
significant moderate positive correlation between the change in elasticity from baseline to 
month three and the change in TFV from baseline to month 12. Using the Free-Trace Q-Box™ 
elasticity data did not change the outcome of the correlation analysis.  
 
Further to this analysis, a correlation analysis was conducted on the change in TFV between 
baseline and month 12 and the change in elasticity from baseline to month one and the 
r-value = 0.616 
p=0.044 
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change in breast elasticity from baseline to month two. The Shapiro-Wilk test suggests that 
the change in elasticity (baseline to 1 month) data violated normality (p-value = 0.042), and 
the change in elasticity (baseline to 2 months) was normally distributed (p-value = 0.558). As 
the change in elasticity from baseline to month one was not normally distributed; the 
Spearman rank-order correlation was used to analyse this data. The change in breast elasticity 
from baseline to month two was normally distributed, and for this reason, Pearson’s 
correlation coefficient was used to analyse the data. 
 
Firstly, the Spearman rank-order correlation produced a rs value of 0.609 (p=0.047) between 
the change in TFV and the change in breast elasticity from baseline to one month. This result 
was a statistically significant moderate correlation between the two variables (Figure 7-7). 
 
 
Figure 7-7: Correlation between change in total fibroglandular volume (baseline to month 12) and change in breast elasticity 
(baseline to month 1) 
The original analysis that was conducted in Chapter 4 using the 6 x 3mm Q-Box™ produced an 
r-value of 0.611 (p=0.046), which again was a statistically significant moderate positive 
correlation between the elasticity change at month one and the TFV change at 12 months. 
Using the Free-Trace Q-Box™ data did not change the overall outcome of the correlation 
analysis.  
 
The last analysis was the correlation between the TFV change and the elasticity change from 
baseline to month two. Pearson’s correlation coefficient produced an r-value of 0.813 
rs value = 0.609 
p=0.047 
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(p=0.002) (Figure 7-8). This result was a statistically significant, high correlation between the 
two variables. 
 
Figure 7-8: Correlation between change in total fibroglandular volume (baseline to month 12) and change in breast elasticity 
(baseline to month 2) 
 
The original analysis that was conducted in Chapter 4 using the 6 x 3mm Q-Box™ produced 
very similar results with an r-value of 0.818 (p=0.002), which was a statistically, high 
correlation between the two variables. Using the Free-Trace Q-Box™ elasticity data did not 
change the overall outcome of the correlation analysis.  
 
7.4.2.3.4 Summary 
These analyses again showed that there were no significant differences in the outcomes 
between the original results using the 6 x 3mm Q-Box™ data and the Free-Trace Q-Box™ 
elasticity data. The conclusions remain that there are moderate to strong correlation between 
the changes in TFV and changes in breast elasticity. Also, the same conclusions remain that 
there is a moderate and strong correlation with early breast elasticity changes seen at one 
month and month two, respectively, with the changes in TFV across 12 months. These results 
may not have changed significantly with the Free-Trace Q-Box™ data as, although the method 
of data collection has a lower CV and it less influenced by the artefacts and black holes, the 
actual spread of the data has remained the same, while the mean elasticity is lower. This 
would conclude the correlations remained mostly the same, yet the data used was different. 
r-value = 0.813 
p=0.002 
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These results show that breast elasticity may be able to predict early the changes occurring in 
the potential changes in TFV at 12 months, which gives promise for breast elasticity being a 
biomarker for changes within the breast tissue with further research. 
 
7.4.3 Comparison of Within-subject Data - Anastrozole and GTx-024: The 
Effect of an Aromatase Inhibitor and Selective Androgen Receptor 
Modulator on Mammographic Breast Density and Breast Elasticity in 
Premenopausal Women 
 
The initial analysis that was conducted in this section was to determine if there was a 
statistically significant difference between the within-subject data points, using the Free-Trace 
Q-Box™ and 6 x 3mm Q-Box™ data. Upon looking at the normality of the data, the Shapiro-
Wilk test showed a significance value of 0.000, which demonstrated that the data was not 
normally distributed, and there was a strong negative skew with the data. There was one 
extreme outlier that sat greater than 1.5 box lengths from the edge of the boxplot. Upon 
further analysis, this figure was deemed a correct figure and kept within the analysis. The Sign 
test was the statistical model chosen as the distribution of the median differences were not 
symmetrical. All data are reported as median values unless otherwise reported. The 
descriptive statistics are presented in Table 7-6. 
 
Table 7-6: Descriptive statistics for the within-subjects data from anastrozole and GTx-024: the effect of an aromatase 
inhibitor and selective androgen receptor modulator on MBD and breast elasticity in premenopausal women 
6 x 3mm Q-Box™ Median 
Elasticity 
Free-Trace Q-Box™ Median 
Elasticity 
Difference 
14.05 kPa 13.77 kPa -0.70 kPa 
 
There was a total of 39 data points within the analysis, 10 had positive differences, 29 
negative differences, and there were zero ties within the differences. The Sign test 
demonstrated that there was a statistically significant median difference of -0.70kPa, the 




7.4.4 Repeat Analyses - Anastrozole and GTx-024: The Effect of an Aromatase 
Inhibitor and Selective Androgen Receptor Modulator on 
Mammographic Breast Density and Breast Elasticity in Premenopausal 
Women 
 
7.4.4.1 Change in Elasticity Over Time with Repeat Measurements 
This analysis is evaluating the repeat measures of the Free-Trace Q-Box™ breast elasticity 
data. This analysis was conducted to determine if there was a statistically significant difference 
in the elasticity data at the different time points and whether this differed from the original 
analyses using the 6 x 3mm Q-Box™. 
 
The data were first analysed to establish the normality of the data and whether there were 
any outliers in the data. The results from the Shapiro-Wilk test are presented in Table 7-7. 
 
Table 7-7: Shapiro-Wilk test for normality for the Free-Trace repeat measures data 
Measurement Shapiro-Wilk Value 
Baseline 0.032 
Month 1 0.321 
Month 3 0.048 
Month 12 0.148 
 
The baseline and month three datasets were both not normally distributed; month one and 
month 12 were normally distributed. There were also two outliers present in the data; these 
were in the month one and month three datasets. Upon further inspection, these data points 
were deemed true values and were left to be included in the analysis. As not all of the data 
were normally distributed, the Friedman test was the statistical model used to analyse the 
data. All values are median values unless otherwise stated. The median values for the breast 




Table 7-8: Descriptive statistics for the Free-Trace Q-Box™ data 
Timepoint Median Elasticity (kPa) Difference in Elasticity from 
Baseline (kPa) 
Baseline 15.00  
Month 1 13.35 -1.65 
Month 3 11.50 -3.50 
Month 12 13.40 -1.60 
 
The Friedman test showed that the breast elasticity was statistically significantly different at 
the different time points throughout the study X2(3) = 10.762, p=0.013. The pairwise 
comparisons are presented in Table 7-9. 
 
Table 7-9: Results from the Friedman test pairwise comparison for Free-Trace Q-Box™ data with adjusted statistical 
significance 
Timepoint Adjusted Significance p-value 
Baseline to Month 1 1.000 
Baseline to Month 3 0.014 
Baseline to Month 12 0.094 
 
These results show that there was a statistically significant decrease in the median breast 
elasticity from baseline to Month 3 however there was a slight increase in the median 
elasticity values from month 3 to month 12, resulting in statistically insignificant changes from 
baseline to month 12. 
 
7.4.4.1.1 Original Results from the 6 x 3mm Q-Box™ One-way Repeat Measures 
ANOVA 
 
The original one-way repeat measures ANOVA using the 6 x 3mm Q-Box™ results are 




Table 7-10: Original one-way repeat measure ANOVA using 6 x 3mm Q-Box™ 
 Value (SD) Change from 
Baseline (SD) 
95% CI p-value 
Breast Tissue Elasticity (kPa) 
Baseline 17.94 (9.35)    
Month 1 14.25 (4.76) -3.69 (9.83) -7.50 to 0.12 0.064 
Month 3 13.94 (7.75) -4.00 (11.18) -8.36 to 0.364 0.097 
Month 12 12.55 (5.34) -5.37 (11.54) -9.85 to -0.92 0.009 
 
The original results which used the 6 x 3mm Q-Box™ presented more dramatic decreases in 
the breast elasticity across the four repeat measurements. The results showed a trend for 
decreasing elasticity values across the three-time points after baseline, with no mean elasticity 




These results demonstrate that when using the Free-Trace Q-Box™ data, there are significant 
differences in the outcomes and conclusions regarding the data. The elasticity decreased from 
baseline in both the datasets; however, when using the Free-Trace Q-Box™ data, the elasticity 
increased slightly at the 12-month repeat measure. This result could demonstrate that the 
breast elasticity has quite rapid acute decreases and then begins to plateau as the timeline 
extends. Further explanations for the discrepancies between the results produced by the two 
elasticity protocols could be that the 6 x 3mm Q-Box™ data is more influenced by artefacts 
and fluctuations in the data and it may have been possible that artefacts were included in the 
baseline images, increasing the mean elasticity and showing greater decreases with the 
follow-up measurements. In addition to this, there may have been areas in the month 12 
images where the shear waves didn’t propagate (black holes), which produces a lower mean 
elasticity and therefore may show greater reductions with time. Furthermore, as the elasticity 
fluctuates across each SWE image and the 6 x 3mm Q-Box™ method requires the operator to 
place the Q-Box™  across the image, it is possible that by chance the Q-Box™  were placed on 
areas on lower elasticity, thus producing a lower mean elasticity at the 12-month time point. 
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Further research needs to be completed to determine if there is a true elasticity plateau at 
some point during the intervention, or to determine if there were measurement errors at any 
point during the study.  
 
7.4.4.2 Correlations Between Elasticity and Per Cent Volumetric Breast Density 
The next group of analyses that were conducted were the analyses of the correlation between 
the %VBD and the breast elasticity values. 
 
7.4.4.2.1 Correlation Between Baseline Per Cent Volumetric Breast Density and Breast 
Elasticity 
The initial calculation conducted was to determine the correlation between the 
baseline %VBD and the baseline breast elasticity values. The Shapiro-Wilk suggested that the 
data was normally distributed (baseline elasticity p-value = 0.778; baseline %VBD p-value = 
0.185). As the data was normally distributed the Pearson’s correlation coefficient was the 
statistical model used the analyse the data. The results from the Pearson’s correlation 
coefficient showed there was no correlation between the two variables with an r-value of 
0.000 (p=0.999) (Figure 7-9). There was no pattern of a relationship between baseline breast 
elasticity and baseline %VBD.  
 
 
Figure 7-9: Correlation between %VBD at baseline and breast elasticity in kPa at baseline 
r-value = 0.000 
p=0.999 
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The original results conducted in Chapter 5 using the 6 x 3mm Q-Box™ data. These 
correlations resulted in an r-value of 0.264 (p=0.528), which was a negligible correlation 
between the two variables. Using the Free-Trace Q-Box™ data did not change the result of the 
correlation analysis.   
 
7.4.4.2.2 Correlation Between End of Study Per Cent Volumetric Breast Density and 
End of Study Breast Elasticity 
The next analysis was to correlation the EOS %VBD values with the EOS breast elasticity 
values. The Shapiro-Wilk results suggested both sets of data were normally distributed (EOS 
elasticity p-value = 0.596; EOS %VBD p-value = 0.576).The Pearson’s correlation coefficient 
produced an r-value of 0.114 (p=0.788); this was a negligible correlation between the two 
variables (Figure 7-10). 
 
 
Figure 7-10: Correlation between EOS %VBD (12-month data) and EOS breast elasticity (12 months) 
This result was similar to the original analysis presented in Chapter 5, using the 6 x 3mm Q-
Box™ data. This analysis produced an r-value of 0.273 (p=0.523), which was a negligible 
correlation between the two variables. Using the Free-Trace Q-Box™ data did not change the 
overall result of the correlation analysis. 
 
r-value = 0.114 
p=0.788 
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7.4.4.2.3 Correlation Between the Change in Per Cent Volumetric Breast Density and 
Change in Breast Elasticity 
The initial calculation was looking at the correlation between the change in breast elasticity 
and the change in %VBD from baseline to the final 12-month repeat measurement. The data 
was normally distributed as per the Shapiro-Wilk test (change in elasticity (baseline to 12 
months) p-value = 0.609; change in %VBD (baseline to 12 months) p-value = 0.435). The 
results from Pearson’s correlation coefficient produced an r-value of 0.315 (p=0.448), which 
was a low correlation between the two variables (Figure 7-11) 
 
 
Figure 7-11: Correlation between change in %VBD (baseline to month 12) and change in breast elasticity (baseline to month 
12) 
These results differed from the original analysis, which used the 6 x 3mm Q-Box™ data. These 
analyses produced an r-value of -0.120 (p=0.997), which was a negligible, negative correlation 
between the two variables. Using the Free-Trace Q-Box™ elasticity data changed the 
correlation from negligible to low. 
 
The final analysis for this section was using the Free-Trace Q-Box™ data to correlate the 
changes in %VBD from baseline to the 12-month measurements, and the change in elasticity 
from the baseline measurement to the one-month time point. The data was normally 
distributed according to the Shapiro-Wilk test (change in elasticity (baseline to one month) p-
value = 0.231; change in %VBD (baseline to 12 months) p -value = 0.435). The Pearson’s 
r-value = 0.315 
p=0.448 
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correlation coefficient produced an r-value of 0.041 (p=0.925); this was a negligible, positive 
correlation between the two variables (Figure 7-12). 
 
Figure 7-12: Correlation between change in %VBD (baseline to month 12) and change in breast elasticity (baseline to month 
one) 
 
These results vary significantly from the original analysis using the 6 x 3mm Q-Box™ data, 
presented in Chapter 5. This analysis produced an r-value of -0.451 (p=0.262), which was a low 
negative correlation between the two variables. Using the Free-Trace Q-Box™ elasticity data 
changed the correlation analysis from moderate to negligible.  
 
7.4.4.3 Correlations Between Elasticity and Total Fibroglandular Volume 
The next group of analyses is correlation the breast elasticity values with the TFV values.  
 
7.4.4.3.1 Correlation Between Baseline Breast Elasticity and Baseline Total 
Fibroglandular Volume 
The initial analysis was to correlate the baseline elasticity values with the baseline TFV values. 
The data was normally distributed as per the Shapiro-Wilk test (baseline elasticity p-value = 
0.779; baseline TFV p-value = 0.264). The Pearson’s correlation coefficient was used to analyse 
the data. The correlation coefficient produced an r-value of 0.078 (p=0.854); this a negligible, 
positive correlation between the two variables (Figure 7-13). 
 




Figure 7-13: Correlation between baseline total fibroglandular volume and baseline breast elasticity 
 
The original calculation produced a similar result to the one just presented. The original 
analysis produced an r-value of 0.273 (p=0.523), which was a negligible, positive correlation 
between the two variables. Using the Free-Trace Q-Box™ elasticity data changed the 
correlation analysis outcome from low to negligible.  
 
7.4.4.3.2 Correlation Between End of Study Breast Elasticity and End of Study Total 
Fibroglandular Volume 
The next correlation conducted was the correlation between the EOS breast elasticity and the 
EOS TFV. The data was normally distributed as per the Shapiro-Wilk test (EOS elasticity p-value 
= 0.596; EOS TFV p-value = 0.462). The Pearson’s correlation coefficient was the statistical test 
used. The results of this test produced an r-value of -0.547 (p=0.161), which was a negative, 
moderate correlation between the two variables (Figure 7-14). 




Figure 7-14: Correlation between EOS total fibroglandular volume (12 months) and EOS breast elasticity (12 months) 
 
The original result presented in Chapter 5 was substantially different from the results just 
presented. The results from Chapter 6 showed an r-value of 0.842 (p=0.009), which was a 
statistically significant, high positive correlation between the two variables. Using the Free-
Trace Q-Box™ elasticity data changed the results from a positive to a negative correlation and 
changed the overall correlation from high to moderate.  
 
7.4.4.3.3 Correlation Between the Change in Breast Elasticity with the Change in Total 
Fibroglandular Volume 
The first analysis in this group of analyses is a correlation the change in elasticity from the 
baseline measure to the 12-month time point with the change in TFV from the baseline 
measure to the 12-month time point. According to the Shapiro-Wilk test the TFV violated the 
test for normality (p=0.034), and therefore the data were transformed using a logarithmic 
transformation. Following the data transformation, the Shapiro-Wilk test demonstrated the 
change in TFV was 0.087, which was normally distributed. The change in elasticity was 
normally distributed (p = 0.609). As both datasets were now normally distributed, Pearson’s 
correlation coefficient was used to analyse the data. This correlation analysis produced an r-
value of 0.657 (p=0.077); this was a moderate, positive correlation between the two variables 
(Figure 7-15). 




Figure 7-15: Correlation between change in total fibroglandular volume (baseline to month 12) and change in breast 
elasticity (baseline to month 12) 
 
The original results in Chapter 5 produced a similar result with an r-value of 0.678 (p=0.139), 
which again was a moderate correlation between the two variables. Using the Free-Trace Q-
Box™ data did not change the overall conclusion from the correlation analysis.  
 
Upon evaluating the change in breast elasticity from baseline to one month, and its 
correlation to the changes in TFV from baseline to month 12. The results from the Shapiro-
Wilk test showed the change in elasticity (baseline to one month) was normally distributed 
(p=0.231). The change in TFV was listed above and was normally distributed with transformed 
data. The results from the Pearson’s correlation coefficient produced an r-value of 0.459 
(p=0.253), which was a positive, low correlation between the two variables (Figure 7-16). 
 




Figure 7-16: Correlation between change in total fibroglandular volume (baseline to month 12) and change in breast 
elasticity (baseline to month 1) 
This result was a similar result to the original analysis in Chapter 5 with an r-value of 0.500 
(p=0.313), which was a positive, moderate correlation between the two variables. Using the 
Free-Trace Q-Box™ data changed the overall correlation from moderate to low; however, the 
actual r-values are quite similar in value. 
 
7.4.4.3.4 Correlation Between Elasticity and Total Breast Volume 
The next group of analyses is between the breast elasticity and the TBV at the different time 
points.  
 
7.4.4.3.5 Correlation Between Baseline Breast Elasticity and Baseline Total Breast 
Volume 
The Initial analysis conducted was the correlation between the baseline elasticity and the 
baseline TBV. The data was normally distributed according to the Shapiro-Wilk test (baseline 
elasticity p-value 0.778; baseline TBV p-value = 0.345), as the data was normally distributed 
the Pearson’s correlation coefficient was used to analyse the data. This correlation produced 
an r-value for this correlation was 0.095 (p=0.822), which was a positive, negligible correlation 
between the two variables (Figure 7-17). 




Figure 7-17: Correlation between baseline total breast volume and baseline breast elasticity 
 
This result was a similar result to the original results presented in Chapter 5, with this 
correlation producing an r-value of 0.246 (p=0.557), which again was a positive, negligible 
correlation between the two variables. Using the Free-Trace Q-Box™ data did not alter the 
conclusion from the correlation analysis.  
 
7.4.4.3.6 Correlation Between End of Study Breast Elasticity and End of Study Total 
Breast Volume 
Upon looking at the EOS elasticity and the EOS TBV, the data was normally distributed (EOS 
elasticity p-value = 0.596; EOS TBV p-value = 0.086). Pearson’s r-value was -0.605 (p=0.112), 
which was a negative, moderate correlation between the two variables (Figure 7-18). 
 




Figure 7-18: Correlation between EOS total breast volume (12 months) and EOS breast elasticity (12 months) 
These results differed substantially from the original analysis presented in Chapter 5; this 
analysis produced an r-value of 0.845 (p=0.007), this being a statistically significant strong 
correlation between the two variables. Using the Free-Trace Q-Box™ data, the results went 
from a positive, negligible relationship to a negative high positive correlation between the two 
variables.  
 
7.4.4.3.7 Change in Breast Elasticity and Change in Total Breast Volume 
The next analysis was to look at the correlation between the change in breast elasticity from 
baseline to 12 months and the change in TBV from baseline to 12 months. The data was 
normally distributed according to the Shapiro-Wilk test (change in elasticity (baseline to 12 
months) p-value = 0.623; change in TBV (baseline to 12 months) p-value = 0.735). The 
Pearson’s r-value was -0.225 (p=0.592). This result was a similar result to the previous analysis 
that was presented in Chapter 5 with that analysis producing an r-value of 0.280 (p=0.502), 
both correlations were statistically insignificant, low correlations between the two variables 
(one a positive, one a negative correlation) (Figure 7-19).  
 




Figure 7-19: Correlation between change in total breast volume (baseline to month 12) and change in breast elasticity 
(baseline to month 12) 
 
The final analysis was to correlation the change in elasticity from baseline to month one and 
the change in TBV from baseline to month 12. Again, the data was normally distributed 
according the Shapiro-Wilk test (change in elasticity (baseline to one month) p-value = 0.231), 
and the change in TBV was listed above. The Pearson’s correlation coefficient produced an r-
value of 0.283 (p=0.497), which was a low, positive correlation between the two variables 
(Figure 7-20). This result was different from the original analysis, which resulted in an r-value 
of 0.585 (p=0.223), which was a positive, moderate correlation between the two variables. 
Therefore, using the Free-Trace Q-Box™ elasticity data changed the overall conclusion of the 
correlation analysis.  
 




Figure 7-20: Correlation between change in total breast volume (baseline to month 12) and change in breast elasticity 
(baseline to month one) 
 
7.5 Discussion 
Within the original experimental studies located in Chapter 4 (HAVAHT+Ai™ study) and 
Chapter 5 (enobosarm and anastrozole study) of this thesis, the whole breast elasticity was 
calculated from SWE images using 6 x 3mm Q-Box™ across eight images (each breast 
quadrant) and then averaging the elasticity from these Q-Box™. Observations of the data in 
these studies revealed substantial within-subject variation, which did not appear to follow a 
pattern or a consistent trend of increasing or decreasing breast elasticity. Due to these 
observations, it was decided that the elasticity data needed to be examined, and that the data 
would be re-acquired using a variety of different Q-Box™ protocols to extract the data from 
the SWE image. Collecting this data was done to evaluate which methods had high levels of 
agreement with the reference standard, and which method had the lowest CV, therefore the 
greatest precision when collecting the elasticity data. In addition, the clinical utility of the data 
collection method was evaluated, as for this research program the focus is the use of SWE in 
clinical research, therefore the chosen SWE method needed to be easily implemented in 
research protocols and be able to be conducted in a timely manner.  
 
The best protocol for collecting the data was determined to be the Free-Trace Q-Box™ 
method, which is the method of tracing the ROI over the image; omitting any areas where the 
r-value = 0.585 
p=0.223 
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shear waves have not propagated and omitting areas where artefacts have corrupted the 
image. When using this method, firstly, there isn’t the same degree of elasticity variation due 
to the areas of extremely high and low elasticity being omitted as per the method stated 
above. Additionally, when using this method, there is a large area to calculate the average 
elasticity, which provides a more accurate representation of the assumed true elasticity from 
the image. When using the 6 x 3mm Q-Box™ protocol, a substantial amount of area in the 
SWE image is not included in the elasticity calculation. As the elasticity in the tissue fluctuates 
to such a great extent, smaller ROIs may substantially alter the value for the whole breast 
elasticity. To determine if changing the method of analysing the SWE images influenced the 
results of the original two experimental studies, the original images were re-evaluated using 
the Free-Trace Q-Box™, and all the relevant analyses that were conducted in these studies 
were repeated with the new dataset to determine if the outcomes differed. 
 
Regarding the within-subject data of the HAVAHT+Ai™ study of Chapter 4, there were no 
statistically significant median differences between the two elasticity datasets (6 x 3mm and 
Free-Trace Q-Box™). However, when analysing the within-subject data of the enobosarm and 
anastrozole study of Chapter 5, there were statistically significant median differences between 
the two datasets. The Free-Trace Q-Box™ had a slightly lower median elasticity of 13.77kPa 
which was 0.7kPa lower than that produced with the 6 x 3mm Q-Box™ method. As mentioned 
in Chapter 6, using different Q-Box™ protocols or sizes and varying the position the Q-Box™ 
are placed can alter the elasticity output, and this was demonstrated within this analysis. From 
this analysis it can be reinforced that it is crucial that a consistent elasticity protocol is used 
amongst researchers to generate the mean whole breast elasticity or measurement error may 
bias the results, increasing the risk of Type 1 errors (false positives). 
 
Regarding the repeat measurements and the analysis of the change in elasticity over time, in 
the HAVAHT+Ai™ study the original data and subsequent analyses using the 6 x 3mm Q-Box™ 
protocol, the results showed statistically significant decreases in the mean breast elasticity 
from the second month with reductions of -3.80kPa (95% CI -6.72 to 0.87;p=0.0004), and 
there was also a statistically significant reduction at the three-month time point with a 
decrease of -5.04kPa (95% CI -7.31 to -2.78; p<0.005). When using the Free-Trace Q-Box™ 
data in the second analysis, the trends of decreasing elasticity were similar, but the overall 
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decreases were slightly less than the original analysis. In the Free-Trace Q-Box™ analysis, as 
with the original analyses, there were statistically significant reductions at month two of -
2.97kPa (95% CI -5.30 to -0.64; p=0.005) and at month three with reduction of -4.04kPa (95% 
CI -5.84 to -2.24; p<0.0005). Both datasets showed a statistically significant reduction at the 
same time points; the Free-Trace Q-Box™ data may have had a smaller reduction due to the 
decreased variability of the data. As the method decreases the potential for elasticity 
extremes, it may have led to observed smaller mean changes. The Free-Trace Q-Box™ data 
also had smaller confidence intervals, which demonstrates a greater level of precision of the 
results. This smaller confidence interval being favourable for clinical research and shows a 
greater indication of efficacy in studies with smaller sample sizes. Overall, these results 
demonstrate that the original conclusions that HAVAHT+Ai™ influenced breast elasticity can 
be maintained.  
 
Similar findings were observed in the repeated measure analysis of the enobosarm and 
anastrozole study from Chapter 5. The original analysis demonstrated that there were 
statistically significant changes in the breast elasticity at the 12-month time point with a 
change of -5.37kPa (95% CI -9.85 to -0.92; p=0.009). The breast elasticity changes also 
approached statistical significance at the one-month time point with a change of -3.69kPa 
(95% CI -7.50 to 0.12; p=0.064). When using the Free-Trace Q-Box™, as the data was non-
parametric, the Friedman test and median values were used. This analysis showed a 
statistically significant reduction at the third month with a change of -3.50kPa (p=0.014) and 
the 12-month reductions plateaued, leading to a statistically insignificant change of -1.60kPa 
(p=0.094). The changes between month three and month 12 were statistically insignificant 
with a breast elasticity increase of 0.58kPa (95% CI -1.58 to 2.69; p=1.000). If the Free-Trace 
Q-Box™ elasticity analysis was redone using a parametric test, as per the Friedman test, there 
were statistically significant changes of -2.76kPa (95% CI -5.39 to -0.12; p=0.094) at the third 
month time point. These results then plateaued and became statistically insignificant at the 
12-month time point with a reduction of -2.18kPa (95% CI -4.57 to 0.209; p=0.094). One of the 
major limitations of this study is that we do not know if this was a true plateau with the tissue 
elasticity or whether there was a measurement error. A future study with more regular SWE 
imaging may be able to provide more insight into what is happening with the breast elasticity 
between the third and 12th month.  
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With the Free-Trace Q-Box™ data, even though the results were not as favourable for the 
hypothesis, this method of data collection produced more precise results with narrow 
confidence intervals. The confidence intervals also had a greater range below zero, showing a 
greater likelihood that the true mean would show a reduction at the 12-month time point. 
Additionally, as the sample size is small, even a slight increase in a participant’s breast 
elasticity could influence the results and lead to statistically insignificant results. With this 
sample size, the confidence intervals may be a better indication of efficacy in this scenario. 
Further explanations for the insignificant results could be that as the mammograms were only 
conducted at baseline and month 12, it is unable to determine if the changes within the %VBD 
and TFV also plateaued at the three-month mark, so it cannot be concluded that the elasticity 
changes reflected changes in the mammography variables. Based on the confidence intervals, 
it can be hypothesised that the elasticity does decrease across the 12 months, but the sample 
size may have influenced the findings. Overall, as seen in the HAVAHT+Ai™ study, reductions 
may occur in the breast elasticity in response to the interventions. Future research needs to 
be done with more regular outcome measures for both breast elasticity and mammography 
for %VBD and TFV.  
 
The next  analysis was the correlations between the mammography variables and breast 
elasticity, and the differences in these correlations when using 6 x 3mm Q-Box™ and the Free-
Trace Q-Box™. From the results of this study, descriptively, there were several variations 
between the different Q-Box™ protocols. An example of this was from the enobosarm and 
anastrozole study, analysing the correlation between the change in %VBD and the change in 
tissue elasticity across 12-months. The original Pearson’s r-value was 0.315, and the 
subsequent r-value was -0.12, although both were statistically insignificant, the change in the 
method of data collection has changed the direction of the correlation, which has the 
potential to lead to a dramatically different conclusion being made from the data. However, as 
most of the correlations were not statistically significant, these changes could have occurred 
due to chance and may not be replicated with a larger study.  
 
From these new data analyses conducted in this chapter, it was re-evaluated whether the 
original conclusions in regard to the thesis objectives were still correct or whether these have 
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changed, and if so, what are the new conclusions that can be drawn from the data. The 
original objectives of the HAVAHT+Ai™ study were to determine the potential effects of 
HAVAHT+Ai™ on breast tissue elasticity, as measured by SWE and whether these changes 
correlate with changes in MBD. The initial results, using the data collected with the 6 x 3mm 
Q-Box™, demonstrated that there were statistically significant changes from the second 
month of the study, and this continued for the third month with again statistically significant 
breast elasticity decreases. From the baseline values to month two, the 95% CI showed values 
of -6.72 to -0.87 with a p-value of 0.004, and the baseline to month three results produced a 
95% CI of -7.31 to -2.78 with a p-value of less than 0.0005. These low p-values and CI that 
favour more significant decreases, alluded to a lower risk of the results occurring due to 
chance and demonstrated quite significant effect sizes in response to the intervention. The 
analysis of this study using the Free-Trace Q-Box™ elasticity data, showed very similar results 
with a significant median decrease of -3.70kPa at two months with a p-value of 0.002 and the 
median decrease of -4.35kPa at three months with a p-value of less than 0.0005. These results 
also present very low p-values which demonstrates a low risk of chance affecting the results. 
The similarities between the results show that even when using a technique that produces 
more precise data, the same conclusions can be drawn from the data, this being that breast 
elasticity may be used as a biomarker of early response to changes in the breast tissue and 
further research is warranted.  
 
The secondary objective of this study was analysing the correlations between the 
mammography variables and the elasticity values. As previously discussed in Chapter 4, the 
most important correlation that needed to be evaluated was the change in the elasticity data 
and the change in TFV. In regard to the HAVAHT+Ai™ study, when observing the change in TFV 
at 12 months and the change in breast elasticity at three months with Free-Trace Q-Box™ 
data, there were both statistically significant moderate correlation between the two variables. 
In addition, when looking at the correlations, with elasticity at one month and TFV at 12 
months, both analyses showed statistically significant moderate correlations. These results 
demonstrated that within the HAVAHT+Ai™ study, there might be a relationship between the 
changes in breast elasticity and TFV, which could be confirmed with more research. 
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In regard to the anastrozole and enobosarm study and the change in breast elasticity and TFV, 
the Free-Trace Q-Box™ data produced a moderate, positive relationship which was 
approaching the traditional level of statistical significance. When looking at the elasticity 
change at one month to the TFV across 12 months, there was an r-value of 0.459 (p=0.253), 
which was close to the original calculation with a moderate correlation of 0.500 (p=0.313). 
Both of the results (old and new) demonstrate that elasticity changes may correlate with TFV 
changes, and elasticity may have the potential to be able to predict an early response of the 
changes in TFV across 12 months of chemopreventative use.  
 
These new results are still favourable for the hypothesis that the changes in elasticity correlate 
with the changes in the mammography variables. However, this hypothesis cannot be ruled 
out as the sample size of the study is small and small variations in the individual’s participants 
results can dramatically change the outcome of the study. A larger study needs to be 
conducted to determine if the breast elasticity changes at one month can correlation with the 
TFV changes.  
 
7.6 Conclusion 
The findings within this chapter demonstrate that even when using a more precise method to 
calculate the breast elasticity, there were still statistically significant reductions in the breast 
elasticity in response to both interventions. These results were seen at the three-month time 
point in both the studies and with statistically insignificant reductions at the 12-month time 
point in the enobosarm and anastrozole study. These results also show that there are still 
moderate correlations between changes in breast elasticity and changes in TFV and these 
correlations may also be seen as early as one month in the breast elasticity measures.  
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Chapter 8 The Behaviour of Breast Elasticity as Measured by Shear 
Wave Elastography in Healthy Women in Regard to Menstrual Cycle 
Changes, Repeatability and Intra-rater Reliability. 
8.1 Background 
Within the first two experimental studies, as previously commented on, it was observed that 
there was substantial within-subject variation with repeated measures when using the SWE to 
measure whole breast elasticity. This observation showed that with some of the repeat 
measures, the breast elasticity would decrease and then subsequently increase with the 
following measurement. In the absence of a control group, there is uncertainty as to how 
much of this variability are genuine changes in the breast and related to hormonal fluctuations 
or other factors, and how much is due to measurement error. This study was designed to 
provide information on these unknowns, analysing the behaviour of breast elasticity through 
repeat measures in women without breast disease and who are not using hormonal 
interventions of any kind. This will provide more insight into the results from the other trials 
within this thesis. 
 
In addition, as using SWE to measure the whole breast elasticity is a new indication and is not 
widely researched, this study aimed to calculate the intra-rater reliability of SWE on whole 
breast elasticity. This analysis allowed us to determine if any of the measured changes are 
occurring due to the interventions in the HAVAHT+Ai™ study and the enobosarm and 
anastrozole study, rather than the assessor’s technique or issues with the images acquired. 
 
This study is a reliability and repeatability study with four repeat measures, every two weeks 
on 19 women who were free from breast disease and any form of systemic hormonal 
intervention. Whole breast elasticity and stage of the menstrual cycle were assessed and 
recorded for each participant. The images were also obtained using two patient positions to 





The primary objectives of this trial were to determine the behaviour of breast tissue elasticity 
with repeat measures on healthy women and to determine whether the hormonal 
fluctuations that occur with the menstrual cycle can influence the breast elasticity 
measurements. 
 
The secondary objectives of this trial were to: 
1. Determine the intra-rater reliability of using SWE to measure the whole breast 
elasticity in a healthy cohort. 
2. Determine whether the arm position changes the breast elasticity output. 
3. Determine the normative breast elasticity values of this healthy cohort to use as a 
comparison for other studies within this thesis. 
 
8.3 Publication Manuscript 
The Statement of Authorship for this publication manuscript is presented in Appendix 5. 
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Shear wave elastography (SWE), is an imaging technique that analyses the elasticity of a tissue 
or organ of interest. SWE has proven to be valuable in breast assessments, and there are 
emerging indications for using the assessment of whole breast elasticity. This study aims to 
determine the behaviour, influence of hormonal fluctuations, patient position and intra-rater 
reliability on breast elasticity across four repeat measures.  
 
Method 
19 premenopausal women who were absent of any breast disease, and not on any form of 
hormonal interventions had four repeat SWE measurements, two weeks apart in two different 
patient positions. Each patient had their stage of menstrual cycle determined via blood 
analysis. Statistical analysis was conducted to determine the intra-rater reliability, the 
difference in breast elasticity across the different stages of the menstrual cycle and difference 
in elasticity measures using differing patient position. The mean whole breast elasticity was 
also calculated.  
 
Results 
Mean breast elasticity during the follicular stage was 6.61kPa (SD 1.86) and 6.70kPa (SD 2.01) 
during the luteal stage; this was a statistically insignificant difference (p= 0.670). The breast 
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elasticity was not statistically different at any time point (p=0.602). There was a statistically 
significant median difference of -1.16kPa (p<0.005) between the two patient positions. The 
intra-rater ICC was 0.98 (95% CI 0.97 to 0.99; p<0.005) for the whole breast measurements. 
 
Conclusion 
Average whole breast elasticity is a reproducible measure for healthy women and has the 
potential to be used as an outcome measure to determine the efficacy of therapeutic 
interventions for breast conditions. 
 
Introduction 
Shear wave elastography (SWE) is an elastography technique that analyses the soft tissue 
mechanical properties of the tissue or organ of interest. SWE uses acoustic radiation force 
impulses, which provide the mechanical excitation through pushing beams that deform the 
underlying tissue of interest. Several of these pushing beams are transmitted at different 
depths, which results in the propagation of transient shear waves. The speed of these shear 
waves is then measured using a scanner with a very fast frame rate, allowing the shear waves 
to be followed in real-time. This is repeated for different lines; allowing a map of a region of 
interest (ROI) to be created from analysing the differences in arrival times and calculating the 
shear wave speeds. A colour-coded image is then displayed on the SWE monitor, and the 
quantitative data is presented as a measure of shear wave speed in meters per second (m/s-1) 
or converted to the Youngs Modulus and displayed as kPa. Throughout the measurement, B-
mode image guidance is possible as the same transducer that generates the shear wave also 
captures their propagation (Bercoff, Pernot et al. 2004, Bercoff, Tanter et al. 2004, Sebag, 
Vaillant-Lombard et al. 2010, Shiina, Nightingale et al. 2015). 
 
To date, within the realm of breast health, the main use of SWE has been differentiating 
breast lesions as being either benign or malignant, with current research showing that there is 
a statistically significant difference in elasticity values between benign and malignant lesions, 
in which malignant lesions predominately have a greater elasticity (Athanasiou, Tardivon et al. 
2010, Chang, Moon et al. 2011, Berg, Cosgrove et al. 2012, Au, Ghai et al. 2014). For this 
indication, the operator places a Q-Box™ (a tool used to calculate the area of elasticity) on the 
SWE image within the area of the greatest elasticity in the lesion to generate the maximum or 
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mean elasticity of the lesion. This indication has been proven reliable with intra-observer 
reliability for maximum and mean elasticity reported as high (ICC = 0.84 and 0.87) and the 
interobserver agreement for maximum elasticity quantification having a Cohens Kappa value 
of 0.66 (95% CI 0.59 to 0.73) (Cosgrove, Berg et al. 2012), which represents a substantial level 
of agreement between the two observers (McHugh 2012).  
 
SWE has proven to be extremely valuable in breast assessments, and with this there are new 
emerging indications that are aiming to assess the whole breast elasticity; rather than the 
selective area of interest. These indications include correlation of the breast elasticity with the 
BI-RAD breast density assessment (Evans 2015). For this indication, the elasticity was obtained 
using a ROI as large as possible within the SWE image rather than selectively choosing an area 
of tissue. There has also been research into monitoring breast pain, inflammation and capsular 
contracture (Rzymski, Kubasik et al. 2011, Rzymski, Kubasik et al. 2011, Sowa, Yokota et al. 
2017). These new indications use different methodologies to that listed above, as rather than 
finding the area of greatest elasticity, the whole breast elasticity is sought. For this, the 
researcher needs to take an image in each quadrant of the breast and select a ROI to calculate 
the elasticity of each quadrant and then the breast as a whole. This type of imaging may be 
used to detect changes within the breast tissue in response to therapeutic interventions. 
Therefore, it is important to know the typical behaviour of breast elasticity in a healthy cohort 
upon repeat measures, this including the effect of natural hormonal fluctuations with the 
menstrual cycle, examination the reliability of using SWE, and determination if the patient 
position has a significant effect on the elasticity measurement. By gaining this information, 
researchers and clinician will have more knowledge about breast elasticity and feel more 
confident using it as an outcome measure in clinical practice or future health research. 
 
Therefore, the aim of this study was to determine the behaviour of breast elasticity across 
four repeat measures, analyse the intra-rater reliability of whole breast elasticity when using 
SWE, and determine if the patient position can significantly alter the elasticity output in a 




Material and Methods 
This study was approved by the Institutional Human Research Ethics Committee at The 
University of Adelaide (approval number H-2018-197.) Informed consent was obtained from 
all participants. Subjects were recruited from the Burnside Breast Centre and Wellend Health 
Pty Ltd, located in Toorak Gardens, South Australia, through Facebook advertising, and 
through word of mouth of the participants. The study population consisted of premenopausal 
women between the ages of 18 and 50 years, who were currently not pregnant or lactating. 
Participants were excluded from this study if they had the presence of breast cancer, had 
breast implants, had any previous breast surgery, the presence of a pacemaker or are 
currently on any hormonal treatments for mammographic breast density (MBD) or systemic 
contraceptive medications with the exception of the Mirena. The participants were required 
to attend four visits, one every two weeks, each comprising of a blood test to measure 
progesterone to determine the stage of the menstrual cycle and the SWE imaging.  
 
Determination of Stage of the Menstrual Cycle 
Forearm venous blood samples (5ml) were collected for each participant prior to the SWE 
imaging at each visit. The blood was allowed to clot, and the serum was separated by 
centrifugation, collected and stored at -80° until further use. Assays were performed by a 
commercial pathology laboratory. Paramagnetic particle-based enzyme immunoassay was 
used for the determination of progesterone from serum samples. The reference limits for the 
follicular stage were <3nmol/L, and the luteal phase was 5-75nmol/L. 
 
Shear Wave Ultrasound Protocol 
The elasticity was evaluated using the Aixplorer® ShearWave™ Ultrasound machine 
(Supersonic Imagine, Aix-en-Provence, France) with a SuperLinear™ SL15-4 linear transducer 
with a bandwidth of 2-10 megahertz, in the default breast pre-set, running in SWE mode. Two 
different positions were utilized during this study, firstly the volunteer lying supine with arms 
relaxed by their sides (position A), the second position was the volunteers lying supine with 
the ipsilateral arm to the breast being imaged resting under their head (position B). A single 
operator conducted all the scans for all the participants and all the repeated measures. The 
imaging protocol is presented in (Figure 8-1), the breast was divided into four quadrants, the 
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outer lower, the outer upper, the inner upper and the inner lower. Each quadrant was 
scanned from the left to right breast, three times in position A and once in position B. The 
transducer head was positioned approximately 2cm away from the nipple and was placed on 
the skin in a parallel manner from the nipple (Figure 8-2). 
 
 
Figure 8-1:  Image sequence of the breast quadrants used in shear wave elastography 
 
 
Figure 8-2: Positioning of the transducer head on the breast 
 
Once the images were acquired, the elasticity values were generated by using the Q-Box™ 
trace function to trace the largest ROI from the image omitting any areas for which the shear 
waves had not propagated (black holes) or any areas for which ultrasound artefacts were seen 
on the image (as these lead to excessively high elasticity values that do not correspond to 
figures on the B-Mode ultrasound image) (Figure 8-3), this again generated values for the Emin, 
Emean, Emax and SD for each quadrant. The Emean of each quadrant were used to produce the 




Figure 8-3: Shear wave ultrasound image with Free-Trace Q-Box™, avoiding a black hole 
 
Statistical Analysis 
All data were entered into in Microsoft Excel (Microsoft, USA), and all statistical analyses were 
performed using SPSS Version 25 Software (IBM, Armonk, NY, USA). The paired samples T-test 
for parametric data, and the Sign test for non-parametric data were used to determine if there 
was a difference in the within-subject breast elasticity values during the different periods of 
the menstrual cycle, and whether there was a difference in the breast elasticity when the 
participant had their arms relaxed by their side or resting above their head. For these 
analyses, data was presented as median or mean (SD) unless otherwise stated. The 
interquartile range (IQR) was used to determine which patient position had the least amount 
of dispersion within the data. The Friedman test was used to analyse the behaviour of the 
average breast elasticity with the repeated measures. Intra-class correlation coefficient (ICC) 
analysis was used to determine the intra-rater reliability of the measurements. Data were 




19 women volunteered to be included in the study; the mean age was 30.56 years (SD 9.10) 
with a mean BMI of 25.04. The patient characteristics are presented in Table 8-1. The average 
estimates of the Young’s Modulus for both breasts combined were 6.80kPa (SD 2.13kPa). 
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Table 8-2 shows the average breast elasticity of each quadrant for each repeated measure and 
the change in position for the participants.  
 
Table 8-1: Participant Characteristics 
Demographic Average (min-max) 
Age 30.56 years (23.25 – 48.77) 
Weight 68.88kg (50 – 90) 
Height 166.25cm (155 – 176) 
BMI 25.04 (19 – 32) 
% of nulliparous participants 78.95% 
% of participants using Mirena 36.84% 
% of participants who previously used systemic contraception 73.68% 








Breast Elasticity and Stage of Menstrual Cycle 
The paired-samples t-test was used to analyse the difference between the average breast 
elasticity in the luteal and follicular stage of the menstrual cycle. With the arms relaxed the 
mean elasticity during the follicular stage was 6.61kPa (SD 1.86) and during the luteal phase 
6.70kPa (SD 2.01). There was a mean difference of 0.09kPa (95% CI -0.37 to 0.55; p=0.670) 
between the two menstrual cycle stages. This was a statistically insignificant difference in the 
elasticity values in the follicular or luteal stage of the menstrual cycle. In regard to the position 
of the arms resting above the participants head, the mean elasticity during the follicular stage 
was 8.26kPa (SD 2.98), and the luteal phase was 8.38kPa (SD 3.13). This was a statistically 
insignificant difference of 0.12kPa (95% CI -0.54 to 0.30; p=0.559). 
 
 
Breast Elasticity with Repeat Measures 
The Friedman test was used to analyse the average breast elasticity over four repeat 
measures. The average elasticity for each time point is reported in Table 2. The breast 
elasticity was not statistically different at any time point (p=0.602). 
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Table 8-2: Median whole breast elasticity at each time point 
Measure Elasticity 
kPa (SD) 
1 6.53 (1.93) 
2 6.75 (1.84) 
3 6.99 (2.59) 
4 6.77 (2.15) 
 
Breast Elasticity and Participant Position 
The descriptive statistics for this data showed the mean elasticity for the arms relaxed was 
6.76 kPa (SD 2.12), and the arms above the participant’s head was 8.31 kPa (SD 3.10) with a 
mean difference of 1.55 kPa, all of the results are reported in Table 3. As the data was non-
parametric, the Sign test was used for the analysis. The results from the Sign test show that 
the median elasticity for arms relaxed was 6.19 kPa, and the arms above the participant’s 
head was 7.53 kPa; this was a statistically significant median difference of -1.16 kPa (p<0.005). 
The IQR was compared for each of these positions, the IQR for the arms relaxed data set was 
3.38, and the IQR for the participant's arms resting above their head was 4.75. 
 
Table 8-3: Mean breast elasticity (SD) for each quadrant in position A and B 
 Position A Position B 
 Measure 1 Measure 2 Measure 3 Measure 4 Measure 1 Measure 2 Measure 3 Measure 4 
Lower 
Outer 
6.20 (2.02) 6.38 (2.41) 6.47 (2.97) 6.30 (2.43) 7.65 (3.42) 8.01 (3.39) 8.06 (3.82) 7.78 (3.07) 
Upper 
Outer 
6.86 (3.00) 7.40 (2.55) 7.54 (3.65) 6.83 (2.67) 6.90 (3.26) 7.58 (3.08) 8.06 (3.84) 7.64 (3.08) 
Upper 
Inner 
6.73 (2.11) 7.00 (2.43) 7.26 (2.84) 7.51 (2.58) 8.18 (3.01) 8.90 (3.99) 10.12 (4.72) 10.15 (4.54) 
Lower 
Inner 






There were 76 datasets (4 quadrants for each breast, each with three repeat measurements), 
the ICC was used to determine the reliability. The reliability of the SWE measurements made 
by the same operator was excellent with an ICC of 0.98 (95% CI 0.97 to 0.99; p <0.005). 
 
Discussion 
SWE is a relatively new form of radiographic imaging that is gaining more traction in regard to 
breast health. Previously in regard to the breast, it has been used to differentiate between 
benign or malignant lesions. However, more indications for this imaging modality are 
beginning to be researched and utilised in clinical practice. For this reason, it is imperative to 
know the behaviour of breast elasticity in women without any breast disease. The population 
of disease-free women in this cohort had an average breast elasticity of 6.80kPa, which was in 
line with a previous study on healthy subjects by Li, Wang et al. (2015) who reported a mean 
elasticity for glandular tissue of 6.60kPa and fatty tissue of 4.86kPa. These results were lower 
than Rzymski, Skórzewska et al. (2011) who found that glandular tissue had a mean elasticity 
of 11.28kPa and fatty tissue of 9.24kPa. Both of these studies reported the glandular and fatty 
tissue separately, which explains the slight variation within the results. The only study using 
the full trace function, similarly reporting the average elasticity, was Evans (2015) who 
reported an average elasticity of 10-13kPa in women; however, these women had varying 
levels of breast density ranging from A to D on the Bi-RAD scale, this meaning the data was not 
normative as dense breast can be considered pathological.   
 
The main focus of this study was to determine the behaviour of breast elasticity on repeat 
measurements and whether the stage of the menstrual cycle influenced these results. Female 
sex hormones, especially oestrogen and progesterone, influence the structure and 
composition of multiple tissues inclusive of the breast parenchyma (Lorenzen, Sinkus et al. 
2003, Rzymski, Wilczak et al. 2012, Kaaks, Tikk et al. 2014). Oestrogens are well-known 
stimulators of collagen biosynthesis and cell growth in several cell types (Beldekas, 
Gerstenfeld et al. 1982, Ernst, Schmid et al. 1988, Surazynski, Jarzabek et al. 2003). Cell 
proliferation is lowest during the follicular stage of the menstrual cycle because of low 
oestrogen and progesterone levels. During the luteal stage, there are higher levels of 
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oestrogen and progesterone, which leads to significant changes in the breast lobules and the 
proliferation of the breast epithelium reaches its peak (Pike, Spicer et al. 1993, Dimitrakakis 
and Bondy 2009). Additionally, Hussain, Roberts et al. (1999) documented a correlation 
between the plasma levels of progesterone and changes in breast volume. Consequently, the 
influence of oestrogen and progesterone on cell proliferation and collagen synthesis may 
influence the breast elasticity. This study reported that there was only a small difference 
between the two stages of the menstrual cycle, with the luteal stage having a slightly higher 
elasticity. This difference was not statistically significant. These results were similar to Li, Wang 
et al. (2015) which found no significant differences in elasticity between glandular and adipose 
tissue throughout the menstrual cycle, with the glandular tissue elasticity being lower on the 
luteal phase than in the early follicular phase. These results demonstrate that the hormone 
fluctuations that occur throughout the menstrual cycle do not significantly influence the 
breast elasticity. If being used for longitudinal studies or for clinical assessment, these results 
show that the stage of the menstrual cycle does not need to be taken into account for when 
participants are to be imaged, and any changes that occur within the elasticity may be due to 
other factors. 
 
Additionally, within longitudinal studies or clinical practice, to determine if a therapeutic 
intervention were able to influence the average breast elasticity, it is necessary to know that 
the elasticity remains stable in disease-free women who are not on any form of intervention 
and that the elasticity would not be influenced by the operator. Within this study, it was found 
that in this demographic, the average breast elasticity did not change over four repeat 
measurements. The results also showed that there was excellent intra-rater reliability with the 
SWE measurements. These findings demonstrate that if used in a longitudinal study, any 
changes that were seen within an intervention group are more likely due to the intervention 
and not measurement errors.  
 
The final variable of this study analysed was whether a change in position would affect the 
average breast elasticity. As SWE for the breast is a relatively new imaging modality, there is 
no protocol for the best position to conduct the imaging. This study demonstrated that there 
were statistically significant differences in the breast elasticity from when the participant had 
their arms relaxed by their side or resting above their head. This indicates that there needs to 
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be consistency within the participant position for longitudinal studies; otherwise, the results 
could be affected. This information may also be important when comparing the results of 
different studies. Due to the decreased IQR, the authors of this study recommended using 
arms relaxed by the participants side. 
 
Conclusion 
These findings suggest that the stage of the menstrual cycle does not influence the average 
breast elasticity. In addition, within a disease-free population, the breast elasticity does not 
change over four repeat measures and the intra-rater reliability is excellent. Consequently, 
average breast elasticity is a reproducible measure and may be used as an outcome measure 
to determine the efficacy for therapeutic intervention for breast conditions. 
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8.4 Publication Summary 
This study was conducted due to the variation seen within the other studies utilising SWE to 
measure breast elasticity. It needed to be researched as to whether these fluctuations that 
were seen in the breast elasticity were due to the effect of the hormonal combinations or 
were due to other influencing factors such as operator changes or error, stage of the 
menstrual cycle or the overall reliability of the SWE machine. This study recruited 19 
premenopausal women between the ages of 18 and 50 years, with an average age of 30.56 
years who were currently not pregnant or lactating or on any form of hormonal intervention 
with the exception of the Mirena. 
 
The first interesting finding from this study was the average breast elasticity was 6.80kPa (± 
2.13kPa), this is significantly different from the other two experimental studies that utilised 
the SWE with the baseline measurement for those studies being 15.18kPa for the study 
utilising enobosarm and anastrozole and 12.81kPa for the study utilising HAVAHT+Ai™. When 
the data from these two studies were combined the average elasticity was 13.81kPa (±3.94), 
which when using the Welch test demonstrated a statistically significant mean difference of 
7.28kPa (95% CI 5.21 to 9.34; p<0.0005) between the data produced in this study. The MBD of 
the participants within this study was not measured, however taking a random sample of 
women with no breast pain is more likely to represent a group with a lower %VBD than a 
group purposively recruited for having a measured high MBD. For this reason, it can be 
hypothesised that women with a greater MBD may have a greater elasticity when compared 
to a healthy cohort. This is a promising finding for the overall aim of this thesis to determine if 
elasticity, as measured by SWE, is a viable biomarker for MBD as with future research it could 
be determined whether the baseline correlation of MBD correlated with breast kPa. 
 
The second important finding of this study is that within this cohort, the stage of the 
menstrual cycle did not influence the breast elasticity. There was a statistically insignificant 
difference of 0.09kPa (95% CI -0.37 to 0.55; p=0.670) when comparing the follicular to the 
luteal stage of the menstrual cycle. This is a beneficial finding as this shows that the timing of 
the SWE in relation to the menstrual cycle should not dramatically influence the output. The 
third important finding was that there was no statistically significant difference in kPa at any 
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time point with the repeat measurements (p=0.602). Both of these findings are of importance, 
as the consistency within this study can allude to the changes being seen in the previous 
studies being due to the hormonal intervention rather than other influencing factors, such as 
the menstrual cycle hormone fluctuations on the repeatability of the SWE machine. This also 
has more supporting evidence as the intra-rater reliability was excellent with an intra-class 
correlation coefficient of 0.98 (95% CI 0.97 to 0.99; p<0.005). 
 
The final important finding of this study was the statistically significant differences between 
the elasticity outcomes of patients who had their arms relaxed compared to their arms above 
their head. The median elasticity for the arms relaxed position was 6.19 kPa, and for the arms 
above head position was 7.53 kPa, this was a median difference of 1.16 kPa. These results 
demonstrate that changing the position of the participants’ arms can significantly change the 
results. The implications of this finding show that the participant position needs to be kept 
constant with repeat measures as it could lead to clinically significant differences. The 
researcher needs to monitor this, as frequently during the SWE examinations during this study 
and the other studies within this thesis, participants would change their arm position for 
comfort reasons and required prompting to return their arms to the position required. If this is 
not kept constant within measures or with repeat measures, there could be significant 
changes occurring which are solely due to the arm position.  
 
8.5 Conclusion 
Overall, this study demonstrates that SWE when being used to measure the average breast 
elasticity is a repeatable and reliable method and is not greatly influenced by fluctuating 
menstrual hormones or the operator, the only factor discovered within this study that can 
influence the average breast elasticity is the patient position. Although further research is 
required, when using SWE to determine the pharmacodynamic effect of a hormonal 





8.6 Future Research 
 
Future research will need to be conducted with women who have high MBD not on hormonal 
intervention. This will help determine if these women have different reliability psychometric 
properties or breast behaviour when their breast elasticity is being measured by SWE. 
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Chapter 9 Discussion and Conclusion 
9.1 Overview 
Breast cancer is one of the most prevalent types of cancer among women, and it is a sizeable 
universal medical issue. Mammographic breast density is a major independent modifiable risk 
factor for breast cancer, and it has been predicted that a third of breast cancer could be linked 
to a woman having highly dense breasts (Boyd, Martin et al. 2010). Currently, MBD is being 
considered as an appropriate baseline breast cancer risk marker, and a surrogate endpoint for 
assessing therapeutic interventions; this due to the strong association between MBD and risk 
of breast cancer. These considerations also allow MBD to be used as a biomarker to evaluate 
the efficacy of interventions that are aimed at reducing breast cancer risk.  
Within the first chapter of this thesis, a literature review was conducted regarding the use of 
mammography and MBD as a surrogate endpoint or biomarker for clinical trials and several 
limitations were identified. These limitations were listed in Section 1.4.1 and include the 
subjective nature of the interpretation of MBD when using a non-automated method of MBD 
quantification. Non-automated methods can also lack the sensitivity to see a significant 
change in the MBD values, which can lead to Type 2 errors and insignificant results in clinical 
trials. Furthermore, the increased imaging quality that comes with improved technologies can 
lead to improved results when using automated methods. In addition, different 
mammography machines can lead to significantly different MBD values for the same patient 
(Kerlikowske, Ichikawa et al. 2007, Vachon, Pankratz et al. 2007, Lokate, Stellato et al. 2013, 
Work, Reimers et al. 2014). Breast pain is also quite common in women, and in particular in 
women, with high MBD; this breast pain and fear of breast pain is a prominent reason for 
women choosing not to attend mammography visits and also for not returning for follow up 
mammograms if they did attend one visit (Kee, Telford et al. 1992, Marshall 1994, Straughan 
and Seow 1995, Elwood, McNoe et al. 1998). The reported fear of breast pain may lead to 
recruitment issues or high attrition rates in research. Another limitation of mammography is 
the ionising radiation that is delivered with each image, which can accumulate during 
longitudinal studies where multiple imaging sessions are required, which in itself is a breast 
cancer risk. 
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One of the most significant limitations of using MBD variables as a biomarker during clinical 
trials is the relative time-insensitivity to detect changes in the mammography variables 
(MBD, %VBD, PMD, TFV, TBV). Despite a drug having an immediate pharmacological effect, 
any potential resultant improvement in breast structure may not be seen for a year, this being 
either due to the typical interval used for mammographic imaging or the time required for the 
intervention to produce an effect on the tissue structure of the breast. Hence long clinical 
trials may need to be designed and implemented to determine whether a treatment is 
effective. Concerning this, within a clinical environment, women on anti-oestrogen therapies 
(which usually have considerable adverse effects) do not have a method of providing timely 
feedback of their response to their intervention, which may contribute to the low compliance 
rates seen with some of these treatments. Due to these limitations, it was concluded that 
there was a knowledge gap regarding a biomarker for MBD for the early detection of changes 
in the breast tissue. Ideally, if a biomarker was found, it could be used in both clinical research 
and within clinical care settings. 
Breast elasticity appeared to be a potentially viable option as a biomarker of MBD. The 
reasons for this being that high MBD tissue has extensive collagen, a more significant number 
of cells, increased ECM and a low adipocyte component (Alowami, Troup et al. 2003, Li, Sun et 
al. 2005, DeFilippis, Chang et al. 2012). These histological components can lead to tissue 
stiffening, as is seen in malignant breast lesions, and this would lead to increased measurable 
elasticity of the tissue of interest. 
This thesis investigated whether whole breast elasticity, as measured by SWE, can be used as a 
biomarker for MBD and to establish a reliable and valid protocol of using SWE to measure 
whole breast elasticity. This chapter will review how the studies included in this thesis 
contributed to the research and development of whole breast elasticity as a biomarker for 
MBD. This chapter will be separated into the following sections; 
1. The use of breast elasticity as a biomarker for MBD 
2. The protocol that should be used to determine whole breast elasticity 
3. The limitations of this research 
4. The clinical and research implications of this work 
5. Conclusion 
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9.2 The Use of Breast Elasticity as a Biomarker for Mammographic Breast 
Density 
The first overarching aim of this research program was to generate evidence into the validity 
of using whole breast elasticity as a biomarker for MBD. Four different studies were 
conducted regarding this research aim. The first key point was that when using SWE to 
measure whole breast elasticity, there was a very strong intra-rater reliability with an ICC of 
0.98 (95% CI 0.97 to 0.99; p<0.0005). Having a strong intra-rater reliability score is essential in 
longitudinal studies; strong reliability allows us to increase our confidence that repeated SWE 
measures will remain consistent when measured by a single individual if no changes are 
occurring within the breast tissue (Roach 2006). Another important psychometric property is 
the inter-rater reliability; however, for feasibility reasons during this research program, this 
measure could not be calculated and will need to be examined with further research. In 
addition to this, within a population of women not on any hormonal intervention, with four 
repeat measures, breast elasticity was not statistically different at any time point. From these 
results, we can conclude that foremost, breast elasticity measured using SWE with a single 
operator is a reliable outcome measure and has favourable psychometric properties that 
would make it a desirable outcome measure for use in clinical trials. However, as will all 
research, these studies will need to be replicated or expanded to further validate the findings 
presented. 
The second key point to examine is the baseline normative breast elasticity values. Two of the 
studies which utilised SWE had recruited women with high MBD (objectively measured with 
VolparaDensity™) and one study recruited women from the general population who had not 
previously had a breast density assessment. Within this third study, it could be hypothesised 
that the population had a lower mean breast density, this being due to the prevalence of high 
MBD in the Australian population (with approximately 50% of the population potentially being 
categorised as heterogeneously dense breasts or extremely dense breasts) (Cording, Smith et 
al. 2018). The participants in this group also did not have breast pain, which is commonly 
associated with high MBD. The average elasticity of the women within the third study who 
were hypothesised as having lower MBD was 6.80kPa (± 2.13kPa) and the mean breast 
elasticity from the studies with women with quantified high MBD was 13.81kPa (±3.94kPa). 
This resulted in a statistically significant difference of 7.28kPa. On face value, this reveals that 
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women recruited due to a higher MBD had greater elasticity than a sample of the general local 
population. As the MBD was not formally measured in the healthy population group, future 
studies need to be conducted in a cross-sectional manner to determine whether there is a 
relationship between MBD and breast elasticity, recruiting a broad sample of women, from 
varying age groups, with varying MBD values. Future research could also aim to correlate the 
baseline TFV and breast elasticity, as TFV represents the volume of the fibrodense region of 
the breast. Through this research program, early evidence has demonstrated a potential trend 
for women with high MBD to have a greater baseline breast elasticity, which contributes to 
the evidence supporting breast elasticity being a biomarker for MBD, warranting further 
investigation.  
The next key finding was that breast elasticity responds and decreases (in a rapid manner) to 
hormonal interventions that have also been shown to reduce %VBD and TFV. The initial study 
in this thesis (Chapter 3) was a cohort analysis of a patient database of women who were 
administered HAVAHT+Ai™. This study concluded that there was a correlation with the use of 
HAVAHT+Ai™ and the reduction of %VBD and TFV. The initial experimental trial (Chapter 4: 
The HAVAHT+Ai™ study), was a three-month pharmacodynamic sub-study within a 
pharmacokinetic study of HAVAHT+Ai™. This study revealed that breast elasticity decreased 
with a single dose of HAVAHT+Ai™; the mean elasticity decreased consistently from baseline 
to the three-month time point, reaching statistical significance at the second and third month. 
In addition to the overall breast elasticity decreases, the final mean elasticity was 8.77 kPa 
(±3.67kPa), which is approaching the hypothesised normative values previously reported of 
6.80kPa in Chapter 8. 
Generally, a similar pattern was observed within the enobosarm and anastrozole study 
(Chapter 5); however, this cohort of women started with a higher mean elasticity at baseline, 
and even with the decreases throughout the study, the values did not approach the 
hypothesised normative values of 6.80kPa. These decreases were statistically significant at the 
three-month time point, with a reduction also being recorded at one month. As this trial had 
an additional breast elasticity measure at month 12, this time point demonstrated a slight 
statistically insignificant increase in elasticity compared to the three-month time point. It can 
be observed that both of these studies had a statistically significant elasticity decrease in the 
first three months from the commencement of the intervention. However, what is unexplored 
 203 
is the histological changes occurring with the breast tissue after this time point. When using 
the 6 x 3mm Q-Box™, the results demonstrated a statistically significant reduction at the 12-
month time point. This reduction is what we hypothesised would represent the changes 
occurring in the breast tissue and what we believed to be the true results. However, these 
results are not consistent with the Free-Trace Q-Box™ results, and there are a few reasons 
why this could have been the case. Firstly, these results may be the correct findings as no 
previous research has been conducted in this area; although it was hypothesised that further 
reductions should be seen at the 12-month time point, the reductions may plateau after the 
three-month time point. Secondly, the small sample size of the study lead to small fluctuations 
within the individual participant results, which had a large impact on the mean overall values. 
For these reasons, it would be beneficial to conduct further research, with a formal sample 
size calculation, to produce significantly powered results. The data generated in this thesis 
would enable such a calculation. Future studies could also be designed with a more frequent 
outcome measure assessment schedule; this could include both SWE and mammography 
imaging. As we hypothesised that the changes in breast elasticity might occur before the 
changes in the breast tissue that lead to quantifiable changes in %VBD and TFV, it would be 
beneficial to create a time profile of the elasticity and MBD changes occurring. Knowing this 
information would also aid the design for future research, in particular, concerning the design 
of the schedule of assessments. 
A further key finding was the trend of strong correlations between the changes in breast 
elasticity and changes in TFV, and the early time point for which these changes correlated. In 
addition to this was the lack of a correlation between the changes in elasticity and the changes 
in %VBD. The HAVAHT+Ai™ study demonstrated a trend of negligible correlations between the 
changes in %VBD from the baseline measure to the month 12 measure and the breast 
elasticity changes from baseline to month three. The enobosarm and anastrozole study had 
similar results with the correlation analyses between the change in breast elasticity and 
change in %VBD from baseline to month 12 showing a trend towards a low correlation. These 
findings demonstrate that within both of these studies, there was a trend towards a negligible 
and low correlation between the changes in %VBD and the changes in elasticity. These results 
establish that within our study populations, there was not a relationship between these two 
variables. However, this low correlation was hypothesised, as with both the HAVAHT+Ai™ and 
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enobosarm and anastrozole interventions, the TFV and TBV decreased. The resultant effect of 
this is %VBD not reducing to the same degree as the other two variables, or it may even 
remain stable as the percentage is calculated from these two variables.  
Due to the reasons mentioned above, the change in TFV and breast elasticity was considered 
the more relevant correlations to explore. This is because the change in TFV reflect changes in 
the absolute fibrodense areas of the breast, which is the area hypothesised to be positively 
associated with breast cancer risk as this is the actual tissue where breast cancer develops 
(Haars, van Noord et al. 2005, Ursin, Hovanessian-Larsen et al. 2005). Furthermore, breast 
elasticity changes occur in response to early functional changes within the structure of the 
breast tissue, whereas measurable changes to a woman's %VBD take a significant length of 
time. For this reason, if there is a correlation between these variables, the lack of correlation 
could have been due to the duration of the study, and there is the potential that if the study 
were longer, there could be a correlation between the changes with the elasticity values and 
the %VBD values. Future longitudinal trials, with multiple yearly, follow-ups, could incorporate 
SWE to quantify breast elasticity as an early measure and then continue with mammography 
and SWE for the extended length of the trial. A trial of this nature is needed to determine if 
changes in %VBD correlation with the elasticity but just at a later time point.  
The correlation between the change in breast elasticity and change in TFV, from both the 
HAVAHT+Ai™ and the enobosarm and anastrozole study demonstrated consistent results. 
Within the HAVAHT+Ai™ study, the correlation between the change in TFV from baseline to 
month 12 and change in elasticity at month 1 and 3, both showed a statistically significant, 
moderate correlation. While the correlation between change in TFV and elasticity at 2 months 
demonstrated a high correlation, this correlation also reaching statistical significance. The 
same pattern was observed in the enobosarm and anastrozole study with a moderate 
correlation between the baseline and 12-month change in TFV and elasticity and a low (r= 
0.459) correlation with the change in elasticity at one month, with the r-value threshold for a 
moderate correlation being 0.500. However, both of these findings did not reach the 
conventional level of statistical significance.  
These results suggest that there is consistency in the two studies showing that breast elasticity 
decreases with a hormonal intervention that also reduces %VBD and TFV, and that there was a 
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relationship with the changes between these variables. There was also consistency in the 
correlation between the changes in TFV and breast elasticity, and these correlations were able 
to be observed at an early time point within the studies. These findings are favourable for the 
objective of this research program, as this evidence suggests that breast elasticity responds in 
a similar manner to the measured mammography variable of TFV, which is a key feature of a 
biomarker. These breast elasticity responses also occurred within the first few months of using 
the interventions, which allows the potential of breast elasticity to predict the changes in TFV 
at an early time point when using a hormonal intervention. The early response is beneficial as 
clinically, breast elasticity as measured by SWE may be able to determine if a patient is a 
responder or a non-responder to hormonal interventions which have been prescribed to 
reduce MBD and aid in the decision making for either the continuation or cessation of 
treatment. Also, within the realm of research, it could shorten the length of time required for 
conducting clinical trials, as breast elasticity is more sensitive to demonstrate a response to an 
intervention and this response occurs within the first few months of treatment.  
9.3 The Protocol that Should be Used to Determine Whole Breast Elasticity 
From the literature review, it was found that using SWE to measure whole breast elasticity is a 
relatively new indication, and for this reason there was no consistently used protocol or 
methodology described in the literature that demonstrated valid and reliable results as the 
psychometric properties were not recorded. A key objective of this research program was to 
develop a protocol for this indication to be used in both the clinical and research settings and 
the development of this protocol was considered to be a priority in this research program. The 
reason for this priority was that within the studies included in this thesis that used SWE, the 
methodology needed to produce valid and reliable elastography results. During the initial SWE 
sessions, there were fluctuating elasticity values within each breast quadrant with the 
repeated measures; with these fluctuations not appearing to follow any trend or pattern. In 
addition to this, through experimentation, it was found that the researcher could easily 
manipulate the data if the Q-Box™ were not placed carefully or consistently on the image. 
Secondly, there is a need for a protocol that other researchers can use when conducting 
further SWE studies for whole breast elasticity. For research purposes, and clinical purposes, it 
is beneficial to use a consistent protocol to produce comparable results; this helps to 
 206 
contribute to the body of evidence regarding whole breast elasticity and helps monitor a 
patient’s health accurately.  
 
Through this research program, different participant positions and a variety of post-hoc 
imaging analysis techniques were explored. These techniques included placing Q-Box™ with a 
predefined diameter or tracing a custom Q-Box™ around the full image to create a large ROI. 
This ROI is the area included in the breast elasticity calculation. To make the decision about 
which technique should be described as the ideal protocol, several key desirable parameters 
were considered; these included the ability to generate a valid breast elasticity results, which 
was an approximation as we did not have a validated reference standard with which to 
compare the results. However, omitting artefacts and "black holes" may provide more valid 
results than if these were left within the ROI.  
 
The ideal technique also needed to have a high level of precision, which demonstrated the 
minimal spread of values of the collected data. Furthermore, another critical parameter that 
needs to be considered was the clinical utility of the outcome measure, with the technique 
ideally needing to be conducted in a timely manner and not be significantly labour intensive 
for the researcher. A further, important additional consideration of the chosen technique 
should be the comfort levels of the patients; the chosen technique should be relatively 
comfortable for the patient or participant, as this has the potential to reduce attrition rates as 
it is already subjectively an uncomfortable experience for some of the participants.  
 
The methodology that was chosen to be described as the standardised technique is described 
below in Section 9.3.1 to 9.3.4. The justification for why these decisions were made are also 
presented. This methodology is appropriate for the SuperSonic™ Imagine Aixplorer® SWE 
ultrasound machine (Figure 9-1) and may differ for other SWE ultrasound devices.  
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Figure 9-1: SuperSonic™ Imagine Aixplorer® Shear Wave Elastography Ultrasound machine 
9.3.1  Patient Position 
The advice regarding patient position requires more research to make a definitive statement. 
From the data analysed in this research program, the suggested position should be the patient 
lying supine on the examination table with their arms resting relaxed by their side. During this 
research program, two positions were researched; one with the participants having their arms 
relaxed by their side and the other position had the participants ipsilateral arm to the breast 
being examined resting above their head. There was a statistically significant difference of 
1.55kPa between the two positions. As previously stated, there is currently no validated gold 
standard to compare the elasticity values to establish which technique is more accurate. There 
were two reasons for the decision that arms relaxed was the ideal position of choice for 
measuring whole breast elasticity. Firstly, the IQR was 3.38 in the arms relaxed group 
compared to 4.75 in the arm above the head group, showing that the relaxed arms group 
produced more precise data. The second reason for choosing this position was the subjective 
interpretation of the body language of the participants, with it appearing that the participants 
were more comfortable with their arms relaxed by their side. 
As suggested, the guidelines for the patient position when using SWE to measure whole breast 
elasticity requires more research. When using traditional ultrasound, the patient is usually 
 208 
lying supine with a pillow placed under the shoulder of the breast to be examined, and the 
patient's arm elevated over their head (Kossoff 2000); this position allows the breast to be 
distributed over the chest wall. Traditional ultrasound, however, is used to investigate specific 
regions of the breast, rather than calculate the tissue properties of the whole breast as we 
have been doing with SWE. In addition to this, breast elasticity can change with gravity-
induced deformations that occur with changes in tissue weight distribution (Griesenauer, Weis 
et al. 2017). So, if using the traditional ultrasound patient position, the rotation of the torso 
would increase the gravitational forces on the breast and may alter the breast elasticity 
measurements. The process of elevating the arm may also increase the strain on the breast 
tissue. This increased strain may contribute to the mean elasticity values being higher in this 
position, out of the two positions measured, which was seen in the result with this position 
producing significantly higher elasticity values in the Chapter 8 study.  
9.3.2 Transducer Setup and Placement Position 
A linear transducer (Figure 9-2) is used, and ample ultrasound gel is placed on the transducer 
head (Figure 9-3) and also directly on the breast (on each quadrant to be imaged).  
 
Figure 9-2: SuperSonic™ Imagine Aixplorer® SWE linear transducer 
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Figure 9-3: Ultrasound gel being placed on the linear transducer head 
The ample ultrasound gel aids the propagation of the shear waves and reduces the extent of 
the artefacts and or areas that the shear waves have not propagated (black holes) within the 
image. In regard to the placement of the transducer head, each breast is divided into four 
quadrants (Figure 9-4); the lower outer (1, 8), upper outer (2, 7), upper inner (3, 6) and lower 
inner quadrants (4, 5). The transducer head is placed horizontally in a perpendicular position, 
2cm away from the nipple (Figure 9-5).  
 
Figure 9-4: Diagram of breast quadrants for shear wave ultrasound images 
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Figure 9-5: Location of the transducer head in relation to the nipple when using SWE 
With the ample ultrasound gel, the transducer is held in the position with no pressure applied 
from the operator for approximately three to five seconds, allowing time for shear waves to 
propagate through the tissue (this allows for a black hole free image). The image is then frozen 
and labelled by using a body mark on the image (Figure 9-6).  
 
Figure 9-6: SWE output image with body mark indicating what breast quadrant has been imaged 
By capturing images of each breast quadrant, it can provide useful information as the elasticity 
values differ between different quadrants and to establish a thorough calculation of the whole 
breast elasticity all quadrants need to be included in the analysis. Once the images have been 
saved, they are analysed post hoc. 
9.3.3 Post-hoc Analysis of the Shear Wave Elasticity Images 
After capturing and saving the SWE images, there needs to be the post-hoc analysis to 
calculate and present the breast elasticity of the ROI. The function on the SuperSonic™ 
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Aixplorer® SWE ultrasound machine that was chosen to do this was the Q-Box™ trace (Figure 
9-7).  
 
Figure 9-7: Q-Box™ trace function command button on SuperSonic™ Aixplorer® SWE ultrasound 
The Q-Box™ trace feature allows the user to define the ROI by tracing the desired area on the 
touch screen using the stylus provided with the SWE machine (Figure 9-8). When using the Q-
Box™ trace, the aim is to include as much area in the ROI as possible but omit areas that 
include artefacts or black holes (Figure 9-9).  
 
Figure 9-8: User using the attached stylus tracing around the desired region of interest 
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Figure 9-9: Free-Trace Q-Box™ on SWE image to omit ultrasound artefacts 
The reasons this method was chosen were due to the analyses in Chapter 6, which include the 
Q-Box™ trace having the lowest CV, again providing the most precise data which is beneficial 
for clinical trials to demonstrate a change in the breast elasticity values. This method also took 
the least amount of time to analyse the images and enter the data into excel due to one 
dataset per quadrant as opposed to the six datasets that were produced per breast quadrant 
with some of the other methodologies. Once the data has been entered into the statistical 
software of choice, the mean, maximum, minimum and SD of the elasticity can be calculated 
for each quadrant (left and right breast combined), the left or right breast or the average 
whole breast elasticity, as was done in this research program. 
9.4  The Limitations of this Research 
As with all research, the studies within this thesis have limitations that need to be considered 
when interpreting the findings and conclusions.  
9.4.1 Pilot Studies and Sample Size 
Firstly, both the enobosarm and anastrozole and HAVAHT+Ai™ trials were pilot studies, and 
for this reason, had small sample sizes with no formal power calculations. Therefore, the 
results produced from the included studies have limited power to detect differences in the 
results. A pilot study was an appropriate research design for this doctoral research program. 
The reasoning for this was due to both the included interventions used being novel therapies, 
and the outcome measure of breast elasticity also being innovative with no published 
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literature reporting the psychometric properties for its use regarding this indication. 
Therefore, by conducting a study of this nature, it allowed us to determine if SWE was an 
appropriate choice of an outcome measure for these studies and we were able to estimate 
the effect of the enobosarm and anastrozole and HAVAHT+Ai™ interventions on breast 
elasticity. However, as the sample size hasn't been guided by a power calculation, there is the 
possibility of making inaccurate assumptions or predictions based on these results (Van 
Teijlingen and Hundley 2001) regarding the validity and the effect of the interventions on 
breast elasticity. In addition, the future response of breast elasticity in further studies cannot 
be guaranteed.  
The information presented above demonstrates that we need to be cautious about 
formulating definitive statements regarding the findings of both of these studies. However, 
both the data from the enobosarm and anastrozole intervention and the HAVAHT+Ai™ 
intervention studies produced statistically significantly higher elasticity values compared to 
the healthy participant study presented in Chapter 8, and the elasticity decreases and 
correlations were consistent in both the enobosarm and anastrozole and the HAVAHT+Ai™ 
studies. These results maintain the provide promising data regarding the validity and clinical 
utility of breast elasticity as a biomarker for MBD. 
9.4.2  Uncontrolled Open-Label Study Designs 
Both of the intervention studies (enobosarm and anastrozole and HAVAHT+Ai™) utilised an 
uncontrolled, open-label trial design. This open-label trial design specifies that everyone 
recruited for the study received the active intervention, and this establishes that there was no 
control group. There are several problems associated with this type of study design. Firstly, as 
the assessor has not been blinded to the intervention group, the study results can be 
influenced by observer bias, which is 'any kind of systemic discrepancy from the truth during 
the process of observing and recording information for a study' (Mahtani, Spencer et al. 2018). 
Even though the SWE is relatively operator-independent due to the fact no pressure is being 
placed through the transducer head (unlike in other forms of elastography), this observer bias 
had the potential to impact the study results. As previously discussed in Chapter 6, the 
placement of the Q-Box™ can significantly alter the results of the study, so the researcher may 
have consciously or unconsciously placed the Q-Box™ in a more favourable position to show 
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better results. We did try and control for this bias by using the Free-Trace Q-Box™, which 
significantly reduced the opportunities of the researcher to manipulate the date as compared 
to the other Q-Box™ methodologies. This attempt at controlling for observer bias was unlike 
other studies which have used SWE for breast tissue analyses, as commonly in these previous 
studies, the Q-Box™ ratio function was used. The Q-Box™ ratio technique requires the 
researcher to place two circular Q-Box™ on the image (one Q-Box™ for fibroglandular tissue 
and one for fatty tissue), which provides the elasticity of the fibroglandular area of the breast. 
Using the Q-Box™ ratio technique can lead to a substantial level of data manipulation, as only 
one Q-Box™ is used for the fibroglandular tissue, the researcher can place the Q-Box™ on a 
region that may provide more favourable results for their hypothesis, whether this be higher 
or lower elasticity, as the elasticity can fluctuate throughout a single image.  
 
Another limitation of the open-label study design and therefore, the studies included in this 
research program, is the lack of a control group. By not having a control arm of either the 
intervention studies, we were unable to compare the breast elasticity changes to a group of 
participants with similar baseline characteristics, who were not utilising the hormonal 
interventions used within these trials. The lack of a control group can result in maturation bias 
affecting the study results, and we are unable to describe the behaviour of the breast 
elasticity in a population not on the intervention. Therefore, the natural progression of 
fluctuations or the breast elasticity in the absence of an intervention were unable to be 
observed and described. We did try to negate for the lack of a control group by incorporating 
the study from Chapter 8 of this thesis, which used four repeat measure on healthy women to 
determine the unbiased behaviour of breast elasticity. This study demonstrated no significant 
differences in the breast elasticity values across the repeat measures or with hormonal 
fluctuations of the menstrual cycle. However, as the women in the intervention studies were 
explicitly recruited for having high MBD, and the women in the reliability were recruited from 
the general local population, there was not a valid comparison group. Any future trials should 
be designed with a placebo-controlled group, and the assessors should be blinded, which will 
negate the maturation bias and also reduce the risk of observer bias or any other researcher-
based biases that can be introduced. 
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9.4.3  Inability to Calculate Baseline Correlations Between Breast Elasticity 
and Per Cent Volumetric Breast Density and Total Fibroglandular 
Volume 
A further limitation of this research program was the inability to conduct a baseline 
correlation between the whole breast elasticity and %VBD and TFV. As a key hypothesis was 
that there would be a higher baseline breast elasticity in women with high MBD due to the 
structure and histology of the tissue. It would have been of value to calculate this correlation 
to provide fundamental evidence to determine if breast elasticity could be used as a 
biomarker for MBD. However, during the studies included in this thesis, the only participants 
that had VolapraDensity™ measurements were the women with high MBD. As we recruited 
women with no signs of breast disease or pathology for the reliability study in Chapter 8, it 
was deemed unethical to expose these women to unnecessary radiation which would occur 
during mammography; therefore, they did not have mammograms and subsequently 
VolparaDensity™ measurements. For this reason, we were forced to assume that these 
women had a lower MBD than the women explicitly recruited for their high MBD, due to the 
reason previously listed in Section 9.2. This allowed us to hypothesise that the baseline 
elasticity values are higher in women with greater MBD but didn't allow us to make a direct 
correlation analysis of the spectrum of MBD and breast elasticity. 
In future research, it would be beneficial to conduct a cross-sectional study using women from 
a breast screening program, who have had a mammogram and also then undertake SWE on 
the breast to measure the elasticity. This would give us a sample of women with varying 
breast densities to conduct correlation analyses with breast elasticity. If there is a strong 
correlation between the two variables, this could aid the research into breast elasticity as a 
biomarker for MBD but could also, when properly validated, be used as a screening tool for 
women under the age of 40, who are concerned about their breast density. These women are 
under the age who are eligible for the Australian government-funded breast screening 
programs; therefore, elasticity may be able to guide the medical practitioner in regard to 




9.5 Future Research 
As previously mentioned, the studies in this thesis are contributing to the early body of 
evidence for elasticity as a biomarker for interventions to reduce MBD. However, as listed in 
Section 9.4, there are limitations in the methodologies of the studies within this thesis. There 
needs to be ongoing research into this area further to validate breast elasticity for use in 
clinical research. This section will state areas of future research which need to be conducted 
to further contribute to the literature.  
Firstly, normative breast elasticity values measured using SWE need to be accurately 
measured and validated. This ideally would have a larger cohort, which would be a larger 
representation of the population, and the averages would be less influenced by individual 
variations of breast elasticity. In addition, future research needs to measure %VBD, TFV and 
breast elasticity measurements of all the participants. These measurements, for feasibility 
reasons during this research program, could not be measured. By doing these additional 
measures, the researcher will be able to accurately state the normative breast elasticity 
ranges of individuals with low MBD and high MBD. Furthermore, with all of these breast 
variables, a linear correlation analysis could be conducted to observe if there is a relationship 
between breast elasticity and %VBD, and TFV. As mentioned in Section 9.4.3, a potential study 
design to uncover this data would be a cross-sectional study. The sample for this study could 
be women recruited from a breast screening program. These women, as a representation of a 
population of women over 50, would have varying degrees of breast density and TFV, these 
participants would also undergo SWE to measure their breast elasticity. This mammography 
data and elasticity data would allow normative values to be calculated, and correlation 
analyses to be made between the variables. This study could also use a sub-group of women 
to have their SWE images captured and the corresponding breast elasticity values extracted by 
two assessors which would allow the inter-rater reliability to be calculated. The inter-rater 
reliability is a vital psychometric property of an outcome measure for longitudinal studies with 
repeated measurements and was unable to be calculated within this thesis due to the inability 
of the researcher to find a second assessor.  
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Furthermore, as the studies included in this thesis were pilot trials, more robust larger studies 
and trials need to be conducted. Ideally, this future research should be designed as a double-
blind, randomised, placebo-controlled trial. Any future studies of this nature also need to have 
a sample size calculation done to determine the adequate sample size to allow the findings to 
be reliable and not due to chance. By running a trial of this nature, the researcher would be 
able to reduce the risk of bias (for example maturation bias and observation bias) and 
determine if there was a statistically sound causal relationship between the intervention and 
the changes in elasticity. In addition, any future works of this nature could have a more regular 
schedule of assessments, both for SWE and mammography. From designing the research this 
way, more information regarding what changes are occurring in the breast tissue after the 
three-month time point and whether mammography variables are also able to detect changes 
at this early time point could be discovered. 
A further plan for supplementary research could be a histological study to determine the 
structure and histological properties of breast tissue of high and low elasticity values. This 
research would provide further information into the similarities or differences between the 
tissue and cellular make up of breasts of high MBD, and breasts of high elasticity and would be 
incredibly useful to further validate the use of breast elasticity as an outcome measure and a 
breast cancer screening tool.    
9.6 Conclusion 
The overall objective of this research program was to determine if breast elasticity, as 
measured by SWE, could act as a biomarker of the early response of breast tissue to 
interventions that reduce MBD. Through the clinical trials and subsequent data analysis, this 
thesis presented early evidence that breast elasticity may prove to be a valid and reliable 
biomarker to be used in clinical trials. Although the studies were small and of low power, there 
were significant reductions in the measured breast elasticity, which trended in the same 
direction of the other MBD variable results, these being a reduction in %VBD and TFV. Also, 
there is early evidence that baseline elasticity is higher in women with a greater MBD 
compared to those with a lower MBD. The findings of this research can be the foundation for 
future research, as we have presented a precise and reliable imaging protocol and evidence 
that breast elasticity responds to hormonal interventions that have also been shown to 
 218 
reduce %VBD and TFV. With further research, if proven valid with more extensive clinical 
trials, breast elasticity could dramatically aid the research into developing novel interventions 
to reduce MBD. Breast elasticity could also have significant clinical uses to guide health 
management decisions and provide early feedback into a patient's response to interventions, 
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Result Out of 
range 
001 Screening 3/02/2017 0920 LH U/L   11.9  
    FSH U/L   5.1  
    Oestradiol pmol/L   1006  
    Progesterone nmol/L   0.3  
    Testosterone nmol/L 0 1.8 <0.4  
    FAI % 0.4 6.0 <0.6  
    DHEAS umol/L 1.7 11.7 1.8  
    SHBG nmol/L 28 150 65  
001 1 Month 07/03/2017 0845 LH U/L   30.5  
    FSH U/L   14.2  
    Oestradiol pmol/L   434  
    Progesterone nmol/L   1.6  
    Testosterone nmol/L 0 1.8 0.4  
    FAI % 0.4 6.0 4.0  
    DHEAS umol/L 1.7 11.7 3.4  
    SHBG nmol/L 28 150 10 *Low 
001 Month 3 1/05/2017 0850 LH U/L   31.1  
    FSH U/L   12.6  
    Oestradiol pmol/L   839  
 257 
    Progesterone nmol/L     
    Testosterone nmol/L 0 1.8 0.6  
    FAI % 0.4 6.0 6.7  
    DHEAS umol/L 1.7 11.7   
    SHBG nmol/L 28 150 9 *LOW 
001 Month 6 07/08/17 0915 LH U/L   1.7  
    FSH U/L   2.5  
    Oestradiol pmol/L   118  
    Progesterone nmol/L   30.0  
    Testosterone nmol/L 0 1.8 <0.4  
    FAI % 0.4 6.0 <4.0  
    DHEAS umol/L 1.7 11.7 3.7  
    SHBG nmol/L 28 150 10 *LOW 
001 Month 9 02/11/17 0936 LH U/L   10.2  
    FSH U/L   6.3  
    Oestradiol pmol/L   105  
    Progesterone nmol/L   <0.5  
    Testosterone nmol/L 0 1.8 <0.4  
    FAI % 0.4 6.0 <4.4  
    DHEAS umol/L 1.7 11.7 3.6  
    SHBG nmol/L 28 150 9 *LOW 
001 Month 12 05/02/18 1220 LH U/L   1.5  
    FSH U/L   2.8  
 258 
    Oestradiol pmol/L   132  
    Progesterone nmol/L   19.2  
    Testosterone nmol/L 0 1.8 <0.1  
    FAI % 0.4 6.0 <0.8  
    DHEAS umol/L 1.7 11.7 2.9  
    SHBG nmol/L 28 150 12 *LOW 
002 Screening 10/02/2017 0815 LH U/L   4.1  
    FSH U/L   2.4  
    Oestradiol pmol/L   1530  
    Progesterone nmol/L   1.0  
    Testosterone nmol/L 0 1.8 0.4  
    FAI % 0.4 6.0 0.3 * 
    DHEAS umol/L 1.7 11.7 3.5  
    SHBG nmol/L 28 150 149  
002 Month 1 15/03/2017 Unknown LH U/L   3.4  
    FSH U/L   6.3  
    Oestradiol pmol/L   65  
    Progesterone nmol/L   0.8  
    Testosterone nmol/L 0 1.8 <0.4  
    FAI % 0.4 6.0 <3.1  
    DHEAS umol/L 1.7 11.7 4.4  
    SHBG nmol/L 28 150 13 *LOW 
002 Month 3 08/05/2017 0920 LH U/L   2.7  
 259 
    FSH U/L   7.8  
    Oestradiol pmol/L   100  
    Progesterone nmol/L   0.5  
    Testosterone nmol/L 0 1.8 <0.4  
    FAI % 0.4 6.0 <4.4  
    DHEAS umol/L 1.7 11.7   
    SHBG nmol/L 28 150 9 *LOW 
002 Month 6 16/08/2017 0800 LH U/L   4.2  
    FSH U/L   2.9  
    Oestradiol pmol/L   198  
    Progesterone nmol/L   0.4  
    Testosterone nmol/L 0 1.8 <0.4  
    FAI % 0.4 6.0 <4.4  
    DHEAS umol/L 1.7 11.7 3.9  
    SHBG nmol/L 28 150 9 *LOW 
002 Month 9 15/11/17 1458 LH U/L   46.2  
    FSH U/L   22.4  
    Oestradiol pmol/L   526  
    Progesterone nmol/L   0.6  
    Testosterone nmol/L 0 1.8 <0.4  
    FAI % 0.4 6.0 <3.3  
    DHEAS umol/L 1.7 11.7 3.7  
    SHBG nmol/L 28 150 12 *LOW 
 260 
002 Month 12 14/02/18 1030 LH U/L   8.2  
    FSH U/L   9.6  
    Oestradiol pmol/L   351  
    Progesterone nmol/L   0.4  
    Testosterone nmol/L 0 1.8 <0.1  
    FAI % 0.4 6.0 <1.0  
    DHEAS umol/L 1.7 11.7 3.7  
    SHBG nmol/L 28 150 10 *LOW 
003 Screening 07/02/2017 0935 LH U/L   4.7  
    FSH U/L   5.0  
    Oestradiol pmol/L   269  
    Progesterone nmol/L   14.0  
    Testosterone nmol/L 0 1.8 0.6  
    FAI % 0.4 6.0 0.8  
    DHEAS umol/L 1.7 11.7 4.3  
    SHBG nmol/L 28 150 71  
003 Month 1 07/03/2017 0915 LH U/L   2.0  
    FSH U/L   2.7  
    Oestradiol pmol/L   109  
    Progesterone nmol/L   10.1  
    Testosterone nmol/L 0 1.8 0.4  
    FAI % 0.4 6.0 4.0  
    DHEAS umol/L 1.7 11.7 5.4  
 261 
    SHBG nmol/L 28 150 10 *LOW 
003 Month 3 03/05/2017 0910 LH U/L   0.5  
    FSH U/L   2.1  
    Oestradiol pmol/L   117  
    Progesterone nmol/L   11.1  
    Testosterone nmol/L 0 1.8 0.6  
    FAI % 0.4 6.0 6.7 *HIGH 
    DHEAS umol/L 1.7 11.7   
    SHBG nmol/L 28 150 9 *LOW 
003 Month 6 10/08/2017 0920 LH U/L   4.7  
    FSH U/L   6.8  
    Oestradiol pmol/L   <50  
    Progesterone nmol/L   1.4  
    Testosterone nmol/L 0 1.8 0.6  
    FAI % 0.4 6.0 6.7 *HIGH 
    DHEAS umol/L 1.7 11.7 5.9  
    SHBG nmol/L 28 150 9 *LOW 
003 Month 9 6/11/2017 0939 LH U/L   8.0  
    FSH U/L   5.8  
    Oestradiol pmol/L   89  
    Progesterone nmol/L   <0.5  
    Testosterone nmol/L 0 1.8 0.6  
    FAI % 0.4 6.0 6.7  
 262 
    DHEAS umol/L 1.7 11.7 5.6  
    SHBG nmol/L 28 150 9  
003 Month 12 09/02/2018 0925 LH U/L   4.7  
    FSH U/L   8.9  
    Oestradiol pmol/L   65  
    Progesterone nmol/L   0.5  
    Testosterone nmol/L 0 1.8 <0.4  
    FAI % 0.4 6.0 <4.0  
    DHEAS umol/L 1.7 11.7 5.8  
    SHBG nmol/L 28 150 10 CS * LOW 
005 Screening 04/02/2017 0910 LH U/L   5.7  
    FSH U/L   2.4  
    Oestradiol pmol/L   331  
    Progesterone nmol/L   2.6  
    Testosterone nmol/L 0 1.8 0.7  
    FAI % 0.4 6.0 0.7  
    DHEAS umol/L 1.7 11.7 2.1  
    SHBG nmol/L 28 150 100  
005 Month 1 08/03/2017 1050 LH U/L   6.6  
    FSH U/L   7.8  
    Oestradiol pmol/L   94  
    Progesterone nmol/L   <0.5  
    Testosterone nmol/L 0 1.8 0.6  
 263 
    FAI % 0.4 6.0 3.5  
    DHEAS umol/L 1.7 11.7 3.0  
    SHBG nmol/L 28 150 17 *LOW 
005 Month 3 27/04/2017 1035 LH U/L   3.9  
    FSH U/L   5.6  
    Oestradiol pmol/L   136  
    Progesterone nmol/L     
    Testosterone nmol/L 0 1.8 0.7  
    FAI % 0.4 6.0 4.7  
    DHEAS umol/L 1.7 11.7   
    SHBG nmol/L 28 150 15 *LOW 
005 Month 6 17/07/2017 1425 LH U/L   3.8  
    FSH U/L   3.1  
    Oestradiol pmol/L   773  
    Progesterone nmol/L   0.5  
    Testosterone nmol/L 0 1.8 0.9  
    FAI % 0.4 6.0 6.0  
    DHEAS umol/L 1.7 11.7 3.4  
    SHBG nmol/L 28 150 15 *LOW 
005 Month 9 06/11/2017 0926 LH U/L   6.0  
    FSH U/L   5.6  
    Oestradiol pmol/L   479  
    Progesterone nmol/L   <0.5  
 264 
    Testosterone nmol/L 0 1.8 <0.4  
    FAI % 0.4 6.0 <3.1  
    DHEAS umol/L 1.7 11.7 3.1  
    SHBG nmol/L 28 150 13 *LOW 
005 Month 12 30/01/2018 0918 LH U/L   7.3  
    FSH U/L   3.9  
    Oestradiol pmol/L   506  
    Progesterone nmol/L   <0.5  
    Testosterone nmol/L 0 1.8 0.5  
    FAI % 0.4 6.0 3.3  
    DHEAS umol/L 1.7 11.7 2.7  
    SHBG nmol/L 28 150 15 *LOW 
006 Screening 04/02/2017 0000 LH U/L   6.8  
    FSH U/L   6.9  
    Oestradiol pmol/L   170  
    Progesterone nmol/L   0.7  
    Testosterone nmol/L 0 1.8 1.1  
    FAI % 0.4 6.0 1.5  
    DHEAS umol/L 1.7 11.7 6.6  
    SHBG nmol/L 28 150 72  
006 Month 1 03/03/2017 0840 LH U/L   4.4  
    FSH U/L   9.0  
    Oestradiol pmol/L   81  
 265 
    Progesterone nmol/L   0.6  
    Testosterone nmol/L 0 1.8 1.2  
    FAI % 0.4 6.0 13.3* HIGH 
    DHEAS umol/L 1.7 11.7 9.8  
    SHBG nmol/L 28 150 9 *LOW 
006 Month 3 28/04/2017 0800 LH U/L   3.7  
    FSH U/L   6.7  
    Oestradiol pmol/L   220  
    Progesterone nmol/L   0.7  
    Testosterone nmol/L 0 1.8 1.3  
    FAI % 0.4 6.0   
    DHEAS umol/L 1.7 11.7   
    SHBG nmol/L 28 150 6 *LOW 
006 Month 6 02/08/2017 0910 LH U/L   3.5  
    FSH U/L   6.0  
    Oestradiol pmol/L   78  
    Progesterone nmol/L   6.0  
    Testosterone nmol/L 0 1.8 0.9  
    FAI % 0.4 6.0 18.0  
    DHEAS umol/L 1.7 11.7 9.8  
    SHBG nmol/L 28 150 5 *LOW 
006 Month 9 06/11/2017 1020 LH U/L   2.9  
    FSH U/L   4.4  
 266 
    Oestradiol pmol/L   287  
    Progesterone nmol/L   0.2  
    Testosterone nmol/L 0 1.8 0.8  
    FAI % 0.4 6.0 13.3* High 
    DHEAS umol/L 1.7 11.7 8.3  
    SHBG nmol/L 28 150 6* LOW 
006 Month 10 29/12/2017 1130 LH U/L   3.9  
    FSH U/L   6.5  
    Oestradiol pmol/L   135  
    Progesterone nmol/L   3.9  
    Testosterone nmol/L 0 1.8 0.9  
    FAI % 0.4 6.0 15.0 *HIGH 
    DHEAS umol/L 1.7 11.7 10  
    SHBG nmol/L 28 150 6 *LOW 
008 Screening 06/02/2017 0915 LH U/L   3.3  
    FSH U/L   6.4  
    Oestradiol pmol/L   187  
    Progesterone nmol/L   54.8  
    Testosterone nmol/L 0 1.8 0.4  
    FAI % 0.4 6.0 0.5  
    DHEAS umol/L 1.7 11.7 3.4  
    SHBG nmol/L 28 150 78  
008 Month 1 07/03/2017 1240 LH U/L   3.2  
 267 
    FSH U/L   4.9  
    Oestradiol pmol/L   119  
    Progesterone nmol/L   22.6  
    Testosterone nmol/L 0 1.8 <0.4  
    FAI % 0.4 6.0 <3.1  
    DHEAS umol/L 1.7 11.7 5.2  
    SHBG nmol/L 28 150 13 *LOW 
008 Month 3 04/05/2017 0000 LH U/L   5.4  
    FSH U/L   7.6  
    Oestradiol pmol/L   66  
    Progesterone nmol/L   3.8  
    Testosterone nmol/L 0 1.8 0.6  
    FAI % 0.4 6.0 6.7 *HIGH 
    DHEAS umol/L 1.7 11.7   
    SHBG nmol/L 28 150 9 *LOW 
008 Month 6 04/08/2017 1037 LH U/L   7.2  
    FSH U/L   14.6  
    Oestradiol pmol/L   <44  
    Progesterone nmol/L     
    Testosterone nmol/L 0 1.8 0.4  
    FAI % 0.4 6.0 5.0  
    DHEAS umol/L 1.7 11.7 5.3  
    SHBG nmol/L 28 150 8 *LOW 
 268 
008 Month 9 14/11/2017 0000 LH U/L   4.0  
    FSH U/L   5.0  
    Oestradiol pmol/L   94  
    Progesterone nmol/L   6.2  
    Testosterone nmol/L 0 1.8 <0.4  
    FAI % 0.4 6.0 <3.3  
    DHEAS umol/L 1.7 11.7 4.9  
    SHBG nmol/L 28 150 12 *LOW 
008 Month 12 06/02/2018 1113 LH U/L   6.1  
    FSH U/L   13.5  
    Oestradiol pmol/L   61  
    Progesterone nmol/L   0.3  
    Testosterone nmol/L 0 1.8 0.5  
    FAI % 0.4 6.0 2.8  
    DHEAS umol/L 1.7 11.7 6.3  
    SHBG nmol/L 28 150 18 *LOW 
010 Screening 06/03/2017 0855 LH U/L   1.1  
    FSH U/L   1.0  
    Oestradiol pmol/L   <44  
    Progesterone nmol/L   0.3  
    Testosterone nmol/L 0 1.8 0.4  
    FAI % 0.4 6.0 0.1  
    DHEAS umol/L 1.7 11.7 1.9  
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    SHBG nmol/L 28 150 281 *HIGH 
010 Month 1 07/04/2017 1040 LH U/L   2.5  
    FSH U/L   2.4  
    Oestradiol pmol/L   182  
    Progesterone nmol/L   36.8  
    Testosterone nmol/L 0 1.8 0.4  
    FAI % 0.4 6.0 1.7  
    DHEAS umol/L 1.7 11.7 3.9  
    SHBG nmol/L 28 150 24 *LOW 
010 Month 3 30/05/2017 0950 LH U/L   8.0  
    FSH U/L   3.9  
    Oestradiol pmol/L   254  
    Progesterone nmol/L   0.4  
    Testosterone nmol/L 0 1.8 0.5  
    FAI % 0.4 6.0 3.6  
    DHEAS umol/L 1.7 11.7 4.3  
    SHBG nmol/L 28 150 14 *LOW 
010 Month 6 13/09/2017 1030 LH U/L   4.4  
    FSH U/L   9  
    Oestradiol pmol/L   127  
    Progesterone nmol/L   2  
    Testosterone nmol/L 0 1.8 0.26  
    FAI % 0.4 6.0 1.5  
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    DHEAS umol/L 1.7 11.7 4.2  
    SHBG nmol/L 28 150 17  
010 Month 9 04/12/2017 0930 LH U/L   7.1  
    FSH U/L   5.9  
    Oestradiol pmol/L   69  
    Progesterone nmol/L   <0.5  
    Testosterone nmol/L 0 1.8 <0.1  
    FAI % 0.4 6.0 <0.7  
    DHEAS umol/L 1.7 11.7 4.3  
    SHBG nmol/L 28 150 15 *LOW 
010 Month 12 13/03/2018 1400 LH U/L   4.0  
    FSH U/L   4.1  
    Oestradiol pmol/L   275  
    Progesterone nmol/L   <0.5  
    Testosterone nmol/L 0 1.8 <0.4  
    FAI % 0.4 6.0 <2.9  
    DHEAS umol/L 1.7 11.7 5.5  
    SHBG nmol/L 28 150 14 *LOW CS 
011 Screening 11/03/2017 0933 LH U/L   3.1  
    FSH U/L   6.8  
    Oestradiol pmol/L   128  
    Progesterone nmol/L   <0.5  
    Testosterone nmol/L 0 1.8 0.2  
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    FAI % 0.4 6.0 0.5  
    DHEAS umol/L 1.7 11.7 3.9  
    SHBG nmol/L 28 150 40  
011 Month 1 06/04/2017 0945 LH U/L   3.1  
    FSH U/L   9  
    Oestradiol pmol/L   pending  
    Progesterone nmol/L   pending  
    Testosterone nmol/L 0 1.8 0.54  
    FAI % 0.4 6.0 7.7  
    DHEAS umol/L 1.7 11.7   
    SHBG nmol/L 28 150 7  
011 Month 3 19/06/2017 0920 LH U/L   4.0  
    FSH U/L   8.5  
    Oestradiol pmol/L   83  
    Progesterone nmol/L   0.7  
    Testosterone nmol/L 0 1.8 <0.4  
    FAI % 0.4 6.0 <1.8  
    DHEAS umol/L 1.7 11.7 4.6  
    SHBG nmol/L 28 150 22 *LOW 
011 Month 6 12/09/2017 1130 LH U/L   5.5  
    FSH U/L   3.7  
    Oestradiol pmol/L   141  
    Progesterone nmol/L   19.0  
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    Testosterone nmol/L 0 1.8 0.5  
    FAI % 0.4 6.0 10.0  
    DHEAS umol/L 1.7 11.7 6.6  
    SHBG nmol/L 28 150 5 *LOW 
011 Month 9 07/12/2017 1032 LH U/L   4.5  
    FSH U/L   6.8  
    Oestradiol pmol/L   120  
    Progesterone nmol/L   <0.5  
    Testosterone nmol/L 0 1.8 <0.1  
    FAI % 0.4 6.0 <1.4  
    DHEAS umol/L 1.7 11.7 5.3  
    SHBG nmol/L 28 150 7 *LOW 
011 Month 12 13/03/18 1420 LH U/L   1.6  
    FSH U/L   1.8  
    Oestradiol pmol/L   124  
    Progesterone nmol/L   12.0  
    Testosterone nmol/L 0 1.8 0.4  
    FAI % 0.4 6.0 5.0  
    DHEAS umol/L 1.7 11.7 6.4  
    SHBG nmol/L 28 150 8 *LOW 
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